Professional Documents
Culture Documents
G. S iest, editor
DRUG EFFECTS ON
LABORATORY
TEST RESULTS
Martinus Nijhoff
for the Commission of the European Communities
DRUG EFFECTS ON LABORATORY TEST RESULTS
DEVELOPMENTS
IN CLINICAL BIOCHEMISTRY
VOLUME 2
editor
G. SIEST, Nancy, France
co-editors
J.G. SALWAY, Guildford, United Kingdom
D. REEDER, Washington, USA
Ν. TRYDING, K ristianstad, Sweden
CA. DUJOVNE, K ansas City, USA
F.W. SUNDERMAN, Farmington, USA
executive editor
D. NOTTER, Nancy, France
Κ
Com. 12.8*0 J
1980
MARTINUS NIJHOFF PUBLISHERS
THE HAGUE / BOSTON / LONDON
for
THE COMMISSION OF THE EUROPEAN COMMUNITIES
Distributors:
for the United States and Canada
Kluwer Boston, Inc.
190, Old Derby Street
Hingham, ΜΛ 02043
USA
EUR 6860 EN
Copyright © ECSC, EEC, EAEC, Brussels-Luxembourg, 1980
All rights reserved. No part of this publication may be reproduced, stored in a retrieval system,
or transmitted in any form or by any means, mechanical, photocopying, recording, or otherwise,
without the prior written permission of the publisher,
Martinus Nijhoff Publishers bv, P.O.Box 566, 2501 CN The Hague, The Netherlands.
LEGAL NOTICE
Neither the Commission of the European Communities nor any person acting on behalf of the
Commission is responsible for the use which might be made of the following information.
Preface
G. Siest IX
List of participants XI
BASIC PROBLEMS
ANALYTICAL INTERFERENCES
Place of reference materials and reference methods in the evaluation of drug effects 49
D.J. Reeder
Effects of drugs and physiological substances on serum and urine creatinine 134
J. Rogulski and A. Pacanis
On the influence of Phenylhydrazine and related compounds on the activity of enzymes 170
D. W. Scheuch
The interaction between antiepileptic therapy and folate absorption and distribution.
A kinetic approach to obtain more meaningful laboratory data 206
J. Hendel, P. Winkel and M. Dam
Differentiation of toxic from spurious abnormalities after drug administration in man 214
CA. Dujovne
PHARMACOLOGICAL EFFECTS
- analytical interferences
- drug effect on specific laboratory tests
- physiological or toxical effects
- general pharmacological effects
Gérard SIEST
LIST OF PARTICIPANTS
CASTILLO DE Torres Adaid j* 508, Col Del Valle, MEXICO D.F., Mexico
SANCHEZ M.L. ZP 12 (Mexico)
ABSTRACT
Drugs and xenobiotics can increase or decrease the level of certain
blood constituents. This effect may be desirable or not. It can be due to
an analytical or to a pharmacological effect.
INTRODUCTION
Clinical chemists, clinicians and drug manufacturers are increasingly
aware of the problems related to the effects of drugs on laboratory tests
(Siest et al., 1980). These effects can assume several aspects :
- a purely analytical aspect, in which the drug and/or its meta-
bolites can perturb the assay of a constituent at any stage ; in clinical
chemistry, the term "interference" can be reserved for this "in vitro"
effect ;
- a biological aspect, in which the drug provokes a change in
a biological parameter by a physiological, pharmacological or toxicological
mechanism. This second aspect constitutes what can be called the unexpected
secondary effects of drug, desirable or not.
Laboratory tests exploring the liver, the kidney, etc, may be carried
out for a person who, without the knowledge of the physician ordering the
tests, takes tranquillizers, hypnotics, or oral contraceptives... So it is
very important to know exactly the sort of drug taken by a patient and the
exact conditions of administration. It is hopeful to get a precise question
naire which can be filled at the same time the blood is drawn. The figure 1
presents an example of sampling form.
Surname . ■ c.c. 5 9 9
First name _ Lab. N"
Age Individual N°
Months
Sex :
N° Nurse :
Time of blood sampling
Are you fasting ?
1 If yes If no 2 breakfast
3 meal at center (700 cal.)
A others
Gynaecology :
Laboratory :
Serum"
Blood hemolyzed"
Plasma a p p e a r a n c e
Normal 0 Lactescent k Icteric and opalescent 8
Opalescent 2 Icteric 5 Various (carotenolds) 9
*1 if yes
Sumane
F i n t nai _ Lab. Ν"
Individual Ν*
Nan· a Nanea
N Nanea
—
( #
=600 I
I
# /
i
1
ft
w
3
(00
~ , Ι >—o 1
200 ·
,, I I 1 .. 1
Ut IU SU 071 U2 in. SU ' 1136
Attor Mc aed IniaoMI Mcorbc Ο Η Ι Ι Ι Μ Ί
r~!
15 — Controls
Orai
contraceptives
IO
2.5 mmol/I
CONCLUSION
Laboratory tests are very useful tools for monitoring the effects of
drugs that provoke changes at the same time desirable and unexpected. Becau-
se these variations are usually small, all other variation factors must be
rigorously controlled. It is essential that clinical chemists get into the
habit of not carrying out laboratory tests on patients who take drugs
unless the person doing the tests knows exactly what substances are being
given, as well as the dosages. This is absolutely necessary for improve-
ment in the interpretation of laboratory tests. The effects of drugs can
lead to false diagnoses if the clinician does not realize the relation
with the drug. In order to better interpret laboratory tests, a list of
interfering drugs must establish for every assay method. But the drugs
12
REFERENCES
Batt, A.M. and Siest, G. : Laboratory tests as indirect indicators of the
activity of drug metabolizing enzymes: use of glucaric acid and
gamma-glutamyltransferase. In this book.
Breuer, J., Gerhards, P., Hajdu, P., Rick, W., Roka, L., Stamm, D. and
Wolf, H.P.: Empfehlungen der Deutschen Gesellschaft für Klinische
Chemie zur Durchführung Klinisch-chemischer Untersuchungen bei der
Prüfung von Arzneimitteln. J. Clin. Chem. Biochem., 14: 161-164, 1976.
Breuer, J.: Empfehlungen zur Durchführung von Klinisch - chemischen Unter-
suchungen bei der Prüfung von Arzneimitteln. Dt. Ges. f. Klin. Che-
mie e.V.- Mitteilungen, 5: 146-147, 1977.
13
Footnote: Thia paper hae been prepared for the Expert Panel on "Drug Effecte
in Clinical Chemistry" of the I nternational Federation of Clinical
Chemistry.
CLINICO-PHARMACOLOGICAL PROBLEMS IN THE EVALUATION OF SIDE EFFECTS OF DRUGS
ABSTRACT
The relatively new field of interactions between therapeutic drug use
and biochemical tests is a challenging occasion for interactive work between
two disciplines which have grown somewhat apart both in research and in
clinical practice.
To optimize the gains likely to be obtained by this approach, a solid
knowledge and sound understanding of what has been achieved in the field
of surveillance of untoward and unexpected drug effects seem desirable.
The methodology of drug monitoring, its main achievements, together with its
limitations and needs, are briefly outlined with the main purpose of offer-
ing a working frame or reference for clinical pharmacologists and clinical
chemists who are active in producing and-more often-in utilizing data on
drug-laboratory test interactions.
Examples taken from pharmacokinetic investigations and clinical trials
are provided to support the thesis that priority should be given to creating
true interdisciplinary teams where real clinical situations of drug use and
biochemical testing are investigated and planned. Much attention and effort
should be given to closing the gap between what is shown in in vitro and
in vivo situations, and to minimizing the risk of unjustified extrapolation
from extreme clinical situations and case reports to general clinical prac-
tice. It is suggested that the experience acquired in the field mainly of
drug kinetics and drug interactions should be carefully assessed. Further-
more the role of a well-oriented policy of transfer of information from
research to routine conditions cannot be overemphasized.
INTRODUCTION
For a clinical pharmacologist, it is interesting to recall a contribu-
tion to the issue being discussed here today, which was delivered during a
seminar on drug interactions held back in 1973 in this same Institution
where the work on which we have been asked to report is in full development
(Young et al., 1974). A clinical chemist was then the last speaker among
a host of pharmacologists; a clinical pharmacological perspective is propo-
sed today to clinical chemists.
15
The reason for the citation is not to plead historical backing, but
to provide a context to the discussion which has continued since, as a
major topic of debate in the field: how can one confidently ensure transla-
tion of tiie results of tube and bench work to clinical interpretation and use?
The question has been·and still is much the sane for drug interactions-
so many reports, so much fine investigation to filter out what is worthy
of consideration for understanding basic mechanisms of inter(action) and
for clinical use.
In this framework, the topic assigned to this paper is not outside
the terms of references of the present Workshop, as it conments
briefly on why and how a clinical pharmacological perspective on (side-)
effects of drugs could be of interest for clinical chemists involved in
assessing the influence of drug Intake and therapy on the use of laboratory
tests. Three main reasons can be found which illustrate the connection
between the two lines of research:
- surveillance of drug effects is a comprehensive task, which requires
intelligent participation and the application of common methodology by
all those in charge of patient care.
- Understanding the possibilities and limits of detecting a causal relation-
ship between drug-exposure and clinical (including biochemical, and more
broadly, laboratory) findings could be facilitated by consideration of
experience and results acquired in the field of monitoring drug side-
effects, which can now be considered a sufficiently established branch of
clinical pharmacology and general medicine.
- A major problem facing clinicians and the man in the laboratory in
evaluating drug effects (especially those outside what is specifically
intended or expected following a specific treatment) is how to distinguish
between a purely casual finding and a result pointing to an event which
could occur with a certain frequency (as yet to be defined or confirmed)
1n the course of identical or similar therapy in the future.
The last point is especially relevant to our topic, and merits more
comment. Frequent discrepancies are known to occur between results obtained
1n experimental settings where predefined conditions are the rule, and data
observed in real life situations where many confounding factors (e.g. multi-
drug therapy, different baseline values because of underlying and evolving
pathology, not to mention interindividual variability) must be taken into
account when looking for grounds for clinical decision. Another well-known
16
distinction should be recalled between anecdoctal vs systematic observation.
The former is worth consideration and reporting as it arouses awareness of
the possibility of the event which can be helpfully recalled in interpreting
individual cases. Only the latter type of observation, however, can be
considered a reliable source of information to be used as an instrument in
clinical surveillance. The relevance of this apparently obvious word of
caution cannot be overestimated. It is just as common an occurrence in
clinical practice to encounter an inappropriate inference from an (un-
expected) occasional finding to a clinical decision as it is to see an
(equally unexpected) result being disregarded as originating from some
source of error, while in fact it perfectly fits a not "normal" distribution.
To remain in the field of clinical pharmacology (where much less work
has been done in this area than in the evaluation of reference values in
biochemical and functional testing) it is worth recalling the still very
much pending and challenging debate on the clinical relevance of so-called
therapeutic drug levels and ranges. Responders to subtherapeutic concentra-
tions, non-responders to drug concentrations which borderline toxic levels
and toxic effects-free patients with toxic levels do not merely represent
"exceptions" to the rule. On the contrary they represent a specific sub-
population within the overall "universe" of treated patients; they should
therefore be considered on their own, and could suggest different causal
links between the underlying pathology and the chosen drug regimen.
According to the basic attitude adopted towards the above observations,
we could expect rather conflicting decision-making practices both with
regard to appreciation of(side-) effects and to the importance attributed
to laboratory data. Recent reviews on the question of blood level monitor-
ing (Pippinger, 1979; Richens, 1979; Sjöqvist et al., 1979; Tognoni et al.,
1980a; Tognoni et al., 1980b) and discussion on the clinical relevance of
side-effect reporting systems (Colombo et al., 1977; Gross and Inman, 1977;
Inman, 1980; Ricadi s, 1980) offer an interesting methodological background
and a rich inventory of examples pertinent to the development of programs
aiming at detecting and using data on laboratory test interferences by. drugs.
OBJECTIVES AND GENERAL STRUCTURE
An exhaustive review of the topic is clearly beyond the aim of this
paper, which therefore will concentrate on quoting key-works and methodo-
logical problems,and on supplying major reference and descriptive sources
for consultation (Table 1 ) . Some examples from representative drug classes
and treatments will also be provided.
TABLE 1 SYSTEMATIC PUBLICATIONS ON ADVERSE DRUG REACTIONS
I. Textbooks
Meyler and Peck, 1962 et Seq. D'Arcy and Griffin,1972 Davies, 1977 Dukes, 1957 et Seq.
- Systematic introductory - Brief introductory - Systematic introductory
chapters remarks chapters
- Disease-oriented - Disease - oriented - Disease-oriented - Drug-oriented
.Inducing drugs .Inducing drugs .Inducing drugs .Induced diseases
- Subject index - Subject index - Subject index - Index of drugs
Cross index of generic Index of generic names Index of side-effects
and proprietary names Drug laboratory tests Index of synonyms
interferences
- References in alphabetical -References in aphabetical - References in alphabetical - References in numerical
order at the end of each order at the end of each order at the end of each order at the end of each
chapter chapter with some further chapter chapter
indications
Merits and pitfalls of the main types of surveillance and detection systems
are recalled in Table 3. Intensive in-hospital monitoring for acute drug-
effects represented an important contribution to this field more because
they raised a more generalized alertness to the problem and gave incidence
TABLE 3 A D HOC METHODS FOR MONITORING SIDEEFFECTS
The last two studies mentioned in Table 4 report data obtained from retro-
spective surveys of medical records 1n specialized wards where a much higher
rate of side-effects 1s certainly to be expected and can easily be docunent-
ed. They are quoted here as an example of the use of data for educational
purposes to sensitize doctors and nurses to the problem, through simple
and periodical programs of drug utilization review (Bergman et al., 1979;
Tognonl et al., 1978; Wardell, 1978). For the topic discussed in this
Workshop a specific message can be derived from Table4; doctors are not
naturally inclined to attribute noxious events to drug action. Any un-
expected finding tends in most cases to be referred to or understood as
part of the disease (this is a real possibility, and its implications for
the reliability of this methodology have been discussed widely, Finney,1955;
J1ck, 1977; Karch and Lasagna, 1975). The same (reinforced) attitude, how-
ever, can be expected when confronted with laboratory findings where drug
interference could be considered a causal factor.
What happens in a hospital setting is all the more valid outside
hospitals. Underreporting is a well-documented fact in all countries,
with however a better degree of compliance from doctors when and where drug
surveillance has become a regular component of drug policy and educational
campaigns and where good feedback 1s sought between public authorities and
doctors (Böttiger et al., 1979; Inman 1980; McQueen, 1974). This is vital
to assure not only the survival but also the development of this approach,
which has in-built shortcomings; but it is likely nonetheless to remain a
substantial component of the surveillance system (Inman, 1977; Skegg and
Doll, 1977). The future of post-marketing surveillance programs is still
under evaluation. More data and experience, besides those produced so far,
are needed to decide whether a favourable, cost-benefit ratio is to be ex-
pected (Harcus et al., 1979; Lawson, 1979; SCRIP, 1979). The expansion of
such systems as the Oxford record-linkage depends by definition on the
structure of various health care systems (Skegg, 1979). The role of short-
and long-term clinical trials, the potentiality of cohort and of case-
control studies, and in particular the advantage of a case-control surveil-
lance system have been the subject of so many publications and debates ·
that we shall not take them up again here (Colombo et al., 1977; Gross and
Inman, 1977; Holland, 1973; Peto et al., 1976; Peto et al., 1977; Roth and
Gordon, 1979).
22
CLINICAL PHA RMA COLOGY A ND DRUG EPIDEMIOLOGY: SOME EXA MPLES
Tables 5 and 6 list model cases selected according to two main criteria:
more direct potential interest for those working in a clinical chemistry
laboratory and looking for a role in drug surveillance;
situations where the different aspects of surveillance are most evident.
The problems used for this purpose are wellknown and will not be described
or discussed in detail. Their implications for the present discussion
should already be evident from the analysis proposed in the Tables. It is
further suggested that a drug surveillance approach should not be restricted
only to sideeffect spotting but should aim at comprehensive evaluation
of positive interaction between drug therapies too.
23
TABLE 6 - DRUG EPIDEMIOLOGY
CONCLUSIONS
The problem of comprehensive monitoring of drug-effects has become an
Important part of clinical pharmacology, as consideration of the benefit-to-
risk ratio 1s a major parameter in drug selection and prescription (WHO,197?.
Kinetics, clinical trial methodology and epidemiology have shown their
potential 1n defining a drug profile where the probability of side-effects
should be predictable or at least spotted in good time, and evaluated
against the relevance of positive effects. Though still from being solved,
the problem 1s however at least being tackled with a greater degree of
awareness than 1t was even a few years ago. Looking for factors which could
condition successful progress in this field and therefore for tasks to be
given priority, the following indications seem appropriate and could be of
Interest for all those, Including clinical chemists, who are willing to
contribute to an Intelligent drug policy and to the proper use of drugs in
and outside hospitals:
- simplification and rationalization of drug therapy is the single most
favourable condition to be achieved, in order to obtain optimal surveillance
strategies and acceptable benefit/risk ratios.
24
1 2 3
N. Tryding , S.G. Johansson and P. Manell
Department of Clinical Chemistry, Central Hospital,
S 29185 Kristianstad, Sweden
2
Uppsola University Data Center P.O. Box 2103, S 75002 Uppsala,
Sweden
Department of Drugs, National Board of Health and Welfare,
P.O. Box 607, S 75125 Uppsala, Sweden
ABSTRACT
A new file containing information on well documented drug
effects on laboratory investigations has been added to the compu-
terized Swedish drug information system. This includes all drugs on
sale as well as adverse drug reactions reported by Swedish clini-
cians since 1965. The information will be published for clinical
use as a new edition of our booklet on drug effects in clinical
chemistry. The content will be continuously updated and brought to
the attention of the clinicians. Local data terminals may be used
to get direct access to the information.
INTRODUCTION
The number of documents useful for the knowledge of drug
effects in clinical chemistry is enormous (cf Young, et al. 1975)
and grows rapidly. However, many of the publications have no signi-
ficance for clinical decisions or may even be misleading. It is
necessary to read the information critically. - A data bank on
clinically significant drug effects is needed. In 1977 the Swedish
Society for Clinical Chemistry and the National Corporation of
Swedish Pharmacies (Apoteksbolaget) published a booklet "Drug
effects on laboratory investigations". The starting point was the
publication by Young et al 1975. The material was reduced very '
extensively by excluding :
- All drugs not registered in Sweden.
- Methods not in routine use in Sweden.
- Reports regarding animals.
28
PRUA Λ. I [süfp.
" j ¡"¿ø*pj ι ft/ir ι
I I
i
η — Τ —ι
,..J... J.
I INDI
I ¿A I
I 1
\ntcK I i/Bit, |
\DM6\ ¡"SST1, [HERB
ΙΝ6Λ |
iT'ON | Ι ι ι
L.JtfA L DP
J L'AS] i...?.'ij~i..?ÄJ L*2i
I
/CD I
Síi£ I I'
L._?Sj L . ' P J
L
" T — H
PRUe
EFFECTS
í5/eV"J
OSI l/V/Wff I
Mb
J ÍA/I
'NV CL "VD/5
T
— t „_T , , _Ί
!..
BES ! f¿/¿"] ΓΙ/" 'I \\*û}\ Γ^'Ι Γ^Ί
I /OCA/ I l
|7» | | \fu-s Ι ι ι ι cmc Ι ι ι ¡Fue |
Ffl L..Í2J Lf'J L_.«J L.*?J L_.^
L.71J l
»IteSEflKHF/iÆS.· l^flR/oí/5 F/iÆS
TlòURB I'STKUCWRB OF SWE DÌS
31
MIMER comprise· α
data definition facility
data manipulation language via a host programming language
query language, MIMAN
data dictionary
program generation facility, LIDAM (Rish, 1978).
CONCLUSIONS
Clinically relevant information on drug effects on laboratory
results has recently been collected from the literature. In 1977 it
was published in a booklet for clinical use by Swedish doctors.
SWEDIS, the computerized Swedish drug information system, contains
the names and complete composition of all drugs for sale in Sweden
as well as all adverse drug reactions reported. The data base system
used was well suited for the addition of a new file containing in-
formation on drug effects in clinical chemistry.
The main advantages with our new information system are:
- Reports from clinicians on drug effects on laboratory results are
included as well as documentation found in the literature.
- The information included is well documented.
- The case reports contain information about the dose and duration
of the drug administration.
- A new edition of our booklet on drug effects on laboratory in-
vestigations will be prepared for clinical use by computerized
photocomposition.
- New drugs on the market will be included automatically.
- New drug effects on laboratory test results will be added
continuously.
- The information will be available via data terminals.
REFERENCES
Apoteksbolaget: Läkemedel» påverkan pâ laboratorieundersökningar
(Drug effects on laboratory tests). National Corporation of
Swedish Pharmacies (Stockholm 1977).
Boman, G.: The Swedish Reporting System for Adverse Drug Reactions
1965-1977. Conference on Computer Aid to Drug Therapy and to
Drug Monitoring. Bern 1978. North-Holland Publishing Company
1978.
Dagerus, B., Johansson, S.G. and Manell, P.: SWEDIS, a Drug Informa-
tion System at the Department of Drugs, National Board of
Health and Welfare, Sweden. Conference on Computer aid to
Drug Therapy and to Drug Monitoring, Bern 1978. North-Holland
Publishing Company 1978.
Johansson, S.G. and Manell, P.: The Drug Information System SWEDIS
and its users. Proceedings of MEDIS' 78, Osaka 19/8.
Manell, P.: Computer aid to the analysis of adverse drug reaction
reports. Proceedings of XIX Congress of the Italian Pharmaco-
logical Society, Ancona 1978.
Meyler's Side Effects of Drugs Volume VIII. Ed. M.N.G. Dukes
(Excerpta Medica, Amsterdam-Oxford 1975).
MIMER. A general purpose data base management system. Report no
M78001. Uppsala University Data Center, P.O. Box 2103,
S 75002 Uppsala, Sweden.
Rish, T.: Compilation of multiple file queries in a meta-data base
system. Linköping studies in Science and Technology Disserta-
tions, 1978.
Young, D.S., Pestaner, L.C. and Gibberman, V.: Effects of Drugs on
Clinical Laboratory Tests. Clinical Chemistry 21: 1-432D, 1975.
A. GALLI
Hôpital de la Salpétrière (i)
75013 Paris
INTRODUCTION
The action or effect of drugs upon laboratory tests may present
two aspects :
- an analytical aspect. The drug and/or its metabolites can affect -
interfere with - the mechanism of the determination. The result thus
obtained is different from the normal or true value but in a totally
artifactitious way, the true value remaining unchanged.
- a biological aspect. Under the action of a drug and/or its metabolites,
some of the constituents measured in the body fluids are submitted to
significant variations by toxicology or primary or secondary mechanisms.
The biochemical aspect is often taken into consideration but the pro-
blems related to haematology and especially to haemostasis are also very
important and will be the topic of a separate study.
Such considerations apply also to a number of immunological determinat-
ions.
It is also important to be aware of the problem of physiological cons-
tituents present in abnormally high concentrations (e.g. bilirubin)
likely to disturb the measurement of other parameters, but this can be
considered as a different problem.
The knowledge of the analytical interferences produced by a drug can
only be acquired by means of a thorough study. This study must be car-
ried out :
1- When studying a drug.
2- When developing an analytical method.
THE INTERFERENCE DRUSS
Most often, the interfering drug is a molecule foreign to the body
and administrated for therapy, or possibly, diagnostic purposes.
(l) This paper is based on the work of the commission "Effet des Medica-
ments sur les Examens de Laboratoire" of the "Société Française de Biolo-
gie Clinique".
40
the same as in plasma, however the proble« of urines has drawn the at-
tention of biochemists for a long time because of the various colors
the drugs are liable to generate either spontaneously or subsequently
to the action of strong bases or acids. However it is relatively easy
to find the origins of these various colorations; the case of dark
urines is more difficult and is highly significant from a diagnostic
point of view (melanoma, alkaptonuria, porphyria, hemoglobinuria).
The study of the physico-chemical disturbing mechanisms of drugs is of
great interest in its previsional aspect. Actually, it should allow us,
as our knowledge in this field will increase, to classify the interfe-
rences according to the structure and the chemical properties of the
evaluated drug. We saw previously that the most interfering drugs have
reducing functions : thiols, phenols or are chelators...
The structural analogy can also be a good guideline : sulfonyl urea
and urea, xanthic bases and uric acid.
I- EVALUATION OF A DRUS
The in vitro study appears as an essential prerequisite before
any animal or human experimentation in order to be sure of the validity
of in vivo result, in order to be able to evaluate with fidelity the
pharmacological or toxicological effects and thus to eliminate any risk
of false therapeutic results. Actually, it would be regrettable that such
a drug should only have an action on the determination itself and that
normal biological results should hide a possible toxicity.
1.1. Product to study
1.1.1. Raw material
Generally, it consists in the raw material used by the manufacturer
or by the Codex variety if the product is registered in the pharmacopeia.
1.1.2. Knowledge of the product ; physicochemical characteristics
1.1.2.1. It is a must to have the analytical file of the manufac-
turer, to know the formula of the product and its main physicochemical
properties.
- Physical properties : crystalline, amorphous, micronized form; solubi-
lity; pH of the solution, etc...
- Chemical properties : knowledge of the chemical functions and of their
degree of reactivity.
1.1.2.2. It is necessary to know the product stability, when solid
and particularly when in solution.
44
3.3· The studied parameter value is plotted against the therapy dose.
The value of the therapy dose retained for further study is taken where
the slope of the curve is maximum.
It would also be possible to work on a very high dose (20 g/l for ins-
tance) then on successive dilutions and then to mathematically or graph-
ically determinate a minimum active dose.
In this way, it would be possible to determine the smallest possible
dose, expressed in mg or ug/l able to induce a perturbation.
CONCLUSION
The analytical interference of drugs upon laboratory tests is ex-
tremely important if one wants to appreciate with accuracy the desired
or unwanted pharmacological effects as well as the possible toxicologica!
action. Existing literature is very abundant but it is often difficult
to make out the contribution of the analytical or toxicopharmacological
perturbations as well as the actual impact of the interferences. There-
fore, studies should be undertaken, according to perfectly defined
procedures, in order to evaluate the disturbing effects of the most
often used drugs and the reliability of the main laboratory tests in
presence of possible administration of drupa. A perfect knowledge of
the action mechanism is of high interest froa the prospective point of
view. If the new drugs and new methods are systematically evaluated in
this direction, we will have in the future a complete and updated
knowledge of this problem.
48
REFERENCES
Bailly M. : Perturbations des résultats d'analyses biochimiques provo
quées par la thérapeutique. C.R. Journées pharmaceutiques interna
tionales, Paris, 1972, 127.
Baselt R.C., Wright J.A., Cravey R.H. : Therapeutic and toxic concentra
tions of more than 100 toxicologically significant drugs in blood,
plasma or serum : a tabulation. Clin. Chem., 1975, 21_, 4462.
Capolaghi B. : Interférences analytiques des médicaments sur les paramè
tres biologiques. Nancy, 1976 Communication par G. Siest.
Caraway V.T. : Accuracy in clinical chemistry. Clin. Chem., 1971, H ,
6371.
Caraway W.T., Kammeryer C.W. : Chemical interference by drugs and other
substances with clinical laboratory test procedures. Clin. Chim.
Acta, 1972, 41, 395434.
Constantino N.V., Kabat H.P. : Drug induced modifications of laboratory
test valuesrevised 1973· Amer. H. Hosp. Pharmacy, 1973, ¿0, 2471.
Delwaide P.A., Jadin Α., Heusghem C. : Interferences des médicaments sur
les déterminations effectuées en chimie clinique. In : Les effets
indésirables des médicaments. Eeusghem C, Le chat P. Ed., Masson
Pubi., 1973, Paris, 698710.
Elking M.P., Kabat H.P. : Drug induced modifications of laboratory test
values. Amer. J. Hosp. Pharmacy, 1968, 25., 485519.
Letellier G., Vinet B. : Etude in vitro de l'influence des drogues sur
les analyses : sérum de contrôle VS sérum frais. 5emes journées
internationales de Biologie Clinique, Tours, sept. 1976.
Marzin D. : Etude de l'interférence de la D penicillamine sur différents
dosages biologiques. Doctorat es sciences pharmaceutiques. Univer
sité Paris Sud, 1979.
Reiss B.S. : Interactions of drugs and laboratory tests. J. Clin.
Pharmacol., 1975, febmar, 135138.
Siest G., Bretaudière J.P., Buret J., Favre R., Gueguen R., Petitclerc
C , Sachs C, Vernet Η., Zender M. : Les variations biologiques
des examens de laboratoire. Inform, sci. Biol., 1978a, 4_, 314.
Siest G., Appel W., Blijenberg G.B., Capolaghi B., Galteau M.M.,
Heusghem C, Hjelm M., Lauer K.L., Le Perron, Loppinet V., Love C ,
Royer R.J., Tognoni C, Wilding P. : Drug interference in clinical
chemistry : studies on ascorbic acid. J. Clin. Chem. Clin. Biochem.,
1978b, 16, 103110.
Siest G., Buret J., Gueguen R., Petitclerc C, Sachs C, Vernet Μ.,
Zender R., Panek E., Drosdowsky M., Guize L. : Modalités pratiques
de production des valeurs de référence. Inform, sci. Biol., 1979a,
í, 2.
Siest G., Bretaudière J.P., Buret J., Gueguen R., Petitclerc C, Sachs C ,
Vernet Μ., Zender R. : Influence des facteurs analytiques sur les
valeurs de référence. Ann. Biol. clin., 1979b, J7, 125126.
Singh H.P., Hebert Μ.Α., Gault M.H. : Effect of some drugs on clinical
laboratory values as determined by the Technicon SMA 12/60. Clin.
Chem., 1972, 18, 137144.
Sunderman F.W. : Drug interference in clinical biochemistry. Crit. Rev.
Clin. Lab. Sci., 1970, 1, 427449.
Wirth W.A., Thompson R.L. : The effect of various conditions and subs
tances on the results of laboratory procedures. Am. J. Clin. Pathol«,
1965, 21, 579590.
PLACE OF REFERENCE MATERIALS AND REFERENCE METHODS IN THE EVALUATION OF
DRUG EFFECTS
Dennis J. Reeder
Organic Analytical Research Division, Center for Analytical Chemistry
National Measurement Laboratory, National Bureau of Standards
Washington, D.C. U.S.A.
ABSTRACT
The presence of analytical errors in clinical laboratory testing may
be the result of many factors. Even though most clinical tests are becom-
ing very precise, reliance on precise tests for accurate analytical values
is not sufficient because of potential bias caused by drug effects. Proper
analytical techniques can minimize the sources of inaccuracies caused by
variabilities and interferences but a true understanding of drug effects
can only be obtained when measurements are placed on an accuracy base.
Assurance that measurements are accurate can best be accomplished by use of
reference materials and reference methods that are free of interferences
and that can establish the accuracy of an analytical value. Development of
new reference materials and reference methods will become increasingly
important for proper health care.
INTRODUCTION
While this workshop is directed towards variations in results of
laboratory tests due to drug intake, we must keep in mind that it is the
Interpretation of test results by the physician that determines the resul-
tant treatment of a patient. If a physician places too much dependence on
a single clinical laboratory result, patients may be given incorrect quan-
tities or types of medication, although many physicians repeat tests to
confirm suspected out-of-normal values. Because of many complex chemical
reactions that are the basis of today's mass-produced, multiphasic, com-
puterized and automated test procedures, it is difficult for a physician to
anticipate aberrent test results that may occur as a result of the influ-
ences of medications on those tests. Furthermore, instances have been
reported in the literature where identical samples were sent to a number of
laboratories, simultaneously, and the ranges of reported values were both
alarming and disheartening. (Pippenger, 1976)
Numerous questions can be raised. How much confidence can be placed
on the analytical results from any single laboratory? Do the more auto-
mated and precise tests give accurate values for comparison? What kind of
Interferences are likely to influence a laboratory test and cause inaccu-
racy in the reported data? In essence, how specific are the analytical
values? Which medications definitely affect results of a clinical
50
laboratory test?· Are all tests affected? And to what extent? What place
does the use of reference materials and reference methods have In the
evaluation of drug effects?
The purpose of this paper is to review some of the factors that can
cause analytical errors in clinical laboratory testing and to suggest
current and expanding_roles for reference materials and reference methods
in making meaningful measurements for health care.
PRECISION OF ANALYTICAL TESTS
In any measurement procedure, precision is demonstrated when the same
numerical value is obtained repeatedly. This measure of precision is
termed repeatability within a single laboratory and is called reproduci-
bility between different laboratories. With the advent of highly sophis-
ticated, automated instruments that sample and pipette reagents and patient
fluids, precision of a given test within a single day has improved consid-
erably. Laboratories that report a high degree of precision in their test
results are often considered to be highly accurate. Often there is a high
and positive correlation between precision and accuracy. However, in
practice, some highly precise systems are sometimes found to be wildly
inaccurate. The important point is that reliance on precise tests for
accurate analytical values must be carefully considered. Drug interfer-
ences on a laboratory test may not alter the precision of the test, but may
grossly bias the reported values.
ACCURACY AND SOURCES OF INACCURACY
Clearly, there are many needs for the development of Certified Refer-
ence Materials and reference methods, particularly in those cases where
serious drug effects have been observed and patient care has suffered as a
result of laboratory analytical errors. Partial resolution of some of
these needs is currently underway at NBS with the certification of electro-
lytes and some organic constituents (such as cholesterol) in a large homo-
geneous batch of freeze-dried human serum. This proposed SRM (No. 909)
57
will have analyte values certified by definitive methods. In addition,
informational values for other analytes will be provided as they are
measured by the best currently available methods. Calibration of instru
mentation with this material may be very useful in elucidating drug effects
and interferences on clinical laboratory tests.
REFERENCES
Anastassiadis, P. Α., and Common, R. H.: Some Aspects of the Reliability of
Chemical Analyses. A nalyt. Biochem. 22: 409423, 1968.
Harris, E. K., Kanofsky, P., Shakarji, G., Cotlove, E.: Biological and
Analytical Components of Variation in Longterm Studies of Serum
Constituents in Normal Subjects. II. Estimating Biological Components
of Variation. Clin. Chem 16:11 10221027, 1970.
Pippenger, C. E., Penry, J. K., White, B. G., Daly, D. D., and Buddington,
R.: Interlaboratory Variability in Determination of Plasma Anti
epileptic Drug Concentrations. A rch. Neurol. 33: 351355, 1976.
ABSTRACT
Drug effects are differentiated into interaction and in-
terference effects. Interference is defined as the effect of a
sample component other than the analyte on the determination
of the concentration or catalytic activity of the analyte.
Three various mechanisms are described.
A screening list of about 60 drugs representing the most rele-
vant preparations presently used are proposed for a scheme to
detect possible drug·interference in method evaluation programs,
T3
d)
3
(0
m
ω
E
II
α>
η
co
c
σι
M\
Present in a c+a c+a
the sample: analyte component
(positive)
nonspecificity interference
i 1
o
E
§ °
o
2co -1
ω
υ
ι
-3
REFERENCES
Barnett, R.N. and Youden, W.J.: A revised scheme for the com-
Darison of quantitative methods. Amer. J. Clin. Pathol.
'54: 454-462, 197o.
Baselt, R.C., Wright, J.A. and Carvey, R.H.: Therapeutic and
toxic concentrations of more than 1oo toxicologically
significant drugs in blood, plasma or serum: a tabulation.
Clin. Chem. 21: 46-62, 1975.
Broughton, P.M.C., Gowenlock, A.H., Mac Cormack, J.J. and
Neill, D.W.: A revised scheme for the evaluation of auto-
matic instruments for use in clinical chemistry. Ann.
clin. Biochem. 11: 2o7-218, 1974.
Büttner, J., Borth, R., Boutwell, J.H., Broughton, P.M.G. and
Bowyer, R.C.: Provisional recommendation on quality con-
trol in clinical chemistry. Part 2. Assessment of ana-
lytical methods for routine use. J. Clin. Chem. Clin.
Biochem. 14: 265-275, 1976.
BUttner, J., Rommel, K., Stamm, D. und Wisser, H.: Charakteri-
sierung der fachgerechten klinisch-chemischen Unter-
suchung. Dt. Ges. f. Klin. Chem. e. V. - Mitteilungen 9:
244-248, 1978.
Haeckel, R.: The use of aldehyde dehydrogenase to determine
H_0--producing reactions. J. Clin. Chem. Clin. Biochem.
14: 1o1-1o7, 1976.
Haeckel, R., Sonntag, 0., KUlpmann, W.R. and Feldmann, U.:
Comparison of 9 methods for the determination of cho-
lesterol. J. Clin. Chem. Clin. Biochem. 17: 553-563, 1979.
Haeckel, R. und Sonntag, 0.: Ektachem, ein neues Analvsen-
system. GIT Labor-Medizin 2: 317-327, 1979.
Haeckel, R. : Statistische Probleme beim Vergleich von klinisch-
chemischen Analysenverfahren. J. Clin. Chem. Clin. Bio-
chem, 198o, in press.
Mathies, H., Stähler, F., Wittner, H. und Vollmar, H.: Beein-
flussung eines neuen enzymatischen Harnsäure-Farbtestes
durch Pharmaka in vitro und in vivo. Med. Klin. 69: 6o7-
612; 1974.
Pentz, R., Strubelt, 0. und Gehlhoff, C : Theraoeutische,
toxische und lethale Arzneimittelkonzentrationen im
menschlichen Plasma. Dt. Ärzteblatt 43: 2815-282o, 1979.
Schulz, V. und Gross, R.: Therapie mit nichtsteroidalen Anti-
phlogista. Dt. Xrzteblatt 43: 2821-2828, 1979.
Stamm, D.: Recommendations for the description of a Selected
Method. J. Clin. Chem. Clin. Biochem. 17: 28o-282, 1979.
Stähler, F., Münz, E. und Kattermann, R.: Enzymatische Be-
stimmung von Gesamt-Cholesterin im Serum. Dt. Med. Wschr.
1oo: 876-887, 1975.
Winek, Ch.L.: Tabulation of therapeutic, toxic and lethal con-
centrations of drugs and chemicals in blood. Clin. Chem.
22: 832-836, 1976.
66
Aldosteronantagonists
spironolactonum Aldaktone 5o 1» 2
Analgestics/antirheumatics
pethidinum DoIantin 3ο 3, 4
levomethadonum LPolamidon 16,7 3, 5
Hoechst
phenylbutazonum Butazolidin 4οο 3, 6
oxyphenbutazonum Tanderil 6οο 7
acidum acetylo Aspirin 5οο 3, 8
salicylicum Colfarit
acidum niflumi Actol 45 9
nicum
Indometacinum Amuno 4ο 3, 1ο
naproxenum Proxen 2ο7ο 11, 12
Dpenicillaminum Metalcaptase 55 13
paracetamolum Benuron 15ο 3,14,15
glafeninum Glifanan 3οο 16
azapropazondi Prolixan 625 17,18
hydrat
Antiallergics
antazolinum Antistin 25 19
Antibiotics
gentamycinum Refobacin 11ο 2ο,21
cephalexinum Ceporexin 3οο 22,23,24
cefazolinum Gramaxiη 148ο 25,26
chloramphenicolum Paraxin 1οο 3,27,28
67
Antidiabetics
tolbutamidum Rastinon 5oo 3,35,36
Antiepileptics
acidum phenyl Luminal 60 3,37,38
aethylbarbi
turicum
acidum valpro Orfiril 5oo 3,39,4o,41
inicum
phenytoinum Phenhydan 5o 3,42,43,44
Carbamazepinum Tegretal 25 3,45
Antihypertonics
dihydralazinum Nepresol 11,5 46,47,48
methyldopa Sembrina 1o9 49,5o
Anticoagulantics
phenprocoumonum Marcumar 26 51,52
Nacitrabe Nacitrate 5 000 53
Naheparinat Liquemin 75o 53
Nafluoride Nafluoride 2 000 53
Naoxalate Naoxalate 3ooo 53
EDTA Titriplex III I000 53
BronchosDasmolytics
theophyllin Euphyllin loo 3,54
monohydrat Solosin
68
Cortocoides
predni solonum SoluDecortin 36 55
Diagnostics
acidum triiod Angiografin 6II00 56,57
benzoicum
adipinyltriiod Biligrafin 6000 58
anilidum
Diuretics
furosemidum Lasix 3o 59
Immun suppressiva
azathioprinum Imurek 1o 65
Plasmaexpander
dextranum 6 % Macrodex 6 % 8125o 66,67,68
Lipidlowering agents
clofibratum C
Dura lofibrat 378,5 69
Psychopharmaca
doxepinum Aponal 1o 3,7o
chlordiazepoxidum Librium 2o 3,71,72
69
Ι. Ν. Ν. example for maximal reference
trade pre plasma
parations concen
tration
mg/1
Chemotherapeutics
Antituberculostacis
isoniazidum Neoteben 1oo 75
Vitamins
Vitamin Β complex Polybion 8oo 76
acidum ascorbicum Cebion 235 77,78
Cytostatics
eyelophosphamidum En do χ an 452 79
acidum methyl Methotrexat 5oo 3,8o,
pteroylgluta
minicum
References to table 2
1. Sadée, W., Schröder, R.f von Leitner, E. and Dagciolu, M. :
Eur. J. clin. Pharmacol. 7: 1952oo, 1974.
2. Sponer, G., Kaufmann, Β. und Kuhr, M.: Krankenhausarzt 49:
569575, 1976.
3. Pentz. R., Strubelt, O. und Gehlhoff, C: Deutsches Xrzte
blatt 43: 2815282o, 1979.
4. Fochtmann, F.W. and Winek, C.L.: J. Forensic. Sci. 14: 213
218, 1969.
5. Olson, G.D.: Science 176: 525526, 1972.
6. Dieterle, W., Faigle, J.W., Mary, H., Theobald, W., Alt, K.
0. and Richter, W.J.: Arzneim. Forsch. (Drug Res.) 26:
572577, 1976.
7. Jakob, R.: Zbl. Phlebol. 7: 162175, 1968.
8. Pütter, J.: Med. Welt 27: 13621365, 1976.
9. Vukovich, R.A. and Di Fazio, L.T.: Research and Develop
ment ZMA 62o, 1975.
10. Alvan, G., Orme, M., Bertilsson, L., Ekstrand, R. and
Palmer, L.: Clin. Pharmacol. Ther. 18: 364373, 1975.
11. Fredeli, E.W.: JAMA 238: 938, 1977.
12. Runkel, R., Chaplin, M.D., Sevelius, H., Ortega, E. and
Segre, E.: Clin. Pharmacol. Ther. 2o: 269277, 1976.
13. Patschke, K., Wegener, L·., Kaller, Η. und Horster, F.Α.:
Ζ. Rheumatol. 36: 961ο5, 1977.
14. Windorfer, Α. und Vogel, C: Klin. PSdiat. 188: 43o434,
1976.
15. Prescott, L.F.: Handbook of Exp. Pharm., Part III.
Chapter 67: 234257, 19751
16. Persönliche Mitteilungen, 1979, Fa. Albert Roussel.
17. Schatz, F., Adrian, R.W., Mixich, G., Molnarova, Μ.,
Relier, J. und Jahn, U.: Therapiewo. 2o: 39, 197o.
18. Klatt, L. und Koss, F.W.: Arzneim. Forsch. (Drug Res.) 23:
920921, 1973.
19. Blomguist, M. , Boström, K., Fri, CG . and Ryhage, R. : Ζ.
Rechtsmedizin 74: 31332ο, 1974.
2ο. Modr, Ζ. und Dvoracek, Κ.: Abstr. Papers 6: 48ο, 1969.
6. Int. Congr. Chemother., Tokio.
21. Nedden, R. : scripta medica merck 12: 1.. Aufl., 1975.
22. Griffith, R.S.: Int. J. clin. Pharm., Beiheft 2: 13o, 1969.
23. Meyers, B.R., Kaplan, Κ. and Weinstein, L.: Clin. Pharma
col. Ther. 1o: 8I08I6, 1969.
24. Marget, W.F. und SchmidtMende, H.: Theraoiewo. 26: 7oo9
7o12, 1976.
25. Vömel, w. und Hoffmann, R.: Infection 2, Suppl. 1: 4o48,
1974.
26. Naumann, P. und Rosin, H.: Internist 19: 664671, 1978.
27. Walter, A.M. und Heilmeyer, L.: Antibiotika Fibel, 2. Aufl.:
245, Thieme Stuttgart.
28. Betzien, G., persönliche Mitteilungen, 1969.
29. Griffith, R.S., Johnstone, D.M. and Smith, J.W.: Antibio
tics Annual, 496499, 19531954.
30. Träger, S.: Dissertation Gießen, 1973.
31. Pelz, K., Herdter, F. and Marcushen, M.: Therapiewo. 27:
85858591, 1977.
71
32. Dimmling, Th. und Vanderbeke, 0.: Med. Klin. 7o: 279285,
1975.
33. Reckendorf, H.K., Castringius, R. und Spinaler, H.: Med.
Welt 15: 816824, 1963.
34. Conklin, J. and Hollifield, R.: Clin. Chem. 12: 69o, 1966
35. Mohnike, G. und Wittenhagen, G.: Dtsch. med. Wschr. 82:
15561557, 1957.
36. Rupp, W., Dibbern, H.W., Hajdu, P., Ross, G. und Van der
Eist, E.: Dtsch. med. Wschr. 1oo: 69o695, 1975.
37. Vajdu, F., Williams, F.M., Davidson, S., Falconer, *.A. and
Breckenridge, Α.: Clin. Pharmacol. Ther. 15: 5976o3,
1974.
38. Schäfer, H., Reith, H., Jacobs, R. und Gabriel, K.H.:
Arzneim. Forsch. (Drug Res.) 27: 12151221, 1977.
39. Weinmann, H.M. und Windorfer, Α.: Fortschr. Med. 95: 2o59
2o63, 1977.
40. Loiseau, P., Brächet, A. and Henry, P.: Epileosia 16: 6o9,
1975.
41. Vree, T.B., Van der Kleijn, E. and KnoD, H.J.: J. Chroma
togr. 121: 15o, 1976.
42. Schmidt, D.t Akt. Neurol. 3: 18119o, 1976.
43. Painter, M.J., Pippenger, C., Mac Donald, H. and Pitlick,
W.: J. Pediat. 92: 315319, 1978.
44. Bock, G.W. and Sherwin, A. L.: Clin. Chim. Acta 34: 971o3,
1971.
45. Morselli, P.L. and Frigerio, Α.: Drug Metab. Rev. 4: 97
113, 1975.
46. Wagner, J., Faigle, J.W., Imhof, P. and Liehr, G.: Arzneim.
Forsch. (Drug Res.) 27: 23882395, 1977.
47. Talseth, T.: Clin. Pharmaco. 2: 317329, 1977.
48. Zak, S.B., Bartlett, M.F., Wagner, W.E., Gilleran, T.G.
and Lukas, G.t J. Pharm. Sci. 63: 225229, 1974.
49. Barnett, A.J., Bobik, Α., Carson, V., Korman, J.S. and Mc
Lean, A.J.: Clin. Exper. Pharmacol. Phys. 4i 331339,
1977.
50. Kwan, K.C., Foltz, E.L., Breault, G.O., Baer, J.E. and
Totaro, J.Α.: J. Pharmacol. Exp. Ther. 198: 264277,
1976.
51. Chriske, H.W., von Smekal, P., Knabe, M. and Kray, D.:
Med. Welt. 24: 162o1621, 1973.
52. Seiler, Κ. and Duckert, F.: Thromb. Diath. Haem. 19: 389
396, 1968.
53. Richterich, R. und Colombo, J.P.: Klinische Chemie, 4. Aufl.
1978, Karger Verlag, Basel.
54. Syva Monitor 1, 1978.
55. Hsueh, W.A., PazGuevara, A. and Bledsoe, T.: J. Clin. Endo
crinol. Metab. 48: 748752, 1979.
56. Kutzner, J. und Van de Weyer, K.H.: Fortschr. Röntgenstr.
114: 7484, 1971.
57. Schiungbaum, W.: Röfö 96: 7958o6, 1962.
58. Mostbeck, Α., Peschi, L. und Sooner, D.: Wien. Klin.Wschr.
88: 627630, 1976.
59. Neuhaus, G.: In: Medikamentöse Therapie bei Nierenerkran
kungen. 4. Freiburger Tagung über Fortschritte der
Nephrologie, 197o. Hrsg. R. Kluthe, Thieme Verlag
Stuttgart 1971, 2o7.
72
Roman Gallmany
Clinical Chemistry Department, C S . Principes España
Hospitalet de Llobregat, Barcelona, SPAIN
ABSTRACT
The effect of a group of anti-inflamatory drugs of anti-rheumatic
action is studied upon the twenty analytic tests most frequently requested
in a laboratory. In the in vitro study, significant interferences are
appreciated, produced by therapeutic doses of D-Penicillamine (Alkaline
Phosphatase and Urate), Chloroquine (Phosphate and LDH), Dexamethasone
(Creatinine) and Methylprednisolone (Phosphate); there are no significant
interferences produced by Phenylbutazone, Oxyphenbutazone, Indomethacine
and Sodium Aurothiomalate in therapeutic doses.
INTRODUCTION
In spite of the disparity in the chemical structure of the antiinfla-
matory non steroid drugs, they all have a series of common characteristics
based on the similarity of their pharmacokinetics properties. In Table I
the values of absoption, metabolism and renal elimination of these drugs
are shown. The most important common characteristics of this group are :
1) high oral absorption 2) high degree of binding to plasmatic proteins
and 3) preferent hepatic metabolism. Due to this, the basic form of admi -
nistration is oral, limited only by the digestive toxicity inherent to these
compoounds.(Champion, et al., 1978)
The binding to plasmatic proteins is between 50 and 99 %. These are
capable of displacing other pharmacos from the places of binding to the
albumin, increasing in this way their free from and their pharmacological
activity. The drugs that are the most frequently displaced are the dicou -
marinics, sulfonylureas, glucocorticoids, diphenilhydantoine, sulfonamides
and tyroxine. There is also competition between themselves, which would
explain that the joint administration of aspirin with indomethacine or
phenoprophen reduces the half-life of these and increases the elimination
of their metabolites.
Acetylsal ic yl ic
acid derivatives 70 40-70 0.2-0.3 97 1-3
Phenylbutazone
derivatives 70 - 80 98-99 48-72 94 1-3
Indoles
derivatives 80 90-99 6-10 97 10-20
Phenylacetic
acid derivatives 85 95-99 8-10 97 2-10
Arylalcanoic
acid derivatives 70 99-100 3 90 1-2
Antranilic
acid derivatives 70 90 4 90 10
76
of the antiinflamatory drugs.
As a concequence of the metabolism of these compounds by the liver,
the amount of unmodified drug eliminated through the urine is less than
15 %, except for high dosages of salicylates and sulphide of sulindac. The
biliary excretion of the metabolites varies between 2 and 50 %, being spe -
cially pronounced for phenylbutazone, indomethacine, Ibuprofen, flutenamic
acid, sulindac, dyclophenac and alclophenac.
The majority of corticosteroids are used systematically as antiinfla -
matory agents (cortisone, hydrocortisone, prednisone, prednisolone, dexame-
thasone and triancinolone) and rapidly absorbed by gastric or cutaneous
routes; ordinarily they have a circulating half-life of 1 to 3 hours and
the maximal biological effect is reached between 2 and 8 hours after admi -
nistration. These compounds are metabolized and conjugated by the liver
before being eliminated.
The increased use of these drugs in clinical therapeutics, their ele-
vated toxicity and secondary effects, with serious pharmacological altera -
tions, confront us with a serious problem : to what an extent do they in -
terfere with our analytic methods and cause an alteration of their results?
In this work we study the effects of these drugs over the twenty test most
frequently requested in our laboratory. We present an study "in vitro"
with the intention of discovering the chemical interferences that the drugs
can provoque on the analytic method we use.
MATERIALS AND METHODS
Cholesterol Lieberman-Burchard.
lues of Urate (137% over 295 umol/1 and 57% over 471 umol/1) and Creatine
Kinase (20% over 685 U/l and 15% over 77 Ü/1).
b) Chloroquine : increase the values of Phsophate, going beyond the
lineality of the analytic method in the three plasmatic levels studied, and
Urate (5% over 270 umol/1 and 2.25% over 487 umol/1) and an inhibition in
Lactate dehydrogenase (56% over 227 U/l and 33% over 431 U/l).
c) Dexamethasone : increase the values of Creatinine, going beyond the
linality of the analytic method, and Creatine Kinase (24% over 400 U/l and
19% over 685 U/l) and inhibition in Urate (9.5% over 294 umol/1 and 6.8%
over 471 umol/1).
d) Methylprednisolone (sodium succinate) : increase the values of
Phosphate in the two plasmatic levels studied (233% over 0.90 mmol/1 and
107% over 1.82 mmol/1).
The results obtained when adding decreasing concentrations of a drug
to a series of samples belonging to a same pool are presented in figures
1 to 4. Upon the vertical scale we represent the percent of variation
(increase or decrease) of a certain test, with relation to its real value,
prior to the addition of the drug, and the horizontal scale the concentration
of drug that produces this variation.
For the D-Penicillamine (fig. 1) we observed an increasing inhibition
of the Alkaline Phosphatase from a concentration of drug of 0.01 mg/ml to
0.5 mg/ml in which the inhibition became total. For the Glucose, the inter -
ference is accentuated starting at a concentration of 1 mg/ml. Urate values
increased after 0.5 mg/ml of drug concentration in serum.
With the addition of Chloroquine (fig. 2) we observe a lineal increase
of the measured levels of Phosphate for a concentration renging from 0.009
mg/ml to 0.30 mg/ml; after 0.45 mg/ml of drug by ml of serum, the increase
goes beyond the lineality of the method. The Lactate dehydrogenase suffers
lineal inhibition at concentration of 0.09 mg/ml or above.
' We observed that Dexamethasone (fig. 3) provoked an increase of the
measured levels of Creatinine above a drug concentration of 0.4 ug/ml
where it goes above the lineality of the method. The interference it pro -
duces in the measurement of Urate is insignificant.
Methylprednisolone produced a strong increase in the meesured levels
of Phosphate (fig. 4 ) , studied using sera containing Phosphate a two
different levels. The variation that corresponds to the lower level is
double of the one that corresponds to the higher level, for an equal amount
81
Varia· Ion
°/o Variation
ί O.OO0 I O J t 0.3O O«
¡t
* eoo
Ι Craatln
•—»Ural·
./ DaXnMaTHASONB
♦ ÌOO /
* SO
O
ΙΟ
ri 1—ι
o.« » «o l a »o so
f almi
Λ» variation
MBTHVLPaiONISOLONI
«οοι
·—a i . i l
1 Η
O. SS—11
O.· l.tO 2.SO1 8
Do··
FIO. 8
82
REFERENCES
Champion, D.G. and Graham, G.G.: Pharmacokinatics of non-steroidal anti-
inflamatory agents. Aust. N. Z. J. Med. 8 (1): 94-103, 1978
Galimany, R., Alsina, M.J. y Fernandez Simo, E.: Two years of experience
and evaluation of the SMAC. International Congress of Clinical Che-
mistry. Mexico, 1978.
Schwartz, M.K., Bethune, V.G., Pennachia, G., Menendez-Botet,C.J., and
Lehman, D.: Chemical and Clinical evaluation of the SMAC. Clin. Chem.,
20 (8): 1062-1070, 1974.
Westgard, J.O., Carey, R.N., Feldbruegge, D.H., and Jenkins, L.M.: Perfor-
mance studies on the Technicon "SMAC" Analyzer: Precision and compa-
rison of values with methods in rutine laboratory service. Clin.
Chem., 22 (4) : 489-496, 1976.
DRUG EFFECTS ON LABORATORY TESTS
DRUG EFFECTS O N LABORATORY TESTS: URIC ACID
J.G. Salway
ABSTRACT
No. of references
SERUM URATE: Decrease 70
" Increase 153
TOTAL 223
86
Because successful clinicians practise medicine without knowledge of most
of this i n f o r m a t i o n , the opinion is sometimes stated that drugs do not seriously
i n t e r f e r e w i t h the interpretation of serum urate results. I t is very d i f f i c u l t to
argue w i t h this opinion. Examples of cases where drug interference w i t h a test
had not been recognised are usually anecdotal and, not surprisingly, are rarely
(and never to my knowledge overtly) published. Occasionally, however, cases are
published as illustrated by the following examples:
Case 1
Bailey, et a l . (1976) described a female patient w i t h polycystic kidneys,
hypertension and chronic renal failure who developed gout (plasma urate 0.B6
mmol/1). She was treated w i t h frusemide and alprenolol. When allopurinol and
colchicine were added she developed an a r t e r i t i s as an unusual side-effect of the
allopurinol; this important observation was the subject of their communication.
However, i f the hyperuricaemic e f f e c t of frusemide (Humphreys, 1966; McSherry,
1968; Keyes, et a l . , 1968; Muth, 1968) had been drawn to the attention of these
physicians, then the above sequence of events, and subsequent adverse reaction t o
allopurinol might have been avoided. Hyperuricaemia is frequently associated
w i t h renal failure, but these patients do not usually develop gout. However,
frusemide is a potent hyperuricaemic agent and long-term maintenance therapy
w i t h frusemide may increase the serum urate by as much as 0.25 mmol/1 and w i l l
precipitate gout. I t is possible t h a t the patient would have benefited had
frusemide been replaced w i t h a diuretic not having a hyperuricaemic effect.
Allopurinol might then have been unnecessary, and the a r t e r i t i s would have been
avoided, Salway (1976).
Case 2
Keyes, et a l . (1968) made a detailed study of the e f f e c t of frusemide on
serum urate concentrations. They recorded the f a c t that one of their patients
was also receiving anticoagulants and aminophylline. However, they failed to
acknowledge that Christeinsen (1964) had reported anticoagulants sometimes have
a uricosuric e f f e c t and could possibly have a f f e c t e d the interpretation of their
results. Moreover, shortly afterwards i t was reported that aminophylline can also
interfere w i t h the interpretation of serum urate results (Paulus, et a l . , 1970).
Subsequent work in many laboratories has confirmed the hyperuricaemic e f f e c t of
frusemide. Nevertheless, i t is paradoxical that a paper reporting a drug e f f e c t
was itself vulnerable to drug interference.
87
Casual inspection of Table 1 indicates the extent of knowledge of drug
interference with serum urate investigations. Coverage of all of these drug-
effects Is beyond the scope of this review. Some idea of the complexity of the
subject is revealed by examining the literature on the apparently simple subject of
paracetamol interference with serum urate determinations.
Urate Paracetamol
mmol/1 mg/100 ml
Day 1 1.84 15
0.43 Undetectable
" 3 0.30 -
•ι n 0.24 _
Patient took 20 Panadol tablets plus a few tablets of bromide and diazepam.
88
practice in that five different wetting agents were used by these laboratories. It
is possible that such details as the nature of the wetting agent could occasionally
be responsible for some of the analytical discrepancies and such minutiae are
rarely mentioned in accounts of experimental details.
Clearly, the problem of drug interference with clinical laboratory
investigations in general is an enormous one. Collaboration between members of
the medical and paramedical professions in collaboration with the pharmaceutical
and diagnostic industries is needed. Our objective should be to identify the most
important effects caused by drugs on laboratory investigation and devise simple
and effective means of communicating this information to the clinician.
REFERENCES
Bailey, R.R., Neale, T.J. and Lynn, K.L., 1976. Allopurinol-associated Arteritis.
The Lancet, ii: 907.
Carey, M.A., Jones, J.D. and G ustineau, C F . , 1971. Effect of Moderate Alcohol
Intake on Blood Chemistry Values. JAMA, 216: 1766-1769.
Christensen, F., 1964. Uricosuric effect of Dicoumarol. Acta Medica. Scand.,
175: 461-468.
Demartini, F.E., 1965. Hyperuricemia Induced by Drugs. Arthritis and
Rheumatism, 8: 823-829.
Gill, C R . , 1966. Iatrogenic G out. J. Kentucky Med. Assoc, 64: 411-417.
Humphreys, D.M., 1966. Acute G out apparently precipitated by Frusemide. Brit.
Med. J., 1: 1024.
Kelley, W.N., 1975. Effects of Drugs on Uric Acid in Man. Ann. Rev.
Pharmacol., 15: 327-350.
Keyes, M.H. and Belle, M.S., 1968. Long-term Maintenance Therapy with a new
Diuretic Furosemide. J. Florida, M.A., 55: 524.
Krakoff, I.H., 1966. Clinical Pharmacology of Drugs which influence Uric Acid
Production and Excretion. Clin. Pharmacol. Ther., 8: 124-138.
Lieber, C S . , Jones, D.P., Losowsky, M.S. and Davidson, C S . , 1962. J. Clin.
Invest., 4 1 : 1B63.
McSherry, J . , 1968. Acute G out complicating Frusemide Therapy. Practitioner,
201: 809.
Munan, L., Kelly, A. and Petitclerc, C , 1976. Am. J. Epidemiol., 103: 369-382.
Muth, R.G ., 1968. Diuretic properties of Furosemide in Renal Disease. Ann. Int.
Med., 69: 249.
Paulus, H.E., Coutts, Α., Calabro, J.J. and Klinenberg, J.R., 1970. Clinical
Significance of Hyperuricemia in routinely screened hospitalized men.
JAMA, 211: 277-281.
Saker, B.M., Toiler, O.B., Burvill, M.J. and Reilly, K.A., 1967. Alcohol
Consumption and Gout. Med. J. Aust., 1:1213-1216.
Salway, J.G ., 1976. Allopurinol-associated arteritis. The Lancet, i i : 1255.
Salway, J.G ., 1978. Drug interference causing misinterpretation of laboratory
results: How to solve the problem? Ann. Clin. Biochem., 15: 44-48.
Salway, J.G ., 1979. Factors causing misinterpretation of laboratory
investigations. Prescriben' J . , 19: 23-28.
90
Singh, H.P ., Hebert, M.A. and Gau I t , M.Η., 1972. E f f e c t of Some Drugs on
C l i n i c a l Laboratory Values as Determined by the Technicon SMA 12/60.
C l i n . Chem., 18: 137-144.
Smith, M. and P ayne, R.B., 1979. Re-examination of e f f e c t of P aracetamol on
Serum U r i c A c i d Measured by P hosphontungstic A c i d Reduction. Ann. C l i n .
Biochem., 16: 96-99.
Wilding, P . and Heath, D.A., 1975. E f f e c t of P aracetamol on U r i c A c i d
D e t e r m i n a t i o n . Ann. c l i n . Biochem., 12: 142-144.
Young, D.S., P estaner, L.C. and Gibberman, V., 1975. Effects of Drugs on
C l i n i c a l Laboratory Tests. C l i n . Chem., 2 1 : 1D-432D.
EFFECTS OF DRUGS ON TOTAL SERUM CHOLESTEROL
ABSTRACT
Both chemical and pharmacological effects of drugs on total serum cho-
lesterol are considered. In none of the determination methodologies used
(Liebermann-Burchard, iron salts and enzymatic) have more than a few drugs
been reported to interfere chemically in cholesterol determination. Never-
theless, investigations intended to detect and classify this type of inter-
ference are frequently incomplete, especially in so far as enzymatic metho-
delogies are concerned, and these will, in the future, progressively re-
place traditional colorimetrie procedures.
On the other hand, drugs likely to increase or decrease the serum cho-
lesterol level through a pharmacological or toxicological effect are nume-
rous and may be classified into various (chemical) categories. The inter-
pretation of these interferences is often difficult. For a large number of
drugs, further investigations are necessary.
INTRODUCTION
The effects of drugs on serum cholesterol have been classified in ma-
jor studies of the effects of drugs on clinical laboratory tests. (Caraway
and Kammeyer, 1972 ; Constantino and Kabat, 1973 ; Young et al., 1975 ;
Hansten, 1979). These effects are of two kinds : pharmacological and chemi-
cal (analytical interference). Both will be considered in turn. However,
where analytical interferences are concerned it is necessary to consider
the methodology used. A brief preliminary reminder of the most widely used
cholesterol determination methodologies is therefore in order.
I - PRINCIPAL METHODOLOGIES OF CHOLESTEROL DETERMINATION
A large number of methodologies for cholesterol determination have
been described (Peynet and Chappuis, 1976 ; Zak, 1977). All make use of an
oxidizing agent which may be either chemical or enzymatic. Three major groups
of methods may be distinguished according to the nature of the reagent.
Colorimetrie methodologies based on the Liebermann-Burchard reaction.
This reaction results in a green coloration, classically measured at 630 run.
This may be. reacted directly with serum, or after various preliminary pro-
cedures (eg. the extraction of lipids, the saponification of cholesterol
esters) designed to produce more specific results.
Colorimetrie methodologies based on the use of iron salts in acid me-
92
diurn (The Zlatkis, Zak and Boyle procedure). A violet coloration occurs
and is read at 550 am. As with the method above, this may, or may not, be
reacted directly with serum.
Enzymatic methodologies.
After denaturation of serum lipoproteins, cholesterol esters are hydro-
lised by a cholesterol hydrolase. In the presence of molecular oxygen the
non-esterified cholesterol is oxidized by the cholesterol oxidase into cho-
lest-4-en-3-one, with formation of hydrogen peroxide.
Several procedures have been proposed as final reactions : for example,
(1) amperometric measurement of oxygen consumed, or (2) measurement of the
hydrogen peroxide produced, by means of an enzymatic coupled reaction (pe-
roxidase or catalase) resulting in a colored or flourescent compound.
TABLE 1 - ENZYMATIC MEASUREMENT OF CHOLESTEROL. MEASUREMENT OF HYDROGEN
PEROXIDE.
Indicator HO H H H
2°2 2°2 2°2
reaction + + +
+
4 amino homovanillic methanol
reduced
antipyrine acid
A.B.T.S.
Phenol
„xx
Enzymatic No interference
Trinder's reaction
ABA. J00
Β Results
Table III summarises analytical interferences recorded for the three
major groups of cholesterol determination methodologies.
The number of such drugs is relatively low.
LiebermannBurchard reaction
In the basic procedures of this reaction only one analytical interfe
rence has, as far as we know, been described : that of Amphotericin Β
(Singh et al., J972) at a concentration of J mmol/liter.
Systematic investigations intended to research the influence of drugs
in vitro on the most widely used biochemical tests, have in fact shown that
a large number of drugs had no effect on the LiebermannBurchard reaction.
(Singh lit al., J972 ; O'Kell et al., 1972a, 1972b ; Young and Panek, Ί976).
Ironsalts acid
Here we encounter the greatest number of interferences. There has been
O'Kell, R.T., Mantzey, L., Knepper, D.F., Elliot, J.R., 1972a. Intravenous
vitamins and clinical laboratory tests. Clin. Chem., 18; 403404.
O'Kell, R.T., Mantzey, L., Knepper, D.F., Elliot, J.R., 1972b. Effect of
drugs on results of laboratory tests. Clin. Chem., 18: 1039.
Pesce, Μ.Α., Bodourian, S.H., 1976. Enzymatic rate method for measuring
cholesterol in serum. Clin. Chem., 22: 20422044.
Pesce, Μ.Α., Bodourian, S.H., 1977. Interference with the enzymic measure
ment of cholesterol in serum by use of five reagent kits. Clin. Chem,
23: 757760.
Peynet, J., C happuis, P., 1976. Dosage du cholestérol : Problèmes actuels
de biochimie appliquée, 8ème série, lipides, lipoprotéines et athéro
sclérose p. 4760 (Hasson, Paris).
Robinson, CA . , Hall, Jr.L.M., Vasiliades, J., 1976. Evaluation of an enzy
matic cholesterol method. Clin. Chem., 22: 1542J543.
Singh, H.P., Hebert, M.A., Gault, M.H., 1972. Effect of some drugs on cli
nical laboratory values as determined by the Technicon SMA J2/60.
Clin. Chem., 18: 137144.
Stern, M.P., Kolterman, O.G., Fries, J.F., Mc Devitt, H.O., Reaven, G.M.,
Alto, P., 1973. Adrenocortical steroid treatment of rheumatic diseases.
Arch. Intern. Med., J32: 97101.
Young, D.S., Pestaner, L.C. and Gibberman, V., 1975. Effects of drugs on
clinical laboratory tests. Clin. Chem., 2J: 1D42JD.
Young, D.S., Panek, E., 1976. Effects of drugs on the analytical procedures
of a Multitest analyser. Drug interference and drug measurement in
clinical chemistry. Proc. 3rd Int. Cell, or Prospective Biology, Pont
ãMousson, p. 1020 (Karger, Basel).
Zak, B., 1977. Cholesterol methodologies. A review Clin. Chem., 23: 1201
12J4.
DRUG EFFECTS ON CHOLESTEROL PLA SMA LIPOPROTEINS FRA CTIONS
ABSTRACT
Only the phoAmacological erecţi o¿ dmigi on cholutenol pla&ma lipo-
pn.otíÀni we/ie investigated. I t iA eaential to moniton, in the coufi&e
0(J a tAeatment, the. ¿,vum lévelo o& ¿oui denbity lipopnotein-choluteAol
(LOLC) in negând to the highly positive connelation demonitnated betaeen
thitt inaction and athenoiclenoiii, the. majon caiue oA ¿ie.ha.emie. heant
duea&e (ItfP). Similan attention ¿hould be paid to the variation* in
high density lipopnotein-choleitenol (HPL C ) known to be negatively conne-
lated with athenoiclenoiii.
The phanmacological e¿]ect¿ oi the fallowing dnugò wene canefally
studied : honmonei, lipid lowening agenti, anti-diabetici, anti-hypen-
tensivei and ml&cellaneoui compound* togethen with the fallowing toxic-
agenti : pesticide* and alcohol.
INTRODUCTION
The literature to date provides very l i t t l e data on analytical
Interferences that may cause disturbances in the separation of plasma
lipoproteins. In addition, a large number of methods are available
(ultracentr1fugat1on, electrophoresis, polyanion or concanavalin A
precip1tat1on) with their Interferences adding to those encountered in
the determination of cholesterol. These methods are treated elsewhere
(Delattre et a l . , 1979).
Atherosclerosis is characterized histologically by the accumulation
of l i p i d s , predominantly cholesterol, in the arterial wall together
with a connective tissue reaction (Adams, 1973). A wide variety of
epidemiologic data indicates that individual lipoproteins or combinations
of lipids and apolipoprotelns are better predictors of coronary artery
disease (CAD ), a major cause of IHD , than are levels total cholesterol
(TC) or triglycerides (TG). Of the four basic classes of lipoproteins"
1n human serum, three promote and one retards the development of CAD :
low density lipoproteins (LD L) and low density lipoproteins cholesterol
(LDLC) is a strongly positive risk factor, particularly at younger ages
100
1 - HORMONES
130
•
•
•
··
120 ^ ··
• J ' s 0.76
Ρ < 0.001
•
110
•
1
I
30 40 50 60 70 80
HDLC (mg/dl)
1.2. Androgens
Androgens lower plasma HDLC (Solyom, 1972 ; Freeman et al . , 1977 ;
Masarel et a l . , 1977). In f a c t , women with idiopathic hirsutism and
elevated levels of free or total plasma testosterone have somewhat lower
plasma HDLC than hirsute women with normal total or free plasma testos
terone (Witztum et a l . , 1979b).
Furthermore, the treatment with oxandrolone in patients with type
IIA, IIb and IV HLP Induced a significant reduction in VLDLTG and HDLC :
hypo HDLC occurred in 7/10 patients with type IV, 3/6 with type I I B ,
1/4 with type IIA. Reciprocal elevation of LDLC in 8/10 patients with
type IV and 1n 2/5 with type IIB was observed (Tamai et a l . , 1979a).
On the other hand, in rats, oxandrolone induced a significant decrease
of both LDLC and HDLC ; VLDLC was not affected while LDLPL (phospho
l i p i d s ) , HDLPL, LDLTG and HDLTG were also altered by the drug ( Freeman
et a l . , 1977).
1.3. Thyroxine
In patients with primary hypothyroidism and treated with thyroxine,
LDLC fell to normal but no significant change occurred in the mean
VLDLC or HDLC (Ballantyne et al., 1979 ) .
104
2 HYPOLIPIDEMIC A GENTS
HDLC IIA = or + + or = = or
(or HS)
IIB = or + or = + or HS = or
III *
IV * * + or HS
V + + +
LDLC IIA
IIB " ~ ~ ~
III _
IV + +
V +
VLDLC IIA ♦
IIB — ~ ♦ ~
III _
IV +
~ ~ ~
'
8
106
1977a ; Arntz et al., 1979). In faet ,the effect on LDL-C was dependent
on the LDL-C (i.) levels. A decrease was noted if the LDL-C (i.) was
above approximately 4.00 mmole/1. At lower initial concentrations, LDL-C
(a.t.) most often increased (see fig.2). The question of a bezafibrate-
induced increment in HDL-C needs further study to resolve conflicting
reports : in thair first report, Olsson et al., 1977a, did not find in-
creases of HDL-C in type II or type IV HLP after Bezafibrate treatment.
Subsequent reports (Olsson et al., 1977b, 1977c, 1978a, 1978b) revealed
that Bezafibrate increased serum HDL-C levels in the range of 20-30 %.
But Wechsler et al., 1977a, 1977b, were not able to demonstrate such
effects.
HDL-C increase was independant of VLDL-TG decrease and there were no
correlations between HDL-C (i.) and its increase or between the decrease
of HDL-TG and increase of HDL-C ; however, a significant relationship
was found between the HDL-TG (i.) and HDL-C (a.t.) rise (Olsson et al.,
1978a). Furthermore, the increases of HDL-C in type IV or V HLP were
less pronounced after six months (+ 9,4 %) than after two months
(+ 15,4 %) (Weisweiler et al., 1979).
2.1.3. Clofibrate (*) and related compounds (**)
(") éthyl ester of c l o f i b r i c acid ( 2 - ( 4 ' - chlorophenoxy)-2 methyl
propionic).
(-") c l o f i b r i d e , e t o f i b r a t e , aluminium or calcium or magnesium salts
of c l o f i b r i c acid.
Even though Clofibrate i s the most widely used ( f o r review see Witiak
et a l . , 1977) and one of the f i r s t developed l i p i d lowering drugs,
u r p r i s i n g l y few studies have appeared on the e f f e c t of t h i s compound on
cholesterol serum lipoproteins either i n experimental animals or in man.
In r a t s , Clofibrate at 200 mg/Kg/day reduced VLDL-C, LDL-C and HDL-C
by 20,22 and 41 %, respectively (Muller, 1977). In normal baboons LDL-C
i s increased by about 50 % at 50 mg/kg and HDL-C i s decreased by appro-
ximately 30 % at 200 mg/kg (Howard et a l . , 1977a).
In man, on type IIA HLP, t h i s drug led to a non-significant decrease
of LDL-C (Rössner et a l . , 1978b) on type I I B HLP to a s i g n i f i c a n t
decrease of VLDL-TG and to a non s i g n i f i c a n t decrease of LDL-C (- 9,6 %)
(Strisower et a l . , 1968 , Rose et a l . , 1976) but on type'lV HLP, i f
Clofibrate led to a highly s i g n i f i c a n t decrease of VLDL-TG, numerous
107
gemfibrozil ; r s 051
·*bezafIbrat·¡ r a 0 . 7 3
2.1.4. Fenofibrate
Isopropyl ester of 2-[ 4-(4-chlorobenzoyl)phenoxy ] -2 methyl propionic
acid.
This new l i p o p r o t e i n modifying agent produces a more favorable e f f e c t
on serum lipoproteins i n man than any agent reported to date.
On d i e t a r y cholesterol r a t serum l i p o p r o t e i n s . Fenofibrate led to a
marked decrease of VLDL-C concomitantly with an increase of HDL-C to
a s i m i l a r degree (Wulfert, 1978).
Rössner e t a l . , 1977 a, 1977b, 1978b, compared Fenofibrate with
C l o f i b r a t e , Bezafibrate and Gemfibrozil in type I I and type IV patients
and found t h a t i t caused a 57 % decrease i n VLDL-TG in type IV, a 37 %
decrease i n LDL-C in type I I (27 % with Bezafibrate, 18 % with Gemfibrozil)
and a 14 % increase i n HDL-C i n type IV. These overall effects were better
than those of any of the other drugs that i t was compared w i t h . These
findings were confirmed l a t e r (Micheli et a l , 1979). In patients with
HLP type I I A , who are treated with Fenofibrate at a dosage of 100 mg,
the high reduction of plasma TC was due not only to a decrease in LDL-C
(-35 %), as expressed by a marked reduction of apo B, but also to a
decrease in VLDL-C, as reflected from a marked reduction i n plasma VLDL-TG
(-50 %). Furthermore, the same authors observed an increase of HDL-C, as
expressed by a marked increase (28 %) of apo A. The same results were
folind with type IIB (VLDL-TG : -40 %, LDL-C : - 32 %). A l l these variations
are highly s i g n i f i c a n t (p< 0.001) and they do not appear to change in
patients who were followed f o r 3 months (Lauwers, 1979). Furthermore,
Colestipol plus Fenofibrate, association used i n severe type I I HLP,
produced greater reductions i n cholesterol levels than Fenofibrate alone
(Sauvanet e t a l . , 1977)
109
2.1.5. Gemfibrozil
2.2.-d1grethy1-5 (2.5.-xylyloxy)-valeric acid.
Although this drug was disclosed only recently, (Creger et a l , 1976 ;
Rodney et a l . , 1976) numerous studies have appeared concerning I t s effects
on serum lipoproteins 1n man (Howard et a l . , 1977b ; Olsson et a l . , 1976 ;
Vessby et a l . , 1976a, 1977a; Ei sal o et a l . , 1976a, 1976b ; NikkilS et a l . ,
1976 ; Janus et a l . , 1976 ; Bremner et a l , 1976 ; Howard et a l . , 1976 ;
Schwandt et a l . , 1979). Howard, 1977b, has summarized these studies.
Gemfibrozil led to a decrease of a l l lipoprotein TG fractions in a l l types
of HLP (VLDL-TG : - 29 t, ( H a ) , - 39 % ( I I b ) , - 57 % ( I I I ) , - 44 % (IV) ;
LDL-TG : - 23 %, - 37 %, - 38 %, - 22 % for the same types, respectively;
HDL-TG : - 25 % and - 23 9Í respectively in hypercholesterolemia (princi-
pally IIb) and hypertriglyceridaemia (especially I V ) . The most pronounced
decreases were found in conditions with VLDL elevation (types I I b , III
and IV). A significant correlation existed between the VLDL-TG ( i . ) levels
and the changes in VLDL-TG ( a . t . ) .
The decrease in serum TC was the net result of mean decreases in
VLDL-C (-69 % and - 49 % in hypercholesterolemia and hypertri glyceri-
daemi a respectively). The effect of Gemfibrozil on VLDL-C was essentially
similar to that on VLDL-TG except in type I I I where the VLDL-C decrease
was very pronounced.
LDL-C decreased - 22 % in type I I a and l i b or - 2 % (or slightly
increased) 1n type IV. In f a c t , in hypertri glyceridaemia, LDL-C levels did
not change significantly. HDL-C was always increased more strongly in
hypercholesterolemia ( + 21 t) than in hypertriglyceridaemia ( + 10 %).
For LDL-C, as for Clofibrate or Bezafibrate, there was a relationship
between LDL-C (1.) levels and the change in LDL-C ( a . t . ) concentrations.
110
2.4.3. Probucol
2.4.4. Ţiadenol
b1s1.10(2hydroxyethylthio)decane.
Ţiadenol treatment in patients with HLP (IIa) led to decreases of
both LDLC and HDLC by 23 % and 36 %, respectively, from basal concentra
tions after 4 months of drug therapy.
No effect on VLDLTG was found (Baggio et al, 1977).
2.4.5. βSitosterol
Recent studies demonstrated the efficacy of ßSitosterol, obtained
from t a l l o i l , in lowering plasma LDLC in patients with type I I HLP
(Lees et a l . , 1977). However, in children with familial hypercholeste
rolemia, ßSitosterol lowered LDLC by only 6 % and HDLC by 15 %. This
insufficient response for LDLC and the marked f a l l of HDLC appears to
advise against the use of this drug in juvenile type I I HLP (Schlierf
et a l , 1978).
2.4.6. Diosgenin
In cholesterolfed r a t s , Diosgenin produced a significantly greater
decrease in LDLC and increase in HDLC than either ßSitosterol or
Cholestyramine. LDLPL levels were also reduced, though to a lesser extent
than LDLC. There was no effect on TG. This agent inhibited cholesterol
absorption without altering bile acid turnover (Cayen et a l . , 1979).
The combination of Clofibrate and Diosgenin produced greater decreases
in LDLC than did either compound alone. Furthermore, the Diosgenin
induced elevation in HDLC was partially reversed by Clofibrate (Cayen
et a l , 1978).
2.4.7. Y:9738
Ethyl2(4chlorophenyl)5ethoxy4 oxazoleacetate.
In rats with experimental hyperßlipoproteinemia, this newly discovered
drug showed a dosedependent lowering effect on LDLC while an upward
trend was noted for HDLC (Kobayakawa et a l . , 1978).
3. ANTIDIABETICS
3.1. Insulin
Controversy exists about the e f f e c t of Insulin on HDL-C in man
(Nikkilä et a l . , 1977 ; Stalenhoef et a l . , 1978). However, several trends
are emerging. One i s that i n s u l i n - d e f i c i e n t diabetics have low HDL-C
levels ( N i k k i l ä , 1973, 1978a ; Schonfeld et a l , 1974 ; Bennion et a l , 1977)
and in large p a r t , the HDL-C returns towards normal with i n s u l i n . Such
patients have a s i g n i f i c a n t c o r r e l a t i o n between HDL-C and the i n i t i a l l y
subnormal levels of HDL-C ( N i k k i l ä , 1978a). Well-controlled I n s u l i n - r e q u i -
ring diabetics have elevated HDL-C levels and t h i s increase may represent
another argument f o r good diabetic control (Durrington, 1978 ; Nikkilä
et al , 1978b ; Calvert et a l . , 1978)
Furthermore, I n s u l i n treatment decreased LDL-C whereas HDL-C/LDL-C
r a t i o was increased. There was a negative c o r r e l a t i o n between i n i t i a l
VLDL-TG levels and changes of VLDL-TG with also a negative c o r r e l a t i o n
between VLDL-TG and HDL-C levels before treatment but not a f t e r treatment
(Tamai e t a l . , 1979b).
On other hand, i n maturity-onset diabetic patients several authors
(Lopes-Virelia e t a l . , 1977 ; N i k k i l ä , 1978a ; Kennedy et a l . , 1978 ;
El keles e t a l . , 1978) found decreases of HDL-C levels but only i f TG
or/and glucose concentrations were elevated. Furthermore, there was no
c o r r e l a t i o n between HDL-C and indices of diabetic c o n t r o l .
4. MISCELLANEOUS COMPOUNDS
4 . 1 . Antihypertensive drugs
Thiazides and betablockers induce changes in serum l i p i d levels
(Helgeland et a l . , 1978) principally a decrease of HDLC (Helgeland et a l . ,
1978b ; Streja et a l . , 1978).
Hydrochlorothiazide only resulted in a significant increase in mean TC
levels on the other hand HDLC concentrations did not increase.
With propanol ol alone, no effect on TC was observed but LDLC and
HDLC decreased while VLDLC increased (Tanaka et a l . , 1976). The
reciprocal changes in the lipoprotein composition might result from the
Inhibition of lipoproteinlipase by propanolol.
4.2. Antihistamine drugs
Cinnarizine.an anti hi stami ni c and vasoactive drug has been used
for several years 1n the treatment of peripheral vascular disorders and
recently was tested for i t s effect on serum lipoproteins in hyperlipo
proteinemic patients ( I I and IV HLP)(Saba et a l . , 1977c). After six
months of treatment with this drug, LDLC and VLDLC were reduced by
35 % and 78 %, respectively.
4.3. Phénobarbital
Phénobarbital is known to induce hepatic microsomal enzymes (Conney,
1967). I t has more recently been suggested that the induction of microsomal
enzymes might be an important factor determining plasma l i p i d concentra
tions (Martin et a l . , 1975).
On the basis of this finding, certain authors (Miller et a l . , 1973 ;
Durrington et a l . , 1976 and Durrington, 1979) investigated the effect
of phénobarbital on plasma HDL levels. After phénobarbital administration,
several subjects showed an increase in both TC and LDLC ( s t a t i s t i c a l l y
significant) while plasma VLDLC levels did not change. LDLTG and LDL
protelns were significantly increased (Miller et a l . , 1973 ; Durrington
et a l . , 1976 ) . An Increase in serum HDLC was also found. Relative
proportions of apoprotein Β and cholesterol in LDL were unchanged by
phénobarbital. Furthermore, the increase of LDLproteins suggested that
116
References
Adams, C.W., 1973. The pathogenesis of atherosclerosis.
J. Clin. Pathol., 26 (Suppl.5) : 38.
Afolali, S.Κ.,1975.Studies on the effects of steroid hormones
on plasma triglyceride metabol i sm. London, Ph.D. Thesis.
Agid, R. and Marquie, G., 1969. Effets préventifs du NN'
dimethylbiguanide sur le développement de l'athérosclé
rose induite par le cholestérol chez le lapin.
CR. Acad. ícv., 5er. D, 269 : 1000.
Agid, R., Marquie, G. and Lafontan, M., 1975. Effets
comparati fs des s ui fami des hypoglycémiants et des
biguani des antidiabéti ques sur les lésions vasculaires
et les troubles 1ipidiques entraînés par des régimes
atherogenes chez le lapin. J ourn. Annu. Diabeto.
Hôtel Dieu. 259.
Arntz, H.R., Leonhardt, H., Lang, P.D. and Vollmar, J ., 1979.
Comparison of Bezafibrate and Clofibrate on primary
hyper 1ipoproteinemia. European Atherosclerosis Group
Meeting, 28 Sept.29 Sept., Lugano, Italy.
Arntzenius, A.C., 'Van Gent, CM., Van der Voort, H.,
Stegerhulh, CI. and Styblo, K., 1978. Reduced HDL in
women aged 4041 using oral contraceptives. The Lancet,
p. 1221.
Baggio, C, Briani, G., Martini, S., Fellin, R. and Crepaldi,
C, 1977. Abstracts of international conference on
atherosclerosis, 912 Nov., Milan, Italy, p.103.
Ballantyne, D., Olsson, A.G. and Carlson, L.A., 1978a.
Acute effect of dietary therapy of type IV hyper 1ipo
proteinaemia on the serum and 1ipoprotein concentrations
and relative composition. Atherosclerosis, 30 : 7987.
Ballantyne, D., Ballantyne, F.D., Stromberg, P., Third, J .H.
L.C and Bedford, D.K., 1978b. Effect of Clofibrate on
the composition of VLDL and LDL sub fractions in type III
hyper 1 ipoproteinaemia. Clin. Chim. Acta., 83 : 117122.
Ballantyne F.C., Ballantyne, D., Forsythe, S., Epenetos, A.
A. and Caslake, M., 1979. The effect of thyroxine
therapy on the composition of LDL subfractions in
primary hypothyroidism. V International Symposium of
Atherosclerosis. 69 Nov., Houston, Texas, USA.
BarOn, H., Landeau, D. and Berry, E., 1977. Serum high
density lipoprotein in diabetics. The Lancet, p.761.
Baraona, E. and Lieber, CS., 1970. Effects of chronic
ethanol feeding on serum 1ipoprotein metabolism in
the rat. J . Clin. Invest., 49 : 769.
Baraona, E., Leo, M.A. and Borowsky, S.A., 1977. Pathogenesis
of alcoholinduced accumulation of protein in the liver.
J. Clin. Invest., 60 ; 546553.
Barboriak, J J. ., 1977. Alcohol and coronary artery disease.
The Lancet, 4 J un., pp. 12121213.
Barboriak, J J. ., Anderson, JA. ., Hoffman, R.G. and King, J .,
1979. Coronary artery occlusion, HDLC and alcohol in
take. V International Symposium on Atherosclerosis.
69 Nov., Houston, Texas, USA.
121
Barclay, M., Barclay, R.K., Skipski, V.P., Terebuskekish,
0., Mueller, C.H., Shah, E . and E lkins, W.L., 1965.
Fluctuation in human serum lipoprotein during the normal
menstrual cycle. Biochem. J., 96 ; 205.
Barr, O.P., Russ, E .M. and E der, H.A., 1951. Proteinlipid
relationships in human plasma in atherosclerosis and
related conditions. Am. J. Med., 11 : 480493.
Bates, C.J., Mandal, A.R. and Cole, T.J., 1977. HDLCholes
terol and vitamin C status. The Lancet, 17 Sept. , p.611.
Beifrage, P., Berg, Β., Hagerstrand, I., Hilsson
E hle, P.
Tornquist, Η. and Hiebe, T., 1977. Alterations of lipid
metabolism in healthy volunteers during long term ethanol
intake. E ur. J. Clin. Invest., 7 : 127131.
Bennion, L.J. and Grundy, S.M., 1977. E ffects of diabets
mel 1 i tus on cholesterol metabolism in man. N. E ngl.
J. Med., 296 : 13661371.
Bierenbaum, M.L., Fleischman, A.I., Stier, Α., Watson, P.B.,
Somol, H., Haso, A.M. and Binder, M., 1979. Increased
platel et agregation and decreased HDLC in women on OC.
V International Symposium on atherosclerosis, 69 Nov.,
Houston, Texas, USA.
Blankenhorn, D.H., Chin, H.P. and Lau, F.Υ.Κ., 1968.
Ischemic heart disease in young adults. Metabolic and
angiographic diagnosi s and the prevalence of type IV
hyperlipoproteinemia. Ann. Intern. Med., 69 ; 2133.
Bostofte, E ., Hemmingsen, L., AllingMoller, K.J., Serup,
J. and Weber, T., 1978. Serum lipids and lipoproteins
during treatment with oral contraceptives containing
natural and synthetic estrogens . Acta E ndocrinologica ,
87 : 855864.
Bradley, D.D., Wingerd, J., Petitti, D.B., Krauss, R.M.
and Ramcharan, S., 1978. Serum high density lipoprotein
cholesterol in women using oral contraceptives, estrogens
and progestins. H. E ngl. J. Med., 299 : 1720.
Bremmer, W.F., Third, J.L.H.C., Clark, B., Corstorphine, C.,
and Lawrie, T.D.V., 1976. CI719 in HLP : interim data.
Proc. Roy. Soc. Med., 69 (Suppl.2) : 8387.
Calvert, CD., Graham, J.J. and Mannik, T., 1978. E ffects
of therapy on plasma high density lipoprotein cholesterol
concentration in diabetes mellitus. The Lancet, pp. 6668.
Camejo, G.,Day, EC. . and Levy, R.S., 1976. Low density
lipoproteins. E ds, Plenum Press, New York, p.351
Carlson, L.A., 1969. The effect of nicotinic acid treatment
on the chemical composition of plasma 1ipoprotein in man.
In Holmes, Carlson and Paoletti, Drugs affecting lipid
metabolism, Plenum Press, New York, Vol.4, p.327.
Carlson, L.A., Froberg, S. and Oro, L., 1972a. A case of
massive hypertriglyceridaemia corrected by nicotinic
acid or nicotinic therapy. Atherosclerosis, 16 : 359. .
Carlson, L.A. and KolmodinHedman, B., 1972b Hyperalpha
lipoproteinemia in men exposed to chlorinated hydrocarbon
pesticides. Acta Med. Scand., 192 : 2932..
Carlson, L.A., Olsson , A.G., Oro, L., Rössner, S. and
Walldius G., 1974. E ffects of hypolipidemic regimes on
serum 1ipoproteins. In : F.G. Schettler and A. Weizel E ds,
122
Atherosclerosis III, Springer-Verlag, Berlin, p.768.
Carlson, L.A. and Ericsson, M., 1975. Quantitative and
qualitative serum lipoprotein analys is Part-2 :
studies in male survivors of myocardial infarction.
Atherosclerosis, 21 : 435-450.
Carlson, L.A., Olsson, A.G. and Ballantyne, D., 1977a. On the
rise in LDL and HDL in response to the treatment of
hypertriglyceridaemia in type IV and type V hyperlipopro-
teinaemias, Atherosclerosis, 26 : 603-609.
Carlson, L.A. and Kolmodin-Hedman, B., 1977b. Decrease in
alphalipoprotein cholesterol in men after cessation of
exposure to chlorinated hydrocarbon pesticides.
Acta.Med. Scand., 201 : 375-376.
Carlson, L.A. and Wahlberg, G., 1978. Relative increase in
apolipoprotein CII content of VLDL and chylomicrons in a
case with massive type V hyper 1ipoproteinemia by
nicotinic acid treatment. Atherosclerosi s, 31 : 77-84.
Carlson, L.A. and Olsson, A.G., 1979. Serum-lipoprotein-
cholesterol distribution in healthy men with high serum
cholesterol concentrations : extrapolation to Clofibrate
trial. The Lancet, 21 Apr., pp. 869-870.
Castelli, Y/. P., Doyle J.T., Gordon, T., Hanes, C.G., Hjortland
M.C., Hulley, S.S., Kagan A. and Zukel, W.J., 1977.
Alcohol and blood lipides : the cooperative 1 ipoprotei η
phenotyping study. The lancet, 23 jul., p.153
Cayen, M.N . and Dvornik, D., 1978, Combined effects of
Clofibrate and Diosgenin on cholesterol metabolism
in rats. Atherosclerosis, 29: 317-327.
Cayen, M.N . and Dvornik, D., 1979. Effect of diosgenin on
lipid metabolism in rats. J. Lip. Res., 20 (2) : 162-174.
Cheung, M.C., and Albers, J.J., 1977. The measurement of
apo 1ipoprotein AI and All level in men and women by
immunoassay. J.Clin. Invest., 60 : 43-50.
Conney, A.H., 1967. Pharmacological implications of
microsomal enzyme induction. Pharmacological Rev., 19 :
317-366.
Creger, P.L., Moersch, G.W. and Heuklis, W.A., 1976.
Structure/activity relationship of Gemfibrozil (CI-719)
and related compounds. Proc. Roy. Soc. Med. , 69 (Suppl.
2) : 3.
Danielsson, B., Ekman, R., Fex, G., Johansson, B.G.,
Kristensson, H., N i 1sson-Ehle, P., and Wadstein, J., 1978
Changes in plasma high density 1ipoproteins in chronic
male alcoholics during and after abuse. Scand. J. Clin.
Lab. Invest.,38 : 113-119.
Day, C.E., 1976. Low density lipoproteins. Day, C.E. and
LEVY, R.S., Eds, Plenum Press, N ew York, p.421.
Day, C.E., Stafford, W.W., Schurr, P.E., 1977. Screoning
for antiatherosclerotic agents in sea Japanese quail:
experience with adamantyloxyani1 i ne.Prot. Biol. Fluids,
25 : 519-525.
Delattre, J. and Bastide P., 1979. Effects of drugs on total
serum cholesterol. The use of laboratory tests results.
Variations due to drug-intake. S.F.B.C., 17-19 dec.,
Pont à Mousson, France.
123
Hiller, E
Ν. . and Nestel, P.J.,1973. Altered bile acid
metabol ism during treatment with phenobarb itone.
Clin. Sci., 45 : 257262.
Miller, C.J., Hiller, EΗ. ., 1975. Plasma high density lipopro
tein concentration and development of ischaemic
heart disease. The Lancet, 1 : 16.
Hiller, E
Ν. ., Forde, O.H., Thelle, D.S., and Hjos, O.D., 1977
The tromso heart study : high density 1 ipoprotei η
and coronary heart disease ; a prospective case
control study. The Lancet, 1 : 965.
Hishkel, H.A., 1974. Alcohol and alpha lipoprotein choleste
rol. Ann. Intern. Hed. 81 : 564.
Hordasini, R., 1978. Abnormal low density lipoproteins in
chi 1 dren with familial hypercholesterolemia. E ffect
of polyanion exchange resines. Klin. Wochenschr.
16 : 805808.
Hordasini, R. , Keller, H., Hiddelhoff, G. and Riesen, W.F.,
1979a. E ffect of Probucol and diet on serum lipids
and 1ipoprotein fractions in primary hypercholeste
rolemia . Doubleblind study vs placebo. E uropean
Atherosclerosis group meeting, 2829 Sept., Lugano,
Italy.
Hordasini, R., Keller, H. and Riesen, W.F., 1979b. Les
lipoprotéines sériques et les apoprotéines majeures
(Β,Al,A2) chez les patients avec hypercholestérolémies
primaires, traités par le probucol. Hed. et Hyg.,
37 : 36493650.
Huller, Κ., 1977. Abstracts of VI International Symposium on
drugs affecting lipid metabolism, Philadelphia,
Pa, 29 Aug.l Sept. p.64.
Hikkilä, E ., 1953. Studies on the 1ipidproteiη relationships
in normal and pathologic sera and the effect of
heparin on serum 1ipoproteins. Scand. J. Clin. Lab.
Invest. , 5 : 158171.
Hikkilä, Ε.Α., 1973. Triglyceride metabolism in diabetes
mel 1itus. Prog. Biochem. Pharmacol, 8 : 271299
Nikkilä, Ε.Α., Ylikahri, R. and Huttunen, J.K., 1976.
Gemfibrozi1 : E ffect on serum lipids, 1ipoproteins,
postheparin plasma lipase activities and glucose
tolerance in primary hypertriglyceridemia.
Proc. Roy. Soc. Hed., 69 (Suppl.2) : 5863.
Nikkilä, Ε.Α., Hormila, P., and Huttunen, J.K., 1977.
Increase of HDL levels and of post heparin plasma
lipoprotein lipase activity in insulintreated
diabetics. Circulation, 56(4) : III23.
Nikkilä, Ε.Α., 1978a. Hetabolic and endocrine control of
plasma HDL. In : high density 1 ipoprotei ns. Gotto
A.H., Hiller, Ν.ε. and Oliver, H.F., E ds, Amsterdam
εlseviernorth Holland, pp. 177192.
Nikkilä, ε.Α., and Hormila, P., 1978b. Serum lipids and
1 ipoprotei ns in Insul i ηtreated diabetes. Diabetes,
27 : 10781086.
Nikkilä, ε.Α., Kaste, Ν., E hnholm, C. and Viikari, J., 1978c
Increase of serum highdensity 1ipoprotein in
Phenytoin users. The Lancet, 8 Jul.
Oliver, H.F. and Boyd, G.G., 1953.Changes in plasma lipids
during the menstrual cycle. Clin. Sci. 12 : 217222
128
Olsson, A.G., Rössner, S., Walldius, G. and Carlson, L.A.,
1976. E ffect of Gemfibrozil on lipoprotein concentra
tions in different types of hyperlipoproteinaemia.
Proc. Roy. Soc. Med., 69 (suppl.2) : 28.
Olsson, A.G., Rössner, S., Walldius, G. and Carlson, L.A.,
and Lang, P.D., 1977a. E ffect of BM 15.075 on
lipoprotein concentrations in different types of
hyper 1ipoproteinemia. Atherosclerosis, 27. 279287.
Olsson, A.G., Rössner, S., Walldius, G., Carlson, L.A. and
Lang, P.O., 1977b. Abstracts of VI International
Symposium on drugs affecting lipid metabolism.
Philadelphia, Pa, 29 Aug.lSept., p.68.
Olsson, A.G., Rössner, S., Carlson, L.A., Walldius, G., and
Lang, P.D., 1977c. Abstracts of International
Conference on Atherosclerosis, Milan, Italy, 912 Nov.
p.270.
Olsson, A.G. and Lang, P.D., 1978a. Doseresponse study of
Bezafibrate on serum 1ipoprotein concentrations in
hyper 1 ipoprotei naemia. Atherosclerosis, 31, 421428.
Olsson, A.G. and Lang, P.D., 1978b. One year study of the
effect of Bezafibrate on serum lipoprotein concentra¬
ions in hyperlipoproteinaemia. Atherosclerosis, 31 :
429433.
Olsson, A.G. and Dairou, F., 1978c. Acute effects of choles
tyramine on serum lipoproteins concentrations in type
II HLP. Atherosclerosis, 29 : 5361.
Olsson, A.G., Oro, L. and Carlson, L.A., 1979. Dose response
study of Cipro fibrate on serum 1 ipoprotei ns in HLP
V Inter national Symposium on Atherosclerosis,
69 Nov., Houston, Texas, USA.
Paoletti, R., 1979. Les HDL ou le cholesterol des HDL
facteurs d'anti ri sque coronarien. Journée Française
de Médecine Interne, Paris, Vendredi 16 novembre 1979.
Pelkonen, R, 1975. Increase in serum cholesterol during
Phenytoin treatment. Brit. Med. J., 4 : 85.
Rhoads, G.G., Gulbrandsen, C.L. and Kagan, Α., 1976. Serum
lipoproteins and coronary heart disease in a
population study of Hawaï Japanese men. N. E ngl.
J. Med., 294 : 293298.
Ricci, G. and Angelico, F., 1979. Alcohol consumption and
coronary heart disease. The Lancet. June 30, p. 1404.
Rifkind, B.M., Tamir, I. and Heiss, G., 1978. Preliminary
HDL findings. The lipid research clinic program. In :
High Density Lipoproteins. Gotto, A.M., Miller, E N. .
and Oliver, M.F., E ds. Amsterdam, E lseviernorth
Holland, pp.109119.
Rodney, G., Uhlendorf, P. and Maxwell, E
R. ., 1976. The
hypolipidaemic effect of Gemfibrozil (CI719) in
laboratory animals. Proc. Roy. Soc. Med. 69 (Suppl.2):
6.
Rodriguez, J., Catapano, Α., Ghiselli, G.S. and Sirtori, CR.
Turn over and aortic uptake of VLDL from hypercholes
terolemic rabbits as a model for testing antiathero
sclerotic compounds. Adv. E xp. Med. Biol., 67 : 169.
129
ABSTRACT
A major problem in serum creatinine measurement is in-
terference from noncreatinine chromogens. The most common
interferences include proteins, glucose, and ketoacids. Ele-
vated concentrations of glucose and ketone bodies in diabetic
patients may result in elevated spurious creatinine values.
Small differences in technics or reagents employed may cause
large discrepancies in the results obtained. The kinetic
method employed in centrifugal analyzers was found to be
especially sensitive to the interference by acetoacetate.
Bilirubin can negatively interfere with kinetic Jaffe creati-
nine determinations. All drugs potentially nephrotoxic should
be considered as interfering with serum and urine creatinine.
Gentamicin and co-trimoxazole are examples of drugs inducing
deterioration in kidney function, which is manifested by the
rise in serum creatinine concentration.
t i o n r a c e . I t was r e c o g n i z e d t h e r e a f t e r t h a t w i t h c r e a t i n i n e
l e v e l s w i t h i n t h e normal range serum g l u c o s e c o n c e n t r a t i o n s
of about 28-39 mmoles/1 could lead to an error of about 15-20%.
Heinegard and Tiderstrom (197U) reported that when
glucose was reacted with alkaline picrate, color formation
was lowest in the pH range between 11.65 and 12.20. Increase
or deorease of pH caused a gradual increase of glucose in-
terference. It is also known that interference by glucose,
as well as by fructose, at 37 is more pronounced than at
25 especially if the time of reaction is prolonged. The
absolute error in creatinine determination due to a given
concentration of"glucose appears similar whether the
solution is serum or urine. Since, however, the creatinine
concentration in urine may be 100 times that of serum, the
per cent error is usually much lower in urine and may be
considered negligible.
The major problem in serum creatinine measurement in
diabetio patients seems to be the interference of ketone
bodies. Watkins (I967) and Husdan and Rapoport ( 1968) showed
that acetoacetate present in serum of ketotic patients
caused a false elevation of the creatinine value, assayed
either with manual or with standard continous-flow technic.
TABLE 2 - KETONE BODIES INTERFERENCE IN CREATININE
MEASUREMENT
Serum creatinine
Diagnosis Ketostix ymoles/1
reaction Autoanalyzer Manual with
Lloyd's reagent
Diabetio
+++
ketoacidosis 442 133
Untreated 141 44
new diabetic
Untreated 80 62
new diabetic
Creatinine /umoles/1
Serum with 5.0 mM with 1.0 mM
acetoace tate pyruvate
(Kammeraat 1978) .
The kinetio method for creatinine determination, perhaps
most widely employed in centrifugal analyzers is based on
the direct relationship between reaction rate and creatinine
concentration. It greatly reduces the effects of those
interferences with reaotion rates much slower than crea-
tinine, e.g., proteins, glucose, asoorbic acid.
In oontrast, acetoacetate reaots much faster than crea-
tinine and interferes strongly in the centrifugal analyzer
in which the reaction is started without significant delay.
The presence of acetoacetate has no effect on the kinetio
139
method with the discrete ACA analyzer because a delay time
of 29 sec at 37° issufficient for completing the reaction
between acetoacetate and picrate. Caraway and Kammeyer
(1972) also reported that by 1 min acetoacetate ceased to
bave any significant effect on creatinine measurement. This,
bowever, does not bold for otber ketoacids. It was also
found by Kammeraat (1978) that Increasing concentrations of
NaOH causes a more intense reaction for acetoacetate.
The effeot of this serious interference in manual methods
and in continousflow methods can be reduced with appro
priate reaotion conditions but not eliminated. Pyruvate
interferes in all direct methods although less strongly than
aoetoacetate.
It should be pointed out that high levels of inter
ference in serum can lead to erroneously low estimates of
glomerular filtration rate.
It is also apparent that the treatment of diabetic
ketoacidosis with insulin would affect creatinine measurement
due to obanges in the level of interferences. This might be
responsible for large discrepancies even between withina
day creatinine determinations.
Considering the consumption of ascorbic acid as vitamin
tablets, juices, vegetables and fruits one may expect
ascorbio aoid interference in creatinine analysis to be re
latively important. Caraway and Kammeyer (1972) found that
14,2 mmoles/1 of ascorbic acid produces color equivalent to 168 μnoles/l
of creatinine. Siest et al (1978) found that at therapeutic concentrations,
ascorbic acid distinctly interferes with the analysis of creatinine. The
extent of interference vary, depending on the technic, kit and apparatus
used.
Bilirubin Creatinine
Endpoint Kinetic
ymoles/1 jimoles/1
214 62 71
224 283 212
213 141 9
158 53 18
233 88 n e g a t i v e 'value
Aoetaminophen, acetophenetidin,
amphotericin B, oapreomycin, carbutamid,
cephaloridine, chlorthalidone, Clonidine,
oolietiniettiate, Colistin, demeclocycline, ., . . .
* * ' Nephrotoxic -
deoxycyeline, gentamicine, kanamycine, . .. ,,
methioillin.* methoxyflurane,
' ' mithramycin.
' * . . .
nephrotoxic
mitomycin C, nalidixic acid, neomycin,
nitrofurantoin, oxacillin, phenacetin,
polimyxin B, streptokinase, tetracycline,
thiazides, triamterene
Arsenicale, mercurio salts, phosphorus, Nephrotoxic
paraldehyd
Mannitol due to dehydration
Clofibrate due to muscle damage
Serum Creatinine
creatinine clearance
uraoles/l ml/min
R e c e n t l y , m a n y a u t b o r e d r e w a t t e n t i o n to t b e d e t e r i o
r a t i o n i n r e n a l f u n c t i o n i n a s s o c i a t i o n with cotrimaxazole
therapy h a l o w s k i et a l ( l 9 7 3 Ì B e r g l u n d et βΐ(ΐ975λ Shouval
et a l (ΐ97β). T h i s d r u g c o n t a i n i n g t h r i m e t b o p r i m a n d s u l p b a
m e t h o x a z o l e b a s n o w r e p l a c e d tbe t e t r a c y c l i n e s a s t h e com
m o n e s t d r u g c a u s i n g a s h a r p d e t e r i o r a t i o n of r e n a l f u n c t i o n .
T h e effect of o o t r i m o x a z o l e w a s s t u d i e d i n p e o p l e w i t h
normal kidney function and rises in plasma creatinine by
about 25 , w i t h c o n c o m i t a n t d e c r e a s e s i n c r e a t i n i n e clearance
by about 30'/b w e r e f o u n d a f t e r treatment with therapeutic
d o s e s of the d r u g . I n p a t i e n t s w i t h a l t e r e d r e n a l f u n c t i o n ,
the d e t e r i o r a t i n g e f f e c t s of c o t r i m o x a z o l e w e r e r e p o r t e d to
be m o r e s e v e r e .
T A B L E 8 E F F E C T S OF C O T R I M O X A Z O L E O N R E N AL F U N C T I O N
Creatinine
Creatinine Urea clearance
ymoles/1 nnr.oles/1 ml/min
J.F. Guelfi
agrégé de pathologie médicale
Ecole Nationale Vétérinaire de Toulouse
Toulouse France
ABSTRACT
The author considers drug effects capable of modifying the hemogram
reference values. Variations due to drug accidents and to the looked-for
therapeutic effect are thus excluded. The drugs concerned interfere mostly
by modifying the cellular compartments. When variations manifest themselves
by a decrease in blood cells, they often imply a depressive effect (toxic,
in particular) that represents actually a first sign of intolerance.
INTRODUCTION
The bounds of our subject must first of all be clearly defined. We
have apOroached it in the Spirit of the "Société Française de Biologie cli-
nique" commission "Effects des médicaments sur les examens de laboratoire",
i.e. we have nrincipally searched for analytical and pharmacological effects
liable to modify unexpectedly the value of the blood parameters most asked
for and thus likely to deceive the practicioner.
Thus, our object is not to review the hematologic accidents due to drugs,
althou,sh their knowledge may help us ; neither is it to describe blood chan-
ges directly related to the therapeutic effect. On the other hand, we have
restricted our research to the blood cells, haemostatic troubles being the
object of a special study. Finally, we have not delt with antineoplastic
therapies.
Our bibliographic research has shown that a exeat number of articles have
been written concerning drug effects on blood tests. However, they often
deal with haematologic accidents ; furthermore, many studies are carried
out "in vitro" or on animals, or else relate to complicated tests. We have
assembled here the elements that seem adapted to our topic.
DROG EFFECTS ON WHITS BLOCH C3LL COUNT. PZATSLET COUNT AND WHITE BLOOD
PICTURE.
Analytical variations
Luke et al..(1971) achieved the comparison between Coulter S automatio
147
ABSTRACT
Plasma aspartate and alanine aminotransferases are very often used
to check the hepatic action of drugs. But the interpretation of an iso-
lated enzymatic activity really requires the control of the enzymatic
reactions and of the analytical variations, the cellular and tissue
localization and the physiological variations, the tissue (hepatic) level
in different pathological and experimental conditions, and the knowledge
of physiological plasmatic variations and the associated changes induced
by drugs in animal liver.
INTRODUCTION
The evaluation of drug toxicity is often based on the activity
measurement of plasma enzymes of hepatic origin. An increase in the
activities of these enzymes in the plasma of treated patients is usually
associated with a toxic effect of the drug on the liver due to necrosis
or cytolysis. These two notions of necrosis or cytolysis are now out of
date. Numerous tissues can release enzymes without damaging the vital
functions of the cells. In addition, physiological phenomena that can
change enzyme levels or activities are generally ignored. The interpre-
tation of an isolated enzymatic activity really requires the knowledge of
the different causes of variation.
We will exemplify these different points, as far as possible, in
humans. Some examples in animals are given only when no report for humans
is available (especially for tissue changes).
160
Heart 160 7
Liver 140 44
Skeletal muscle 100 5
Kidney 90 20
Pancreas 28 2
Spleen 14 1.2
Lung 10 0.7
Serum 0.02 0.02
Age
Between children and adults females 45.3 9.8
males 22.5 31.5
20-30 to 40-50 years females 10.0 23.1
males 9.4 21.3
Sex
Between males and females (20-30 years) 21.0 37.5
Body weight
40-100 kg females 5.5 38.8
50-100 kg males 9.8 86.6
Meals
Before/after females 2.2 1.2
males 3.1 0.8
Oral contraceptives
Treated/control 12 32
Anticonvulsant drugs 36 36
Analytical variations
Day-to-day (coefficient of variation) 4.0 4.8
163
1
Antibiotics AST ALT ß lactamines AST ALT
Tetracyclines Pencillin G
/ / /
Tetracycline
Chlortetracycline / /
taninosides Penicillin A
Kanamycin
Gentamycin
/
/
Ampicillin
Carbenicillin
/
/ 4
iacrolides Penicillin M
Oleandomycin / /
Oxacillin / /
Chloramphenicol / / Cephalosporines
y y
Cephaloridine
Cephalothin y y
(Λ increase)
Many other examples may be found in the litterature. But the studies very
often describe isolated cases of overdosed people or patients not tolerant
to their treatment. Moreover, it is not enough to know that a drug
increases or decreases an enzymatic activity in the plasma. These varia
tions must be calculated to be useful.
In our laboratory, we have done some studies by comparing treated and
control people using the method described elsewhere (Steinmetz et al.,
1980). The variation due to drugs for ALT are shown on the figure 1.
166
Vasodilator ι =b Vasodilator ! C ¡
1 Hypoliptmic ¡ ^ι
Vasoconstrictor ι C Vasoconstrictor ι ^ '
Analgesic ■ Analgesic ι I !
Antidepressant ■ ; Antidepressant ¡ f ¡
1 Antianginal ιC ·
Tranquilizer ¡
Tranquilizer ¡C ¡
Antigout !
Antigout ¡ ιI
Anticoagulant ¡
Anticoagulant ¡ ] ¡
> 1 Antidiabetic ) ■ι
Antihypenention ι !
Cardiotonic ! • 1
Hypnotic ι ι ; Hypnotic ι
Anticonvulsant ι
72!
Anticonvulsant ¡
Oral contraceptive ι
¡
(2030 years) J ! *
Agr (2030 io 5060 !
' ι
Se« Ittiwccn niales and ■
¡ femelei (2030 vean) females (2030 years) !
1 ι—'—
20 10 0 Κ) 20 10
ALT females ALT malei
REFERENCES
Bailey W.C., De Rouen T.A., Ziskind M.M. and Greenberg H.B.: Autoanalytic
(colorimetrie) determinations of SGOT in isoniazid recipients are
reliable. Am. Rev. Respir, dis., Ill: 237-238, 1975.
Borei C.L., Ryser H. and Frei J.: L'élévation de deux transaminases hépa-
tiques considérée comme adaptation enzymatique du rat au régime
carné. Schweiz. Med. Wschr., 6: 135-137, 1958.
Boyd J.W.: The intracellular distribution, latency and electrophoretic
mobility of L-glutamate-oxaloacetate transaminase from rat liver.
Biochem. J., 81: 434-441, 1961.
Chang Y.Y.H. and Ho I.K.: Effects of acute and continuous morphine adminis-
tration on serum glutamate oxaloacetate transaminase and glutamate
pyruvate transaminase activities in the mouse. Biochem. Pharmacol.,
28: 1373-1377, 1979.
Dhami M.S.I., Drangova R., Farkas R., Balazs T. and Feuer G.: Decreased
aminotransferase activity of serum and various tissues in the rat
after cefazolin treatment. Clin. Chem., 25: 1263-1266, 1979.
Evans L., Hassanyeh F., Gallacher J. and Leitch J.M.: The effect of
intramuscular chlorpromazine on the serum transaminases (SGOT and
SGPT). Europ. J. clin. Pharmacol., 10: 289-292, 1976.
Fowler U.M., Gardner G.U., Kazerunian H.H. and Lawsted W.A.: The effect
of exercise on serum enzymes. Arch. Phys. Med. Rehabil., 49: 554-
565, 1968.
Galteau M.M.: Etude du phénomène de sortie d'enzymes musculaires. Relations
avec les variations des metabolites et des enzymes au cours de
l'exercice. Thèse de Pharmacie Nancy, 1973.
Galteau M.M., Ratanasavanh D. and Siest G.: Effect of galactosamine
treatments on hepatic and plasmatic enzymes in rats. In preparation.
Ideo G., Morganti A. and Dioguardi N.: Gamma-glutamyltranspeptidase: a
clinical and experimental study. Digestion, 5: 226-336, 1972.
168
D. W. Scheuch
Department of Pathological Biochemistry
Medical Academy Dresden, G. D. R.
ABSTRACT
In model experiments with erythrocytes, hemolysates,
crystalline enzymes, the mechanism of the hemolysing action
of Phenylhydrazine has been investigated and a new scheme of
the interaction of Phenylhydrazine with glutathione and SH-
enzymes in red blood cells has been developed.
INTRODUCTION
It is well known that injection of phenylhydrazinechlo-
ride (10 mg/kg body weight) causes within a week severe ane-
mia with nearly 100 % reticulocytes. Oxyhemoglobin is de-
stroyed by Phenylhydrazine and ultimately results in the de-
naturation of globin to a green pigment and hemin (Warburg,
0. et al. 1931; Beaven, G. H. et al. 1954). In this process,
glutathione is involved which protects hemoglobin and is
oxidized by Phenylhydrazine to form mixed disulfides with
hemoglobin socalled "Heinz Bodies" (Jandl, J. H. et al.1960;
Allen, D. M. et al. 1961). We were interested in obtaining
insight into the mechanism of Phenylhydrazine action on the
metabolism responsible for destroying the erythrocytes.
RESULTS
Incubation of washed rabbit blood cells with phenyl-
hydrazine (3 . 10 mol/1) for 10 hours, 37 °C in a Warburg
apparatus with air as the gas-phase, induced a pronounced
decrease in the activity of hexokinase (HK), glucose-6-phos-
phate dehydrogenase (G-6-PD), NADPH-glutathione oxidoreduc-
tase (GSSG-RI), and phosphoglycerinaldehyde-NAD-oxidoreduc-
tase (TPD) (Fig. 1 ) . We found parallel to the decrease of
enzyme activities a decrease of intracellular concentration
of glutathione (GSH). Addition of glucose (1,5 · 10" mol/1)
protected GSH partially as well ae the enzymes, while addi-
171
Activity
¡.Ο
ΙΟ
10
Z2 ^
^ ν^77λ
esH HK Θ6Ρ0 6SS6M TPD
Activity
• anaenò
3.0 pH
PH PH PH
♦GSH ♦Hb
•GSH
t)·
5
1
Fip. 6 Inact ivation Of ATPaae By Phenylhydrazine With Or
Without Additions '777>{ N /C0
:^o„ ¡Π 2
CONCLUSIONS
Sumuarizing our findings we propose the following scheme
of the action of Phenylhydrazine on erythrocytes (Pig. 7 ) .
Hb denot.
Pig. 7 Action Of Phenylhydrazine On Hemoglobin, GSH And
SHEnzymes
176
By inactivation of the SHenzytnes of the glycolytic pathway,
there must be, consequently, a decrease in intracellular ATP
concentration with consecutive hemolysis. This decrease of
ATP is shown in Pig. 8.
ATP
»without HA
■»with HA
ABSTRACT
Laboratory tests are increasingly important in the surveillance of
drug treatments. People in charge of clinical laboratory science must now
become aware of a new development,·the use of some tests as indicators of
the activity of drug-metabolizing enzymes, especially of the induction of
such enzymes. Ideally', the activity of such enzymes should be measured in
the tissues. In man, however, easier indirect methods are now most often
used : measurement of antipyrine half-life, urinary and plasma drug metabo-
lites, specific protein and enzyme levels in plasma, changes in endogenous
substrates and endogenous metabolites, and enzymes in circulating blood
cells. Of all these, two examinations are now widely performed, those for
urinary glucaric acid and plasma gamma-glutamyltransferase. The value and
limitations of these two tests are discussed.
INTRODUCTION
To improve drug efficacy and safety, it has been necessary to develop
clinical methods to establish the individual pattern of drug metabolizing
enzymes in patients and also their inducibility.
Let us first consider what the implications of induction are in clini-
cal medicine to day. There are examples where enzymes induction leads to
1. The loss of efficacy (detoxification)
2. The increase of toxicity (toxification)
3. Cancerogenicity
4. Substrate deficiency
5. Therapeutic mechanism
Many drugs and environmental xenobiotics can activate or inhibit en-
zymes, including those enzymes which convert them. These enzymes are dis-
tributed in various tissues (mainly the liver, kidney, intestine, lungs
and skin) and in various cell compartments. A large group being found in
the endoplasmic reticulum, but some of them belonging to the plasma membra-
nes, or to the soluble, cytoplasmic fraction of the cells.
179
ronic acid. The biosynthesis of glucaric acid (Burns and Connery 1966 ;
D Glucose
UDP-Galactose ^ - u c o s e — niycoqen
ϋΡΓ,-DH
UDPGLUCURONIC ACID
Rillrubin
>^ Accepte
Acceptor Steroids
hOh
UOP Ν.
G l u c u r o n i c a d d 1 P. BGlucuronides
H
Phospha taseXy^O 2°v/flrl
^ ? \ \S B G l u c u r o nl d a s e
^ >v Y \\cceptor
Mucopoly ^ GLUCURONIC
ΓΛ uriiDnMTQ ACID *
saccharides
Myoinositol 4
Uronolactonase ucuronate reductase
GL DH
Hydrolysis
D Glucaric a d d
Khil 1976) includes two major steps, the synthesis of free glucuronic acid
followed by its conversion into terminal metabolites, especially glucaric
acid. Free glucuronic acid can be converted via three different metabolic
pathways, in which we are interested here, depends first on the action of
a D-glucurono-delta-lactone hydrolase. This enzyme is found both in micro-
somes and in the cytoplasm of hepatocytes and leads to the formation of
D-glucuronolactone. This compound in then oxidized into 1,4-saccharo-6,3-
dilactone by an irreversible process that requires the presence of NAD and
is catalyzed by a soluble enzyme already identified as D-glucuronolactone
NAD oxidoreductase. The dilactone produced hydrolyzes spontaneously into
two monolactones, 1,4-saccharo-lactone and 6,3-saccharolactone, which can
both convert into glucaric acid without the intervention of any enzyme.
All the methods for assaying glucaric acid are delicate. The techni-
ques most often used are based on the inhibition of beta-glucuronidase by
1,4-glucuronolactone obtained by heating glucaric acid in an acid medium.
Chemical and gas-chromatographic methods have also been developed.
Reference values obtained by these various methods are quite different
since besides the problems of accuracy and precision, physiological varia-
tions are not yet well understood.
TABLE 1 - GLUCARIC ACID ELIMINATION IN HEALTHY HUMANS (see Marselos 1976)
Chromatographic method
References Drugs
UDP glucose dehydrogenase UDP glucuronyltransferase UDPCA pyrophosphatase Glucuronolactone detydrogenase Glucaric Acid
TREATMENT timóles NAD X ran"' nmoles p.nilrophe ol χ rain-1 nmoles Pi χ min ' nmoles NAD X ran-' 'moles χ uH creatinine
-1
g" liver 7ig~l protein g"1 liver ι; protein g liver mg protein g liver mg protein
Control (8) o7 728.5 * 68.3 9.50 S 1.51 166.2 t 23.3 5.60 : 0.81 566.0 ; 46.1 14.07 ± 1 . 1 0 503 1 B9 6.55! I.I 21.6 t 2.2
Phénobarbital ( 8 ) 913.5 t 34.1 10.83 : 0.36 311.3 1 25.1 7.15 I 1.07 450.2 ! 30.8 8.19 1 1.03 1146 t 245 13.50 i 2.7 39.3 1 1.5
100 mg/kg 6/tt tt tt ttt ttt
i . p . 5 jours
Control ( 5 ) 480.0 ! 95.9 7.14 i 1.51 123.2 1 35.9 '.30 J 0.83 334.6 i 31 5.02! 0.6
Diphenylhydantoin (5) 544.0 : 48.8 7.86 ! 1.70 189.0 ! 38.4 -.58 ! 0.83 515.2 i 71 7.46! 1.06
100 mg/kg t tt tt
i . p . 5 'jours
Control ( 5 ) 508.0 2 163.2 6.58 t 2.44 154.1 t 62.3 ..13 s 1.26 442.3 : 140.4 11.13 ! 2.76 678.6 ± 163.4 7.94 1 23.5 15.6 t 3.5
C l o f i b r a t e (5) 596.0 ! 48.8 7.63 t 0.61 187.4 ! 21.5 '.82 ! 0.07 356.3 ! 99.6 9.26 t 1.92 1184.0 t 104.2 14.34 ! 1.26 34.7 ! 7.6
Control ( 5 ) 821.9 ! 72.9 12.96 í 2.43 219.1 t 31 .9 ..16 S 0.89 789.1 4 74.7 22.21 i 2.27 230.3: 94.9 3.71 ! 1.40 27.4 ! 10.9
Procetophene (5) 428.0 1 130.9 7.31 i 2.23 194.8 i 14.4 '.55 1 0.24 681.4 ! 46.7 19.48 t 1.90 369.7 t 132.9 6.21 1 1.85 31.7 ! 15.8
10 rog/kg
'tt tt t
Control ( 5 ) 587.5 i 156.6 7.64 i 2 . 1 3 94.2 S 17.3 ■40 1 0.95 385.4 ! 2.74 11.24 i 3.35 136.7! 24.8 1.77! 0.34 22.1 ! 11.2
Procetophene (5) 244.2 ! 68.4 2.74 t 0.49 72.5 i 32.6 ■29 i I.Ol 106.6 ! 3 3 . 1 4.95 ± 0.73 639.7 t 78.1 7.06 t 0.34 35.9 ! 13.5
100 mg/kg
tt tt t tt ttt ttt
lecular forre and in the tissues one part is bound to membrane structures.
The method that is currently most often used to measure this activity is
based on the transfer of a glutamyl residue from a synthetic substrate,
gamma-glutamylparanitroanilide, onto an acceptor, usually glycylglycine
(Szasz, 1976).
The GGT activity in human liver is to some extent elevated during va-
rious hepatic disorders (Schmidt, 1978). It seems that the fetal form is
often found in carcinomas (Sawabu et al., 1978). Experimentally, it is re-
latively easy to provoke an increase of GGT activity in rat liver by liga-
ture of the bile duct. Other types of cholestasis can also increase the ac-
tivity of this enzyme. It is important to recognize this effect before in-
terpreting a drug's enzyme inducing effect, since drugs often stimulate bile
secretion (Chivrac et al., 1978 ; Ohnhaus, 1979).
The activity in plasma is usually low and its distribution in an unse-
lected population is not Gaussian. In humans, the plasma GGT activity falls
from birth, until 3 years old, then rises slowly until forty or fifty years
of age. It is much lower in women than in men and depends greatly on the
amount of fat and of overweight (Schiele et al., 1977). Alcool consumption
is an important factor in increasing the activity.
When a population is selected to eliminate the main variation factors,
a much narrower distribution of the activity of this enzyme is obtained. It
is therefore necessary to choose carefully the individuals who constitute
the reference sample for plasma GGT, since in unselected population many
persons show high activities. Thus among men 40 to 60 years old, the 97.5
percentile is at 200 U/l, whereas it is at 65 U/l in the reference sample
of subjects of that age and sex (Figure 2 ) .
Unaltered results sometimes come from the fact that this increase is
small and therefore difficult to measure in liver homogenates or in micro-
somes from certain animal species, such as the rat. This is chiefly becau-
se GGT is located mainly in the cell membranes. The administration of phe-
187
WOMEN
4060
years
HL
♦
2040
years
Efi réf
tol
MEN
♦
4060 II 1 I I I
years 1 | tot
οι ι ι
4
2040
years llll 1 1 1 ·*' | to.
M♦i l
0 50 100 150 200 °° T m / , )
Figure 2. D i s t r i b u t i o n of the plasma GGT a c t i v i t y i n an unselected popula
t i o n in Nancy (France) ( t o t ) and i n a r e f e r e n c e population define by age
and sex ( r e f ) .
I
VModileior j Ζ Vnodiljior C
ι
Hypollptfmc ¡ I
VMocontttKlor
An*tgnic
I
¡ 1
3 VMoconunctor
AnaiotMC
C
] i
AWwtipflMêlH • Anttdapfttunt
Anilonçinol ι ι Antenori*! [
TrenquillMT · ι Tranqu*lu«r D;
Anttoout 1 I
Anticoagulant
AnlWUjtMtlC ¡
ι
AnilrtvotrttmJon ¡ , Ι
Cwdtolonie ¡ Cardiotonic
Hypnotic ι • Ι Hypnotic
Antfconvulunl ι ι i 200
Orii contraceptiv·
12030 yMnl
¡
ι φ" ξ° Ao» 1 2 0 3 0 to
ι
• lima kt 12030 v—ni ramam 12030 rmnì
» β η » 20 β Χ) 20
ΟΟΤΙι GGTnita
Figure 3. Effect of long term drug intake on GGT activities in males and
females 4060 years old as a percentage of the median.
188
nobarbital increases the GGT activity much more in the plasma membranes
than in the microsomal fraction (Tazi et al., 1979).
The effect of inducers other than phénobarbital is less clearly esta-
blished. It seems that they operate not only in the liver, but also under
certain conditions in other organs, particularly the kidney and the intes-
tine. However, we have not found any significant changes in certain circu-
lating blood cells, such as granulocytes (Tarallo, 1978).
The GGT activity is present in hepatocytes and in non-parenchymal
cells isolated from control or phenobarbital-treated rats (Galteau et al.,
in press). The percentages of some other membrane enzymes in the cytoplas-
mic fraction were higher after the administration of inducers.
Chlorpromazine, like deoxycholate, can solubilize GGT from microsomes
and from plasma membranes ; the solubilization is easier when the membrane
preparations" are obtained from phenobarbital-treated animals. Thus phéno-
barbital does not act solely by increasing protein synthesis ; as is now
well known, it also alters the flow and secretion of bile and the lipid
composition of membranes. A more recent study of solubilization by litho-
cholate, deoxycholate, and cholate shows that the dihydroxy bile salts
solubilize membrane enzymes more easily than the trihydroxy salts do (Tazi
et al.,1979). It is important to be aware of this result, because the rela-
tive proportions of the various bile salts can also vary under the influ-
ence of inducing drugs.
Liver tumoo
SSO BUuy a n h o *
600 ObKractm janadfc·
500 Drag kteraa
400 Alcohol toxic drraoak
300 Alcohol toxic »epatiti·
Chronic K t m bepatitia
200 Vini hepatita
Myocardial Infarction dlabtta
150 Non apedfkreactivehepatite
Rhranataanal diaman
Infecţiei» mooooudeod·
120 Fatty Ihcr · Chronic pcnbtcal bepuiti·
105 Ownwifht \
80 Indnrnii ånt> " " * *» phninbareltal l ful
. 70 | Values
(peroraţiei 95) ♦ 40
f Reference ¡attrai (perccntika 95) 1
Maka 2030 yean old ! . II 1 Femalei 2030 yean old 1
7
4 Druga inch aa hypoiponka |
2
0 Deficiency of GGT activity (labora cuor of metaboasn)
CONCLUSION
In conclusion,we think that determining uric glucaric acid and plasma
ganrnaglutamyltransferase are potentially valuable for detecting the enzyme
inducing effects of new drugs for therapy and or experimentation on animals.
Furthermore, we believe that in the near future, these two tests in all cli
nical chemistry laboratories will prove useful for following the course
of therapy with drug combinations that include at least one enzymeinducing
drug (especially when the expected therapeutic results are not obtained).
REFERENCES
Aarts, E.M., 1968. Drugs induced stimulation of the glucuronic acid free
and combined. Thesis Nimegen University.
Bagrel, D., Siest, G. and Galteau, M.M., 1978. Interpretation des varia
tions de l'activité de la gaimnaglutamyltransferase. Etude de l'effet
des médicaments. In : Siest G. et Heusghem C. Ed., Mises au point de
Biochimie Pharmacologique. Masson Pubi., Paris, 2 pp. 236
Burns, J.J. and Connery, A.H., 1966. Metabolism of glucaric acid and its
lactone. In : Dutton G.J., Glucuronic acid free and combined. A cademic
Press, pp. 365.
Cerella, M., D'Arienzo, Α., Manzillo, G. and De Ritis, F., 1976. An eleva
tion of urinary Dglucaric acid excretion during acute hepatitis in
man. Am. J. Dig. Dis., 23 : 18
190
Chivrac, D., Dumont, M. and Erlinger, S., 1978. Lack of parallelism between
microsomal enzyme induction and phenobarbitalinduced hypercholeresis
in the rat. Disgestion, 17 : 516.
Cunningham, J.L. and PriceEvans, D.A., 1974. Urinary Dglucaric acid ex
cretion and acetanilide pharmacokinetics before and during diphenyl
hydantoin administration. Eur. J. clin. Pharmacol., 54 : 778.
Davidson, D.C., Mc Intosh, W.B. and Ford, J.Α., 1974. Assessment of plasma
glutamyl transpeptidase activity and urinary Dglucaric acid excretion
as indices of enzyme induction. Clin. Sci. mol. Med., 47 : 279.
Davis, M., Simmons, C.J., Dordoni, Β., Maxwell, J.D. and Williams, R., 1973.
Induction of hepatic enzymes during normal human pregnancy. J. Obst.
Gyneaco., 80 : 690.
Escartin Marin, P., Rossi, I. and Arenas Mirave, I., 1976. Enzimoinduceion
en cirrosis alcohólicas y criptogenéticas. Rev. Esp. Enf. Αρ. Digest.,
47 : 329·.
Foliot, Α., 1977. Communication personnelle.
Galteau, M.M., Siest, G. and Ratanasavanh, D., (in press). Effect of phéno
barbital on the distribution of gammaglutamyltransferase between
hepatocytes and nonparenchymal cells in the rat. Cell. Molec. Biol.
Gangolli, S.D., Longland, L.D. and Schilling; W.H., 1974. A gas liquid
chromatographic method for the determination of Dglucaric acid in
urine. Clin. clim. Acta, 50 : 237.
Gilbert, J.C., Scott, A.K., Galloway D.B. and Petrie J.C., 1974. Ethosuxi
mide : Liver enzyme induction and Dglucaric acid excretion. Br. J.
clin. Pharmac, 1 : 249.
Hänninen, 0., 1968. On the metabolic regulation in the glucuronic acid
pathway in the rat tissues. Ann. Acad. Sei. Fenn., (Sci. A. C hem.).
142 : 1.
Herzberg, M., Terrenbaum, E., Fishel, Β. and Wiener, M.H., 1977. Dglucaric
acid and gammaglutamyltransferase as indices of hepatic enzyme induc
tion in pregnancy. Clin. Chem., 23 : 596.
Herzberg, M. and Wiener, M.H., 1978. Increased Dglucaric acid excretion
by jaundiced patients. Clin. Chem., 24 : 1759.
Hildebrandt, A.G., Roots, I., Speck, M., Saalfrank, Κ. and Kewitz, Η., 1975.
Evaluation of in vivo parameters of drug metabolizing enzyme activity
in man, after administration of clemastine, phénobarbital or placebo.
Eur. J. clin. Pharmacol., 8 : 327.
Hunter, J., Maxwell, J.D., Stewart, D.A., Parksons, Κ. and William, R.,
1971. Altered calcium metabolism in epileptic children on anticonvul
sants. Br. med. J., 4 : 202.
Khodjet El Khil, R., 1976. Effets d'antiépileptiques et d'hypolipémiants
sur le métabolisme hépatique de l'acide glucuronique. Thèse Pharmacie
Nancy.
Latham, A.N., Turner, P., Franklin, C. and Maclay, W., 1976. Phenobarbitone
induced urinary excretions of Dglucaric acid and 6 ghydroxycortisol
inman. C an. J. Physiol. Pharmacol., 54 : 778.
March, J., Turner, W.J., Shanley, J. and Field, J., 1974. Values for urina
ry excretion of Dglucaric acid by normal individuals. Clin. Chem.,
20 : 1155.
Marselos, M., 1976. Glucaric acid synthesis in the hepatic glucuronic acid
pathway. Thesis University of Kuopio (Finland).
Marsch, C.A. and Carr, A.J.,· '965. Changes in enzyme activity, related to
Dglucaric acid synthesis with age, pregnancy and malignancy. Clin.
Sci., 28 : 209.
191
Meister, Α., 1978. Current status'of the gatuna glutamyl cycle. In : Sies Η.
and Wendel Α. Ed., Functions of glutathione in liver and kidney. Sprin
gerVerlag, Berlin, 2 pp. 43.
Mezey, E., 1976. Increased urinary excretion of Dglucaric acid in alcoho
lism. Res. Commun. Chem. Pathol. Pharmacol., 15 : 735.
Miettinen, T.A. and Leskinen, E., 1970. In : Fisshman W.H. Ed., Metabolic
conjugation and metabolic hydrolysis. Academic Press, pp. 157.
Mowat, A.P., 1968. Developmental effects on liver D glucuronolactone dehy
drogenase levels and on Dglucaric acid excretion in urine. J. endo
crinol., 42 : 585.
Ohnhaus, E.E., 1979. Methods of the assessment of the effect of drug on
liver blood flow in man. Br. J. clin. Pharmac, 7 : 223
Roberts, C., and Jackson, L. and Homeida, M., 1976. Glutethimide and enzy
me induction. Br. Med. J., 2 : 1256.
Rycroft, D. and Daniel, J.W., 1976. The excretion of Dglucaric acid in
the urine of human volunteers following the administration of diso
pyramide. J. Int. Med. Res., 4 : 59.
Sawabu, N., Nakagen, M., Yoneda, M., Makino, H., Kameda, S., Kobayashi, Κ.,
Hattori, N. and Ishii, Μ., 1978. Novel glutamyl transpeptidase isoen
zyme specifically found in sera of patients with hepatocellular car
cinoma. Garin., 69 : 601 ·
Schiele, F., Guilmin, A.M., Détienne, H. and Siest, G., 1977. Gammagluta
myltransferase activity in plasma : Statistical distributions, indivi
dual variations and reference intervals. Clin. Chem., 23 : 1023.
Schiele, F., Neuman, J.L., Le Perron, Β., Galteau, M.M. and Siest, G., 1979.
Plasma enzyme reference intervals : influence of medication taken on
a longterm basis. In : Siest G. and Young D.S. Ed., Drug measurement
and drug effects in laboratory health science. Karger Pubi., Basel,
pp. 185.
Schmidt, F.W., 1978. Rational for the use of enzyme determinations in the
diagnosis of liver disease. In : Demers L.M. and Shaw L.M. Ed., Evalu
ation of liver function. Uraban & Schwarzenbert Pubi., Munich, pp.51
Siest, G., Batt, A.M., Galteau, M.M., Weber, M. and Tridon, P., 1974. In
terference des contraceptifs oraux et des antiépileptiques sur les
paramètres plasmatiques chez l'homme. Etude particulière des enzymes.
Thérapie, 29 : 907.
Simmons, C.J., Davis, M., Dordoni, B. and Williams, R., 1974. Urinary D
glucaric acid assay by an improved enzymatic procedure. Clin. Chim.
Acta, 51 : 47.
Smith, S.E. and Rawlins, M.D., 1974. Prediction of drug oxidation rates in
man : lack of correlation with serum gammaglutamyl transpeptidase
and urinary excretion of Dglucaric acid and 6 ßhydroxy Cortisol. Eur.
J. clin. Pharmacol., 7 : 71.
Sorrell, M.F., Burnett, D.A., Turna, D.J. and Barak, A.J., 1976. Paradoxical
urinary excretion of Dglucaric acid in acute viral hepatitis. Clin.
Pharmacol. Ther., 20 : 365.
Sotaniemi, E.A., Medzihradsky, F. and Eliasson, G., 1974. Glucaric acid as
an indicator of use of enzyme inducing drugs. Clin. Pharmacol. Ther.,
15 : 417.
Szasz, G., 1976. Reaction rate method for γglutamyl transpeptidase activi
ty in serum. Clin. Chem., 22 : 2051.
Talafant, E., Hoskova, A. and Pojerova, Α., 1975. Glucaric acid excretion
as index of hepatic glucuronidation in neonates after phénobarbital
treatment. Pediat. Res., 9 : 480.
Tarallo, P., Lahrichi, M., Batt, A.M. and Galteau, M.M., 1978. Effect of
anticonvulsants drugs on alkaline phosphatase and gamma glutamyltrans
192
J.-J. Himberg
Department of Clinical Pharmacology, University of Helsinki
and Finnish Red Cross Blood Transfusion Service
Helsinki 29, Finland
ABSTRACT
Presently available data of drug effects on vitamin levels has been
reviewed. Antiepileptics, oral contraceptives and cortiocosteroids have a
well documented effect on vitamin concentrations.Antiepileptics increase
serum vitamin A concentration and decrease concentrations of 25-(OH)-chole-
calciferol in serum, vitamin B.. in cerebrospinal fluid and folic acid in
serum, erythrocytes and cerebrospinal fluid. Oral contraceptives increase
concentration of vitamin A in serum and decrease concentrations of toco-
pherol and vitamin B._ in serum, folic acid in serum and erythrocytes, and
ascorbic acid in leuKocytes. Prednisone decreases 1-alpha, 25-(0H). chole-
calciferol concentration in serum. Because the vitamin concentrations also
depend on other factors like 'diet, the lack of controlled studies with
modern analytical methods is evident.
October 1974. The purpose of this paper has been to collect the relevant
data and references presently available. The data has been organized ac-
cording to the vitamins by classical definitions (Kutsky, 1973) but some of
the water-soluble vitamins are not included because of lack of information
on interactions. The drugs which have by definition an effect on vitamins
(i.e. antimetabolites, anticoagulants) can be found in textbooks (Goodman
and Gilman, 1975) and the effects of ethanol or non-therapeutic drugs and
toxins are not included.
FAT-SOLUBLE VITAMINS
VITAMIN A
The compounds having vitamin A activity can be measured reliably with
chemical methods and they reflect the vitamin A status in man (Körner and
Völlm, 1976) . In the transportation of vitamin A in the blood the retinol
binding protein has an important function and some of the changes found
in vitamin A levels are correlated to the changes in the concentration of
the beta-lipoprotein (Smith and Goodman, 1976).
Curtis and Swicord (1976) surveyed one thousand mentally retarded
patients. They found that of the drugs used, only phénobarbital, diphenyl-
hydantoin and thioridazine as well as isosorbidedinitrate had a slight
increasing effect on plasma vitamin A levels.
The oral contraceptives were found to have a significant increasing
effect in three months on vitamin A plasma levels (Gal et al., 1971). In
the study the control group was matched by age and cyclus. The estrogens
were ethinylestradiol and mestranol, and the progestagenes were nore-
thisterone, lynesterol, ethynodioldiacetate and megestrolacetate. No toxic
vitamin A levels were found. Other studies confirm the results (Briggs and
Bennun, 1972) and the mechanism might be secondary to the increased beta-
lipoprotein levels in serum (Heilmann, 1979).
Perorally administered neomycin decreases serum vitamin A levels as
well as the levels of carotenes (Faloon, 1970) .
Cholestyramine decreases vitamin A levels in plasma at a dose of
0.6 g/kg/d during two years treatment in children with familial' hyper-
cholesterolemia (West et al., 1975).
VITAMIN D
During the last fifteen years the metabolism of vitamin D has been
largely discovered and the active metabolites have been found to be acting
like hormones (DeLuca, 1976). After having the methods for measuring the
195
plasma 25OHD, levels at doses 1015 g/d during two years therapy of
children with familial hypercholesterolemia (Tsang et al., 1978).
VITAMIN Κ
The effect of drugs on vitamin Κ levels are seldom of clinical value
because the prothrombin status can be measured with other methods. Many
drugs change the prothrombin levels or interfere with the haemostasis in
other ways. For a review see standard textbooks (i.e. Goodman and Gilman,
1975).
VITAMIN E
The oral contraceptives decrease the alphatocopherol levels in serum
but it may be secondary to the changes of serum lipid or lipoprotein
levels (Aftergood et al., 1975).
Clofibrate at a dose of 400 mg/d for six months together with poly
unsaturated fatty acid rich diet increased the plasma tocopherol levels
in hyperlipidemic patients compared to healthy controls (Vessby et al.,
1977).
Cholestyramine, at a dose of 0.6 g/kg/d, decreased serum tocopherol
levels during two years therapy but the levels remained in normal range
(West et al., 1975).
WATERSOLUBLE VITAMINS
THIAMINE
Thiamine is assayable chemically from biological material but the
techniques have not been practical for clinical purpose. The erythrocyte
transketolase activity has been used for evaluation of vitamin B. status
(Brin, 1962; Dreyfus, 1962). The enzyme activity correlated well with the
thiamine levels in blood (Brubacher et al., 197.2).
Some antimetabolites are known to alter the thiamine levels in man
(Baker and Frank, 1968).
RIBOFLAVIN
The riboflavin blood levels do not correlate well with the vitamin B_
status. Usually the erythrocyte NAPDH_glutathione reductase is used for
the evaluation (Baker and Frank, 1968; Glatzle et al., 1970; Körner and
Völlm, 1976; Kutsky, 1973) though it has to be pointed out that many drugs
and their metabolites also change the glutathione levels (C hasseaud, 1974).
Chlortetracycline at a dose of 13 g/d and Oxytetracycline 2.5 g/d
are found to increase the excretion of riboflavin in urine (cited in
Goodman and Gilman, 1975).
197
NICOTINIC ACID
The evaluation of vitamin B. status on the basis of the nicotinic acid
levels has not been found to be clinically meaningful (Kutsky, 1973; Baker
and Frank, 1968; Körner and Völlm, 1976). One has to consider also that
tryptophan is a precursor of nicotinic acid and many drugs affecting
vitamin B, levels also affect the conversion of tryptophan to nicotinic
acid. In some cases the metabolites have been measured (Körner and Völlm,
1976).
Chlortetracycline increases the urinary excretion of N-methyl-
nicotinamide (Goodman and Gilman, 1975).
VITAMIN B 6
The vitamin B, blood levels correlate well with the vitamin B, status
in man (Körner and Völlm, 1976). In addition to the classical tryptophan
loading test (Wachstein and Gudaitis, 1952) some plasma or erythrocyte
enzymes like aspartate aminotransferase have also been used in the B,
status evaluation (Hamfelt, 1967; Stanulovic et al., 1967).
Antiepileptic drugs hydantoin and succinimide were found to lower
serum pyridoxal levels in four weeks in a prospective study (Reinken,
1973). This confirms the earlier results based on the tryptophan loading
test (Woodbury et at., 1972). The author refer apparently to diphenyl-
hydantoin and ethosuximide by generic names.
The oral contraceptives have a well documented effect on vitamin B,
status (Heilmann, 1979) which was also found with the tryptophan loading
test (Rose, 1966). Norethisterone alone does not change the pyridoxal
metabolism (Rose-Adams and Strong, 1973).
Ieoniazide and cycloserine as well as penicillamine and many natural
compounds are known as vitamin B, antagonists (Brin, 1978).
FOLIC ACID
The effect of drugs on folic acid status are reflected both in haema-
tological parameters and the folate levels. The effects of drugs on
folates have been reviewed by Waxman et al. (1970) and Blakley (1969).
The first megaloblastic anemia induced with antiepileptic drugs was
rapported in 1952, decades after the introduction of the classical anti-
epileptics. Phénobarbital, diphenylhydantoin and primidone decrease
folate concentration in serum, erythrocytes and cerebrospinal fluid in a
high proportion of epileptic patients but macrocytosis develops only in
few patients. The effect is well documented but the mechanism is still
198
VITAMIN B.
The earlier findings can be found in reviews (Corcino et al., 1970;
Waxman et al., 1970).
Longterm anticonvulsant therapy lowers the cerebrospinal fluid
vitamin B.. levels without effect on the serum B. ? and with no sign of
megaloblaetosis (Frenkel et al., 1973).
The oral contraceptives have been found to lower serum vitamin Β η _
levels (Wertalik et al., 1971; Heilmann, 1979) and after prednisone treat
ment the unsaturated B..binding capacity is significantly decreased in
pancytopenic patients (Wysocki et al., 1978).
The treatment of gout with colchisin, tuberculosis with paraamino
salicylic acid and intestinal infections with neomycin lowers the absorp
tion of vitamin B._ measured with Schillingtest (Corcino et al.,1970;
Faloon, 1970).
Both melphalan and busulfan normalize the increased unsaturated B.»
binding capacity in the therapy of polycytemia vera (Rachmilewitz et al.,
1977).
Metformin decreases the absorption of vitamin B... and some diabetics
have decreased serum vitamin Β , levels (Berchtold et al., 1971; Tomkin
et al., 1971). The effect has been confirmed also in volunteers with a
dose of 1.5 g/d for two months (Berchtold et al., 1971).
ABCORBIC A CID
The oral contraceptives have effect on ascorbic acid levels in serum,
leukocytes and thrombocytes as well as on the urinary excretion (Heilmann,
1979). In a study of healthy women using oral contraceptives, sequential or
combined, for at least a year and comparing them to the control group
matched by age, weight, parity and educational level, McLeroy and Schendel
(1973) showed significant lowering of leukocyte ascorbate level of the
group on the pill, regardless of whether or not they took ascorbic acid
supplement. Harris et al. (1973) have found the excretion of ascorbic acid
in urine to be halved in women using oral contraceptives. The mechanism of
the effect of oral contraceptives on ascorbic acid levels is not known, but
it might be secondary to the increased ce nilopläsmin level which activates
ascorbate oxidase (Heilmann, 1979).
Acetosalicylic acid increases the plasma ascorbate levels and the
excretion in the urine but lowers the leukocyte levels at dosages 600 mg/
g.i.d. in four days (Loh et al., 1973).
200
VITAMIN A
serum vitamin A phénobarbital cholestyramine
diphenylhydantoin neomycin
thioridazine
isosorbidedinitrate
oral contraceptives
VITAMIN D
serum 25-(0H)D, phénobarbital
diphenylhydanto in
primidone
colestipol
serum 1 alpha, 25-(0H)„D3 prednisone
VITAMIN E
serum tocopherol Clofibrate oral contraceptives
cholestyramine
RIBOFLAVIN
urine riboflavin Chlortetracycline
Oxytetracycline
cont.
201
VITAMIN B6
serum p y n d o x a l p h o s p h a t e diphenylhydantoin
ethosuximide
VITAMIN B 2
serum vitamin Β 12 oral contraceptives
metformin
cerebrospinal fluid B._ anticonvulsants
Schillingtest/absorpfion
/absorption colchisin
paraaminosalicylic acid
neomycin
metformin
FOLIC ACID
serum, erythrocyte, phénobarbital
cerebrospinal fluid diphenylhydantoin
primidone
serum, erythrocyte phenothiazines
oral contraceptives
methotrexate
pyrimethamine
trimethoprim
Pentamidin
triamteren
metformin
isoniazide
cycloserine
cholestyramine
methionine
ASCORBIC ACID
serum/plasma acetosalicylic acid
leukocytes oral contraceptives
acetosalicylic acid
tetracycline
urine oral contraceptives
tetracycline
REFERENCES
Aftergood, L., Alexander, A.R. and AlfinSlater, R.B., 1975. Effect of
oral contraceptives on plasma lipoproteins, cholesterol and alpha
tocopherol levels in young women. Nutr. Rept. Intern., 11:295304.
Aftergood, L. and AlfinSlater, R.V., 1974. Oral contraceptive alpha
tocopherol interrelationships. Lipids, 9:9196.
Baker, H. and Frank, 0., 1968. Clinical vitaminology. Methods and inter
pretations. Johan Wiley & Sons., Inc., N.Y.
Blekley, R.L., 1969. The biochemistry of folic acid and related pteri
dines. NorthHollan Publishing Co., Amsterdam.
Barragry, J.M., Corlees, D., Auton, J., Carter, N.D., Long, R.G., Maxwell,
J.D. and Switala, S., 1978. Plasma vitamin Dbinding globulin in
202
Hahn, T.J., Halstead, L.R. and Haddad Jr., J.G., 1977. Serum 25hyroxy
vitamin D concentrations in patients receiving chronic corticosteroid
therapy. J. Lab. Clin. Med., 90:399404.
Hahn, T.J., Hendin, B.A., Scharp, C.R., Boisseau, V.C. and Haddad, J.G.,
1975. Serum 25HCC levels and bone mass in children on chronic anti
convulsant therapy. New Engl.J.Med., 292:550554.
Hahn, T.J., Hendin, B.A., Scharp, C.R. and Haddad, J.G., 1972. Effect of
chronic anticonvulsant therapy on serum 25hydroxycalciferol levels
in adults. New Engl. J.Med., 287:900904.
Hamfelt, Α., 1967. Pyridoxal phosphate concentration and amino trans
ferase activity in human blood cells. Clin.Chim.Acta, 16:1928.
Harris, A.B., Hartley, J. and Moor, Α., 1973. Reduced ascorbicacid
excretion and oral contraceptives. Lancet, 2:201202.
Heilmann, E., 1979. Orale Kontrazeptiva und Vitamine. Dtsch. med.
Wschr., 104:144146.
Herbert, V., 1973. Metabolism in folic acid in man, J.Infect. Dis.,
128:S601606.
Hjortshöj, Α., Elsborg, L. and Jensen, E., 1978. Folate status during
longterm therapy with trimethoprim and sulphdiazine. Chemotherapy,
24:327331.
Karlin, R., Dumont, M. and Long, B., 1977. Etude des taux sanguinis
d'acide folique au cours des traitements oestroprogestatifs. J.
Gyn.Obst.Biol.Repr., 6:489495.
Klein, R.G., Arnaud, S.B., Gallagher, J.C., DeLuca, H.F. and Riggs, B.L.,
1977. Intestinal calcium absorption in exogenous hypercortisonism.
Role of 25hydroxyvitamin D and corticosteroid dose. J.Clin.
Invest., 60:253259.
Körner, W.F. and Vollm, J., 1976. Vitamine. In: H.P. Kueramerle, E.R.
Garrett and K.H. Spitzy (Editors), Klinische Pharmakologie und
Pharmakotherapie, 3rd edn. Urban & Schwarzenberg, MünchenBerlin
Wien, pp. 361402.
Kruse, R., 1968. Osteopathien bei antiepileptischer Langzeittherapie.
Mschr. Kinderheilk., 116:378380.
Kutsky, R.J., 1973. Handbook of vitamines and hormones. Van Nostrand
Reinhold Co., N.Y.
Labadarios, D., Dickerson, J.W.T., Parke, D.V., Lucas, E.G. and Obuwa,
G.H., 1978. The effects of chronic drug administration on hepatic
enzyme induction and folate metabolism. Br.J.Clin. Pharmac, 5:
167173.
Latham, A.N., Millbank, L., Richens, A. and Rowe, D.J.F., 1973. Liver
enzyme induction by anticonvulsant drugs, and its relationship to
disturbed calcium and folic acid metabolism. J.Clin.Pharmacol.,
13:337342.
Loh, H.S., Watters, K. and Wilson, C.W.M., 1973. The effects of aspirin
on the metabolic availability of ascorbic acid in human beings.
J.Clin.Pharmacol., 13:480486.
Lukert, B.P. and Adams, J.S., 1976. Vitamin D metabolism in man: effect
of corticosteroids. Arch. Intern.Med., 136:12411248.
Maxwell, J.D., Hunter, J., Stewart, D.A., Ardeman, S. and Williams, R.,
1972. Folate deficiency after anticonvulsant drugs: An effect of
hepatic enzyme induction? Brit.Med.J., 1:297299.
McLeroy, V.J. and Schendel, H.E., 1973. Influence of oral contraceptives
on ascorbic acid concentrations in healthy, sexually mature women.
Amer.J.Clin.Nutr., 26:191196.
Mosekilde, L., Christensen, M.S., Lund, B., Sørensen, O.H. and Melsen, F.,
204
Waxman, S., Corcino, J.J. and Herbert, V., 1970. Drugs, toxins and
dietary amino acids affecting vitamin B12 or folic acid absorption
or utilization. Amer.J.Med., 48:599608.
Weissman, Y., Andriola, M., Reiter, E., Gruskin, A. and Root, Α., 1979
Serum concentrations of 25hydroxyvitamin D in Florida children:
Effect of anticonvulsant drugs. South Med. J., 72:400401.
Wertalik, L.F., Metz, E.N., Lobuglio, A.F. and Balcerzak, S.P., 1971.
Decreased serum B12 levels secondary to oral contraceptive agents.
Amer.J.Clin.Nutr., 24:603.
West, R.J., Fosbrooke, A.S. and Lloyd, J.K., 1975. Treatment of children
with familial hypercholesterolaemia. Postgrad. Med. J., 51.
(Suppl. 8 ) : 8286.
Wickramasinghe, S.N., Williams, G., Saunders, J. and Durston, J.H.J.,
1975. Megaloblastic erythropoiesis and macrocytosis in patients on
anticonvulsants. Brit.Med.J., 2:136137.
Wilms, K., Wiedmann, K.H. and CastrillónOberndorfer, W.L., 1979. Schwere
megaloblastäre Anämie durch Triamteren bei einem Patienten mit alko
holischer Leberzirrhose. Dtsch.Med.Wschr., 104:814817.
Wilson, C.W.M., 1974. Vitamins and drug metabolism with particular refer
ence to vitamin C. Proc.Nutr.Soc., 33:219226.
Windsor, A.C.M., Hobbs, C.B., Treby, D.A. and Astley Cowper, R., 1972.
Effect of tetracycline on leukocyte ascorbic acid levels. Brit.Med.
J., 1:214215.
Woodbury, D.M., Penry, J.K. and Schmidt, R.P. (Editors), 1972. Antiepi
leptic drugs. Raven Press Books Ltd, New York.
Wysocki, H., WieruszWysocka, B., Fenrych, W. and PrazmowskaOwczarek,
B., 1978. Lysozyme activity and unsaturated vitamin B12binding
capacity in the serum after prednisone in patients with bone marrow
aplasia with pancytopenia. Acta Haematol.Pol., 9:231236.
Young, D.S., Pestaner, L.C. and Gibberman, V., 1975. Effects of drugs on
clinical laboratory tests. Clin.Chem., 21:1D432D.
THE INTERACTION BETWEEN ANTIEPILEPTIC THERAPY AND FOLATE AB-
SORPTION AND DISTRIBUTION. A KINETIC APPROACH TO OBTAIN MORE
MEANINGFUL LABORATORY DATA.
POA- PGA
Figure 1.
Metabolic
scheme of intra-
DHF· cellular folate
pathways
Ihymtdl
datoiyuridln·
-
e.10-CH,-THF
5-CHO-THF -5-CHO-THF
c »·.<" ,,..P>
200
Figure 2.
β . oco» mm' Plasma concentration curve
(t 00047 m»!' after an intravenous bolus
injection of 3 mg PGA.
100
300 minutes
/jg PGA
excreted F i g u r e H.
Amount of PGA eliminated
in urine versus corres-
400 ponding area under curve
of PGA plasma concentra-
tion.
200 -
plum« PQA^ig/l
Figure 5 .
200
PGA concentration curves
from the same volunteer
after oral as well as after
i.v. administration of 3 mg
PGA.
100
I I I I I I
20 40 Μ M 100 120 minut·«
Carlos A. Dujovne
Department of Clinical Pharmacology
University of Kansas Medical Center
College of Health Sciences and Hospital
Kansas City, KS 66103 U.S.A.
ABSTRACT
My experience in selecting tests and interpreting clinical laboratory
results during clinical trials is described. Examples of possible problems
in interpreting the abnormalities in commonly performed tests are given.
By keeping in mind the possible mechanism of alterations of test results
following drug administration one may learn to choose tests adequately
and/or to interpret correctly the results of tests used to monitor drug
effects.
INTRODUCTION
While taking care of patients and performing clinical trials with new
and old drugs over the last ten years, I have become increasingly aware of
some of the pitfalls in the interpretation of various clinical laboratory
tests performed to monitor drug toxicity during therapeutic trials or
disease treatments in man (Dujovne et_ aL· , 1971a,b; 1974; 1976a,b; Dujovne,
1977; Dujovne et_ al_., 1979). To evaluate toxic effects by means of the
change in the normal value of a clinical test after administration of a
drug, one must be aware that many causes other than toxic effects of the
drug itself could account for that change. Table 1 includes some of these
possible causes.
REFERENCES
Acocella, G., Nicolis, F.B. and Tenconi, L.T.: The effect of an intraven
ous infusion of rifamycin SV on the excretion of bilirubin, bromosul
phalein, and indocyanine green in man. Gastroent. 49:521525, 1975a.
Bark, C.3.: A rtificial elevation of serum alkaline phasphatase following
albumin infusions. A m. J. Clin. Path. 52:466467, 1969.
Cohen, G.A ., Goffinet, J.Α., Donabedian, R.K. and Coun, H.O.: Observations
on decreased serum glutamic oxalacetic transaminase. (SGOT) activity
in azotemic patients. A nn. Int. Med. 84:275280, 1976.
Dujovne, C.A. and Strauss, H.W.: Changes in liver and spleen scans on pa
tients during treatment with two hypolipidemic drugs. Radiology 98:
682684, 1971a.
Dujovne, C A. , Weiss, P. and Bianchine, 3.R.: Comparative clinical thera
peutic trial with two hypolipidemic drugs, Clofibrate and nafenopin
(SU13437). Clin. Pharmacol. Ther. 12:117125, 1971b.
Dujovne, C A. , Hurwitz, Α., Kauffman, R.E. and Azarnoff, D.L.: Colestipol
and Clofibrate in hypercholesterolemia. Clin. Pharmacol. Ther. 16:
291296, 1974.
Dujovne, C A. , A zarnoff, D.L., Huffman, D.H., Pentikainen, P., Hurwitz, A.
and Shoeman, D.W.: Oneyear trials with halofenate, Clofibrate, and
placebo. Clin. Pharmacol. Ther. 19:352359, 1976a.
Dujovne, C A. , A zarnoff, D.L., Pentikainen, P., Manion, C., Hurwitz, A.
and Hassanein, K.: A twoyear crossover therapeutic trial with halo
fenate and Clofibrate. A m. J. Med. Sc. 272:277284, 1976b.
Dujovne, C A. : A clinical pharmacologist's view of drug hepatotoxicity.
Pharmacol. Res. Comm. 9:115, 1977.
Dujovne, C A. , A zarnoff, D.L., Pentikainen, P., Manion, C and Hurwitz, Α.:
Clofibrate and nicotinyl alcohol tartrate in hyperlipoproteinemic
patients. A m. J. Med. Sc. 277:255261, 1979.
220
ABSTRACT
Heme oxygenase (PO) is a microsomal enzyme in spleen, bone marrow,
liver, kidney, brain and other organs which cleaves the a-methene bridge of
heme to liberate blllverdln, iron and carbon monoxide. Hepatic HO activity
is induced by (a) methemalbuminemia and hemoglobinemia, (b) hypoglycemia and
fasting, (c) hormones (e.g., Insulin, glucagon and epinephrine), (d) organ-
ic xenoblotlcs (e.g., zymosan and bromobenzene), and (e) metal compounds
(e.g., cobalt chloride and gold sodium thlomalate). Induction of HO acti-
vity in liver and other organs may possibly result in increased serum
concentrations of bilirubin and iron, and increased rate of endogenous pro-
duction of carbon monoxide.
INTRODUCTION
During the past decade, research on heme oxygenase (EC 1.14.99.3;
abbreviated HO) has provided Insight into a previously unrecognized mechan-
ism whereby certain xenoblotlcs Influence the metabolism of bilirubin, iron
and carbon monoxide (Bonkowsky et al, 1979). As a consequence, HO has
become a focus for current investigations in laboratories of pharmacology,
toxicology, and clinical biochemistry. The objectives of this manuscript
are: first, to summarize the biochemistry of HO; second, to list the tech-
niques for HO assay; third, to discuss the pathophysiology of HO; fourth,
to tabulate xenoblotlcs which induce HO activity in hepatic microsomes;
fifth, to consider measurements of HO activity In tissue biopsies from
patients; and finally, to suggest that stimulation of HO activity by
hormones, metabolites, and xenoblotlcs may result in increased serum
concentrations of hillrubin and iron, and increased rate of endogenous
production of CO.
BIOCHFMISTRY OF HEME OXYGENASE
Tenhunen et al (1968,1969) showed that microsomes in rat liver and
spleen possess a mixed-function oxidase enzyme (HO), which cleaves the a-
methene bridge of heme. As Indicated in Flg.l, HO has requirements for
NADPH and O2. The products of the HO reaction are CO, Fe and biliverdin-
IXa, which subsequently is reduced by biliverdin reductase to yield bill-
ruhin-IXa. A flavoproteln, NADPH-cytochrome P-450 reductase, is a cofactor
M ν
HC=T^J=CH NADPH
Ρ M
HEME
M V M P P M M V
BILIVERDIN K a
M V M Ρ Ρ M M V
"UUOΠ.
Ν H Ν ^ Ν H V
NADP T
Fig. 1
BILIRUBIN IXa (See legend on
next page)
UROPORPHYRINOGEN HI
ILIVERÛIN H »
Fig. 2
(See legend on
next page)
223
ENDOPLASMIC RETICULUM
■NADP*
(7NADPH)
HO)HVDROXYHEME
©
&■ CO
-►Fa'·
|(?Branch Pathway)
I
,,
BILVERDIN ΓΧ·
► NADP*
FÎŞ. 3
BILIRUBIN LX«
(See legend below)
for HO activity (Schacter et al, 1972; Hino & Minakami, 1979). Some prop
erties of microsomal HO are listed in Table 1.
The relationships between the heme biosynthetic pathway, microsomal
hemoproteins, and the heme degradative· pathway are diagramed in Fig.2.
Mitochondrial δALA synthetase is the initial and ratelimiting enzyme in
heme synthesis. According to a general principle of molecular biology, the
flux of substrate down an unbranched metabolic pathway is often regulated
by endproduct repression of the gating enzyme. C onsonant with this prin
ciple, 6ALA synthetase is repressed by heme. The inhibitory effect of
heme on δALA synthetase activity is responsible for the therapeutic effi
cacy of hematin in acute porphyria (Lamon et al, 1979). The intracellular
heme pool also regulates microsomal HO activity, which is the initial and
ratelimiting enzyme in the pathway of heme catabolism. Thus, the Intra
cellular heme pool exerts a negative feedback effect on heme synthesis by
repression of δALA synthetase activity, and positive feedback effect on
heme degradation by induction of HO activity. The probable reaction
sequence in heme catabolism is shown in Fig.3 (Yoshida & Kikuchi, 1978b).
In step #1, HO binds with ferriherae in a specific configuration so that
only the amethene bridge is accessible for attack by molecular O2· In
•step #2, ferrlheme is reduced to ferroheme by NADPHcytochrome P450 reduc
tase, with consumption of NADPH. In steps #3 and #4, activated oxygen
attacks the amethene bridge of ferroheme to form ahydroxyheme, which is
further oxidized by 2 molecules of O2 to form ferrlbilirubinIXa complex,
with evolution of C O. The requirement for molecular O2 was proven by
18
experiments with 0 2 and H 2 1 8 0 , which showed that the terminal lactam
oxygens of biliverdinIXa and the C O oxygen were derived from molecular O2
and not from water (Tenhunen et al, 1972). Doublelabelling experiments
revealed that the terminal oxygens of the bile pigment were derived from
225
two different 0 2 molecules (King & Brown, 1978). The postulatlon that <*-
hydroxyheme is an intermediate Is supported by an observation that a-oxy-
mesoferrlheme-3H yields mesoblllverdln-3H (Kondo et al, 1971). Epoxides
have been suggested as intermediates in the oxidative attack on ferroheme
(step #3) (Hamilton & Dolphin, 1977). According to Yoshlda and Kikuchi
(1978b), the Fe[III]-blllverdln-IXa complex is reduced by NADPH-cytochrome
P-450 reductase in step #5, with release of biliverdin-IXa and iron.
Yoshlda and Klkuchl (1978b) inferred that step #5 may be the rate-limiting
stage of the over-all HO reaction.
In Pig.3, a dashed arrow has been inserted in the reaction sequence
after step #5 to indicate the possible existence of a branch pathway in
heme degradation. Landaw et al (1970) administered heme- C by iv injec-
tion to rats that had been treated with allylisopropylacetamide (AIA), and
observed that the molar ratio of '''CO production to bilirubin-ll4C produc-
55
tion was significantly >1.0. Raffin et al (1974) measured release of Fe
55
and production of bilirubin from heme- Fe by post-mitochondrial superna-
55
tant of rat intestinal mucosa. On a molar basis, the rate of Fe-release
significantly exceeded the rate of bilirubin formation. Pimstone et al
(1971b) noted that in assays of HO activity in rat and rabbit macrophages,
the rates of heme consumption consistently exceeded the rates of bilirubin
production. Lodola et al (1979) also observed that the rate of heme disap-
pearance exceeded the rate of bilirubin appearance during heme cataholism
by rat hepatic post-mitochondrial supernatant. From these studies, it
appears that biliverdin and bilirubin, albeit predominant, may not be the
only pyrrole-containing products of heme degradation.
Del Ivor iaPa padopoulos, M., Cobiirn, R.F. & Forster, R.E. : Cyclic variation
of rate of carbon monoxide production in normal women. J. A ppi. Phy
siol., 36:4951, 1974.
De Hattels,F.: Irondependent degradation of liver haem in vivo. In: Por
phyrins in Human Diseases, M. Doss (Ed.), S. Karger, Basel, pp. 3742,
1976.
Eiseman, J.L. & Alvares, A.P. : Alterations induced in heme pathway enzymes
and monooxygenases by gold. Mol. Pharmacol., 14:11761188, 1978.
Frydman, R.B., A wruch, J., Tomaro, M.L. & Frydman, B. : Concerning the
specificity of heme oxygenase: The enzymatic oxidation of synthetic
hemlns. Biochem. Biophys. Res. Commun., 87:928935, 1979.
Gemsa, D., Woo, C.H., Fudenberg, H.H. & Schmid, R. : Stimulation of heme
oxygenase in macrophages and liver by endotoxin. J. Q in. Invest., 53:
647651, 1974.
Gu zel ian, P.S. & Elshourbagy, Ν. Α. : Induction of hepatic heme oxygenase
activity by bromobenzene. A rch. Biochem. Biophys., 196:178185| 1979.
Hamilton, A .D. & Dolphin, D. : On the formation of bile pigments from heme
proteins. Heterocycles, 7:817829, 1977.
Hino, Y., Asagami, H. & Minakaml, S.: Topological arrangement in microsomal
membranes of hepatic haem oxygenase induced by cobalt chloride. Bio
chem. J., 178:331337, 1979.
Hino, Y. & Minakaml, S. : Electrontransport pathway of the NA DHdependent
haem oxygenase system of rat liver microsomal fraction induced by
cobalt chloride. Biochem. J., 178:323329, 1979.
King, R.F.G.J. & Brown, S.B.: The mechanism of haem catabolism. Biochem.
J., 174:103109, 1978.
Kondo, T., Nicholson, D.C., Jackson, A .H. & Kenner, G.W. : Isotopie studles
of the conversion of oxyphlorins and their ferrihaems into bile pig
ments in the rat. Biochem. J., 121:601607, 1971.
Krasny, H.C. & Holbrook, D.J. , Jr.: Effects of cadmium on heme oxygenase
and hemoproteins in smooth and rough endoplasmic reticulum of rat
liver. Biochem. Pharmacol., 27:364366, 1978.
Lahdevlrta, J. & Tenhunen, R.: Heme catabolism in human kidneys: Effect of
various nephriditee. Clin. Chim. Acta, 77:125130, 1977.
Lamon, J.M., Frykholm, B.C., Hess, R.A . & Tschudy, D. P. : Hematin therapy
for acute porphyria. Medicine, 58:252260, 1979.
Landaw, S.A ., Callahan, E.W., Jr. & Schmid, R. : Catabolism of heme in vivo:
Comparison of the simultaneous production of bilirubin and carbon mon
oxide. J. Clin. Invest., 40:914925, 1970.
Lod ola, Α., Hendry, G.A .F. & Jones, O.T.G. : Haem oxygenase: A reappraisal
of the etoicheiometry. FEBS Letters, 104:4550, 1979.
Lundh, B., Johansson, MB., Mercke, C. & CavaliinStahl, E.: Enhancement of
heme catabolism by caloric restriction in man. Scand. J. Clin. Lab.
Invest., 30:421427, 1972.
Lynch, S.R. & Moede, A.L.: Variation in the rate of endogenous carbon mon
oxide production in normal human beings. J. Lab. Clin. Med., 70; 85
95, 1972.
Mahonen, Y., Anttlnen, M., Vuopio, P. & Tenhunen, R. : Bone marrow: Its con
tribution to heme catabolism. A nn Clin. Res., 8(Suppl.l7) :^538, 1976.
Maines, M.D. : Role of trace metals in regulation of cellular heme and
hemoprotein metabolism: Sensitizing effects of chronic iron treatment
on acute gold toxicity. Drug Metabolism Rev., 9:237255, 1970.
Maines, M.D., Ibrahim, N.G. & Kappas, Α.: Solubilization and partial puri
fication of heme oxygenase from rat liver. J. Biol. Chem., 252: 5900
5903, 1977.
Maines, M.D. & Kappas, Α.: Cobalt stimulation of heme degradation in the
liver. J. Biol. Chem., 250:41714177, 1975a.
Maines, M.D. & Kappas, Α.: Study of developmental pattern of heme catabo
lism in liver and the effects of cobalt on cytochrome P450 and the
rate of heme oxidation during the neonatal period. J. Exper. Med.,
141:14001410, 1075b.
Maines, M.D. & Kappas, Α.: Studles on the mechanism of induction of haem
oxygenase by cobalt and other metal ions. Biochem. J., 154:125131,
1976a.
234
Maines, M.D. & Kappas, Α.: The induction of heme oxidation in various tis
sues by trace metals: Evidence for catabolism of endogenous heme by
hepatic heme oxygenase. Ann. Clin. Res., 8(Suppl.l7):3946, 1976b.
Maines, M.D. & Kappas, Α. : Induction of hepatic heme oxygenase by metals.
In: Porphyrins in Human Diseases, M. Doss (Ed.), S. Karger, Basel, pp.
4352, 1976c.
Maines, M.D. & Kappas, Α.: Nickel mediated alterations in the activity of
hepatic and renal enzymes of heme metabolism and heme dependent cellu
lar activities._ In: C linical C hemistry and C hemical Toxicology of
Metals, S.S. Brown (Ed.), Elsevier, Amsterdam, pp. 7581, 1977a.
Maines, M.D. & Kappas, Α.: Metals as regulators of heme metabolism.
Science, 198:12151221, 1977b.
Morrison, B., Shenkin, Α., McLelland, Α., Robertson, D.A., Barrowman, Μ.,
Graham, S., Wuga, G. & C unningham, K.J.M.: Intraindividual variation
in commonly analyzed serum constituents. C lin. C hem., 25:17991805,
1979.
Necheles, T.F., Rai, U.S. and Valaes, T.: The role of haemolysis in neo
natal hyperbilirubinaemia as reflected in carboxyhaemoglobin levels.
Acta Paediat. Scand., 65:361367, 1976.
Pasternak, A. & Tenhunen, R. : Low serum bilirubin in chronic renal failure:
Relation to haem metabolism. C lin. Chim. Acta, 67:8592, 1976.
Pimstone, N. R., Engle, P., Tenhunen, R., Seitz, P. T., Marver, H. S. &
Schmid, R. : Inducible heme oxygenase in the kidney: A model for the
homeostatic control of hemoglobin catabolism. J. C lin. Invest., 50:
20422050, 1971a.
Pimstone, N.R., Tenhunen, R., Seitz, P. T., Marver, H. S. & Schmid, R. : The
enzymatic degradation of hemoglobin to bile pigments by macrophages.
J. Exp. Med., 133:12641281, 1971b.
Raffin, S.B., Woo, C.H., Roost, Κ. Τ., Price, D.C. & Schmid, R. : Intestinal
absorption of hemoglobin iron: Heme cleavage by mucosal heme oxy
genase. J. C lin. Invest., 54:13441352, 1974.
Roost, K.T., Pimstone, N.R., Diamond, I. & Schmid, R. : The formation of
cerebrospinal fluid xanthochromia after subarachnoid hemorrhage.
Neurology, 22:973977, 1972.
Sassa, S., Walther, R. & Kappas, Α.: Radioactive assay for microsomal heme
oxygenase activity utilizing 55FeprotoporphyrlnIX as substrate. Fed.
P r o c , 38:460 (Abstract #1224), 1979.
Schacter, B.A. : Assay of microsomal heme oxygenase in liver and spleen. In:
Methods in Enzymology, S.P. C olowick & N.O. Kaplan (Eds.), Academic
Press, New York, Vol. LIIc, pp. 367372, 1978.
Schacter, B.A. & Mason, J.I.: The effect of phénobarbital, 3methylcholan
threne, 3,4benzpyrene and pregnenolone16acarbonitrile on microsomal
heme oxygenase and splenic cytochrome P450. Arch. Biochem. Biophys.,
160:274278, 1974.
Schacter, B.A., Nelson, E.B., Marver H.S. & Masters, B. S. S. : Immunochemical
evidence for an association of heme oxygenase with the microsomal
election transport system. J. Biol. Chem., 247:36013607, 1972.
Schacter, B.A. & Waterman, M.R.: Activity of various metalloporphyrin pro
tein complexes with microsomal heme oxygenase. Life Sci., 14:4753,
1974.
Schacter, B. A., Yoda, B. & Israels, L.G.: Human spleen heme oxygenase and
microsomal electron transport system component activity in normals and
in patients with hemolytic anemia, idiopathic thrombocytopenic purpura
and lymphoproliferative disorders. J. Lab. C lin. Med., 93:838846,
1979.
Shibahara, S., Yoshida, T. & Kikuchi, G. : Induction of heme oxygenase by
hemin in cultured pig alveolar macrophages. Arch. Biochem. Biophys.,
188:243250, 1978.
Stewart, R.D., Fisher, T.N., Hosko, M.J., Peterson, J. Ε., Baretta, E.D. &
Dodd, H.C .: C arboxyhemoglobin elevation after exposure to dichloro
methane. Science, 176:295296, 1972.
Sunderman, F.W., Jr. & Downs, J.R. : Assay of heme oxygenase activity. In:
Seminar Manual of Procedures for Biochemical Hematology, F.W. Sunder
man (Ed.), Institute for C linical Science, Philadelphia, pp. 2642,
1979.
235
0
Laboratoire du Centre de Médecine Préventive (Dir.Pr G.Siest), 2 Avenue
du Doyen Jacques Parisot 54500 Vandoeuvre-lès-Nancy, France
00
Chef du Service de Médecine Interne orientée vers l'alccologie
Centre Hospitalier Régional de Nancy, 29 Avenue du Maréchal de Lattre de
Tassigny, Case Officielle n°34, 54037 Nancy Cedex, France
ABSTRACT
After having received the principle mechanism of alcohol metabolism,
the authors reaffirmed the high correlation between GGT and an increasing
consumption of alcohol. Moreover the variations of this parameter before
and after the detoxication cure, reconfirm the effect of alcoholic con-
sumption on this enzyme. The authors demonstrate a significant decrease
in the levels of AlAT in males and in females, when the declared consump-
tion of alcohol is higher than class 22-44 g of alcohol daily. In the
males, the mean comparison showed a significant decrease in the level of
ceruloplasmine according to increased alcohol consumption.
However, if it is necessary to have as exact as possible an estima-
tion of a patient's alcoholic intake, still more discriminative biolo-
gical indices of alcohol consumption must be sought.
INTRODUCTION
It has been shown that habitual ethanol exposure results in profound
biochemical and morphologic changes (Lieber, 1975). Ethanol can be synthe-
tized endogenously in trace amounts but it is primarily an exogenous
compound that is readily absorbed from the gastro-intestinal tract. Only
2 to 10 % of the amount absorbed is eliminated through the kidneys and
lungs. The rest must be oxidized in the body, principally in the liver.
The main hepatic pathway for ethanol disposition involves alcohol
deshydrogenase, an enzyme that catalyses the conversion of ethanol to
acetaldehyde. Hydrogen is transfered from ethanol to the cofactor
nicotinamide adenine dinucleotide (NAD), which is converted to its
reduced form (NADH). The acetaldehyde which is newly produced loses
hydrogen and is converted to acetate. In addition, ethanol can also be
metabolized by an accessory pathway that requires NADPH as a cofactor and
is localized in the endoplasmic reticulum (figure 1). The rate of the
non ADH mediated oxidation varied depending on the concentrations of
ethanol used, from 20 to 25 %, to half or more of the total ethanol
metabolism.
237
HYPERURICEMIA ■ HYTERLACTACIDEMIA E
MUCOS
c
'fc
%
^ROCHOWMQ,
PYRUV»tf · * '
1. Little or none
2. Less than 1/4 liter per day
3. Between 1/4 and 1/2 liter per day
4. Between 1/2 and 1 liter per day
5. Between 1 and 2 liters per day
6. More than 2 liters per day
239
GGT activity in all of the subjects confirms that the median and dis-
persion of the values increase as the avowed consumption of wine increases
(figure 2 ) . This variations was also observed in subjects aged between
20 to 30 years old, who where selected from a male population ranging from
20 to 100 years. The study of the 5, 50 and 95 percentiles confirm this
increase in GGT activity parallel with an avowed increase of wine
consumption (table II) .
GOT (D I )
MEN
A(* a o . l o o
ol&aa of ooMumptlon
Percentiles
Reported consumption Ν 5 50 95
(wine)
Class of consumption
0.961
0.937
0.901
0.700
Ν .88
m . 108.83
• .181.M
β S ** S
s ; ; s § s s s s
Figure 4: Histogram of GGT activity before a desintoxication cure
Ν.84
m . S3,27
a . 62.21
s
= . Ş ς ş 3 S S E ! ij Ι °° τ
3 ; S 5 S 3 Ï S S S H
Figure 5: Histogram of 66T a c t i v i t y afiter a d e s i n t o x i c a t i o n cure
As f a r as s p e c i f i c p r o t e i n s are concerned t h e l e v e l s of A.AT in a
subpopulation of 675 i n d i v i d u a l s o l d e r than 20 (319) males. The d a i l y
consumption of alcohol was c a l c u l a t e d i n grams according to the following
classification:
l e s s than 10 g
10 t o 22 g
22 t o 44 g
44 t o 88 g
more than 88 g alcohol in a d a i l y b a s i s ( f i g u r e 6)
We were thereby able t o demonstrate a s i g n i f i c a n t e f f e c t of h a b i t u a l
alcohol consumption i n the l e v e l s of A.AT. Indeed, we confirmed a s i g n i f i
cant decrease i n the l e v e l s of A AT i n males ( t » 3 . 0 8 , ρ > 0.01) and in
females ( t = 3 . 9 3 , ρ > 0 . 0 0 1 ) , when the d e c l a r e d consumption of alcohol
i s h i g h e r than c l a s s 2244 g of alcohol d a i l y . However, an alcohol i n t a k e
h i g h e r than 44 g leads t o an i n c r e a s e in the l e v e l s A.AT compared with
values observed i n t h e preceding c l a s s .
We were a l s o i n t e r e s t e d by another s p e c i f i c p r o t e i n namely c e r u l o
plasmine. This p r o t e i n was determined on a p o p u l a t i o n of 639 i n d i v i d u a l s
of both sex and o l d e r than 4 y e a r s . In the males, the mean comparison
(determined by s t u d e n t ' s t e s t ) showed a s i g n i f i c a n t decrease in the l e v e l
of ceruloplasmine according t o i n c r e a s e d alcohol consumption (a < 0 . 0 1 ) .
243
i/i
i.*o
i.T»
U t
t.M IA·
f/l
01M
0,·!· ati·
o,*oa o.ao«
0 10 44 88
Aloohol oooBUmaUon/dvy Alcohol oonaumptkio/dagr
CONCLUSION
We have reaffirmed Che high correlation between GGT and an increasing
consumption of alcohol. Moreover the variations of this parameter before
and after the detoxication cure, reconfirm the effect of alcoholic con
sumption on this enzyme. Nevertheless as a reported in an earlier article,
GGT, by itself, appears to have an insufficient discriminative power.
(Bagrel, 1979). However, after having tested different variables (iron,
GGT, mean erythrocyte volume (MCV), mean erythrocyte hemoglobin concentra
tion, urea, uric acid and alanine aminotransferase). We showed that the
three variables that correlated most significantly with alcohol consum
ption were GGT, MCV and the use of tobacco.
The work involving AjAT and ceruloplasmine permits us to confirm
that alcohol, as a result of its effect in the rough endoplasmic reticu
lum, leads to a decrease in protein synthesis.
The variations in GGT and the decrease of certain specific proteins
may be investigated in a multiparametric analysis. However, critical
evaluation leads us to conclude that still more discriminative biological
indices of alcohol consumption must be sought.
We have two motivating reasons to establish the real alcoholic
consumption in our population:
1. Firstly, due to the risk which chronic alcoholism constitutes for the
individual himself, for his family and the immediate environment
2. Secondly, before interpretation of the results of laboratory tests,
it is necessary to have as exact as possible an estimation of a patient's
alcoholic intake.
REFERENCES
Bagrel, Α., D'Houtaud, Α., Gueguen, R. and Siest, G.: Relations between
reported alcohol consumption and certain biological variables in an
"unselected" population. Clin. Chem., 25: 12421246, 1979.
Lieber, C S . : Interference of ethanol in hepatic cellular metabolism.
Ann. N.Y. Acad. Sci., 252: 2450, 1975.
Lieber, C S . : Metabolic aspects of alcoholism. MTF ed., 1977.
EFFECTS OF DRUGS"ON THYROID FUNCTION TESTS
Kristian Lievendahl
Department of Clinical Chemistry, University of Helsinki,
and Minerva Foundation Institute, Helsinki 29, Finland
ronines other than T., mono and diiodotyrosines and iodoproteins, the
proportion of which can increase in various thyroidal and nonthyroidal
diseases. Iodinated drugs that bind to serum proteins, spuriously elevate
the serum PBI. The number of such drugs is very large and includes, among
others, expectorants, local disinfectants, intestinal antiseptics and
radiographic contrast media. The effect on the PBI can last from a few
days to many years depending on the amount of drug ingested, the affinity
between drug and serum proteins, and the rate of drug elimination.
Urographie and other intravenous contrast media usually cause false PBI
values for a few weeks, whereas the effect of cholecystographic contrast
media and clioquinol may last for several months. After the use of oily
contrast media elevated PBI values can persist for many years (see
reviews by Liewendahl, 1968; Acland, 1971).
interindividual variations in dietary iodide and the use of this test has
declined as a result of the introduction of specific hormone assays. It
must also be recognized that chronic administration of excess iodide
occasionally results in hypothyroidism (Wolff, 1969), particularly in
patients with an underlying thyroid abnormality such as autoimmune thy-
roiditis (Liewendahl and Turula, 1972), and that excess iodide can pre-
cipitate hyperthyroidism in susceptible individuals (Liewendahl and
Gordin, 1974).
ANTICONVULSANT DRUGS
In patients given diphenylhydantoin (DPH) the serum PBI is depressed
(Oppenheimer et al., 1961; Wolff et al., 1961). This observation has been
verified in subsequent studies using T, competitive protein-binding (CFB)
procedures (Stjernholm et al., 1975; Liewendahl and Majuri, 1976) and T^
radioimmunoassay (RIA) (Liewendahl et al., 1978). It is particularly
interesting that although these patients also have decreased serum free
T, levels they remain eumetabolic. The decrease in T. and free T_ was
found to be quite small, therefore providing an explanation, at least
partly, why clinical euthyroidism is maintained and why there is no signi-
ficant effect on serum TSH or the TSH response to TSH-releasing hormone
(TRH) (Liewendahl and Majuri, 1976; Peyma et al., 1977).
High concentrations of DPH displace T, from its binding sites on T,-
binding globulin (TBG) (Wolff et al., 1961; Oppenheimer and Tavernetti
1962). However, the in vitro displacing effect of therapeutic concentra-
tions of DPH is much too small to explain the average decrease in T, and
free T, of about 25 X seen in patients (Liewendahl et al., in press).
There is now, indeed, substantial evidence that the effect of DPH on
serum T, is mainly due to an accelerated T. metabolic clearance rate
(Larsen et al., 1970). DPH is a potent stimulator of hepatic microsomes
(Hvidberg and Dam, 1976) and the increased T, clearance rate is probably
due to induction of T, metabolizing enzymes. In rats DPH stimulates the
hepatic enzyme converting T, to T, (Hiifner and Knöpf le, 1976). Assuming
that DPH also increases the production of T. from T, in man via stimula-
tion of the converting enzyme the almost normal serum T, despite an -
accelerated T- metabolic clearance rate, becomes understandable.
Carbamazepins (CBZ) was recently found also to decrease serum total
and free T,, whereas the effect on total and free T 3 was small (Liewen-
dahl et al., 1978; Rootwelt et al., 1978). CBZ is a stimulator of hepatic
248
PSYCHOTROPIC DRUGS
Studies on the in vitro effects of benzodiazepine derivatives have
shown that diazepam and, to a lesser extent, chlordiazepoxide, by com
peting with thyroid hormones for binding sites on TBG, raise the T, (C PB)
and T U tests (Schussler, 1971; ElHazmi, 1975). Although the results of
in vivo studies are controversial the main bulk of evidence favours the
conclusion that therapeutic doses of these drugs have no significant
effect on thyroid function.
The tricyclic and tetracyclic antidepressant drugs amitriptyline and
mianserin did not affect serum total or free thyroid hormones (Liewendahl
et al., in press). Neither did treatment with the tricyclic antidepres
sants chlorimipramine and nortriptyline influence the basal or TRHstimu
lated level of TSH (Widerlöv et al., 1978).
Lithium therapy can cause goitre and hypothyroidism but the exact
mechanism by which the lithium ion inhibits thyroid hormone biosynthesis
is still a matter of dispute (Blomqvist et al., 1977) . Patients with an
underlying thyroidal abnormality appear to be particularly susceptible to
lithium and in this respect the effect of lithium resembles that of excess
iodide. There is usually reversal of hypothyroidism after withdrawal of
lithium and iodide.
Raised serum PBI levels during treatment with perphenazine have not
been confirmed with methods specific for Τ,, and appear to have been caused
by iodine contaminants in some drug formulations (Mølholm Hansen and
SiersbaekNielsen, 1967). The phenothiazine drugs chlorpromazine and
thioridazine suppress the serum TSH response to TRH but do not affect
thyroid function (Lamberg et al., 1977). This effect might be due to the
alfaadrenoreceptor blocking property of these drugs since phentolamine,
a specific alfaadrenergic antagonist, also inhibits the TSH response to
TRH (Nilsson et al., 1974). Administration of Ldopa, or its metabolite
dopamine, also inhibit the TSH response to TRH without affecting the serum
thyroid hormones (Spaulding et al., 1972). These and other studies with
central neurotransmitter agonists and antagonists indicate the existence
of stimulatory alfaadrenergic and inhibitory dopaminergic physiological
mechanisms regulating the pituitary secretion of TSH (Scanlon et al.,1978).
Patients with alcoholic liver disease may have elevated serum free T,
and TSH, and low serum T, and free T, (C hopra et al., 1974) , but no acute
effects of ethanol on serum thyroid hormones and basal or TRHstimulated
251
serum TSH have been observed (Ylikahri et al., 1978). During the hangover
period, the prolactin response to TRH was totally blocked indicating that
withdrawal symptoms are associated with increased dopaminergic activity in
the hypothalamus (Ylikahri et al., 1978).
ADDICTIVE DRUGS
The use of heroin, its active metabolite morphine, or methadone can
result in increased serum T, and T. due, at least partly, to an increase
in TBG, whereas the free hormone concentrations remain essentially normal
(Webster et al., 1973; Bastomsky et al., 1977; Chan et al., 1979). The
increase in TBG is accompanied by a retarded T, metabolic clearance rate,
but the T, degradation rate is normal in accordance with the clinical
euthyroidism in narcotic addicts (Azzizi et al., 1974). Since hepatic
dysfunction in drug addicts was usually mild other pathogenetic mechanisms
responsible for the observed abnormalities in thyroid hormone metabolism
probably exist.
ENVIRONMENTAL TOXIC SUBSTANCES
The highly toxic tetrachlorodibenzo-p-dioxan (TCDD), a contaminant
in herbicides and pesticides, also seems to be an environmental risk
factor from the point of view of thyroid function: in the rat TCDD, a
potent inducer of hepatic microsomal enzymes, was found to increase
biliary excretion of T,, but not of T_, resulting in decreased serum T,,
increased TSH and goitre (Bastomsky, 1977).
Carbon disulphide (CS~) seems to be another environmental factor with
adverse effects on thyroid function since a significant decrease in serum
T, with increased duration of exposure to this compound in viscose factory
workers has been reported (Cavalieri, 1975). Whether this decrease in
thyroid function is due to a direct effect on the thyroid gland, altera-
tion of T> metabolism, or results from involvement of hypothalamic or
hypophyseal functions is unclear. Clinical hypothyroidism during exposure
to CS2 seems unlikely since a decrease in serum free T, or T- does not
occur (Wägar et al., personal communication).
MISCELLANEOUS
When added in vitro to serum salicylates displace T, and T, from
their binding to TBG and TBPA thereby increasing their free fractions
(Larsen, 1972). Administration of therapeutic amounts of salicylate
results in a decrease of about 25 X in serum T, and T., and also, due to
a higher percentage increase in the corresponding free hormone fractions,
252
SUMMARY
Suppression: Enhancement:
chlorpromazine theophylline
thioridazine amiodarone
phentolamine iopanoate, ipodate
Ldopa, dopamine estrogens (in men)
bromo cr i ptine
glucocorticoids,
salicylates
REFERENCES
Acland, J.D.: The interpretation of the serum proteinbound iodine.
A review. J. C lin. Path. 24: 187218, 1971.
Azzizi, F., Vagenakis, A.6., Fortnay, G.I., Braverman, L.E. and Ingbar,
S.H.: Ann. Int. Med. 80: 194199, 1974.
Bastomsky, C.H.: Enhanced thyroxine metabolism and high uptake goiters
in rats after a single dose of 2,3,7,8tetrachlorodibenzopdioxin.
Endocrinology 101: 292296, 1977.
Bastomsky, C.H., Dent, R.R.M, and Tolis, G.: Elevated serum concentrations
of thyroxinebinding globulin and caeruloplasmin in methadonemain
tained patients. C lin. Biochem. 10: 124126, 1977.
Blomqvist, Ν., Lindstedt, G., Lundberg, P.A. and Wålander, J.: No inhibi
tion by L i + of thyroxine monodeiodination to 3,5,3'triiodothyronine
and 3,3',5'triiodothyronine (reverse triiodothyronine). C lin. Chim.
Acta 79: 457464, 1977.
Burger, Α., Dinichert, D., Nicod, P., Jenny, M., LemarchandBéraud, T.
and Vallotton, M.B.: Effect of amiodarone on serum triiodothyronine,
reverse triiodothyronine, thyroxine and thyrotropin. J. Clin. Invest.
58: 255259, 1976.
Biirgi, H. , Wimpfheimer, C., Burger, Α., Zaunbauer, W., Rosier, Η. and
LemarchandBéraud, T.: Changes of circulating thyroxine, triiodo
thyronine and reverse triiodothyronine after radiocontrast agents.
J. Clin. Endocr. 43: 12031210, 1976.
Cavalieri, R.R., Sung, L.C. and Becker, CE . : Effects of phénobarbital on
thyroxine and triiodothyronine kinetics in Graves' disease. J. Clin.
Endocr. 37: 308316, 1973.
Cavalieri, Α.: Serum thyroxine in the early diagnosis of carbon disulfide
poisoning. Arch. Environ. Health 30: 8587, 1975.
Chan, V., Wang, C. and Yeung, R.T.: Effects of heroin addiction on thyro
trophin, thyroid hormones and prolactin secretion in men. C lin.
Endocr. 10: 557565, 1979.
255
Chopra, I.J., Solomon, D.H., Chopra, U., Yound, R.T. and Chua Te Teco,
G.N.: Alterations in circulating thyroid hormones and thyrotropin in
hepatic cirrhosis: evidence of euthyroidism despite subnormal serum
triiodothyronine. J. Clin. Endocr. 39: 501511, 1974.
Chopra, I.J., Williams, D.E., Orgiazzi, J. and Solomon, D.H.: Opposite
effects of dexamethasone on serum concentrations of 3,3'^'triiodo
thyronine (reverse T) and 3,3',5triiodothyronine (T3). J. Clin.
Endocr. 41: 911920, 1975.
Duick, D.S., Warren, D.W., Nicoloff, J.T., Otis, C.L. and Croxson, M.S.:
Effect of single dose of dexamethasone on the concentration of serum
triiodothyronine. J. Clin. Endocr. 39: 11511154, 1974.
Elfving, S. and Peltola, P.: The antithyroid effects of naturally oc
curring goitrogen 5vinyl2thiooxazolidone. 10th Annual Meeting of
the European Thyroid A ssociation. A nn. d'endocrinol. 40: 14A, 1979.
ElHazmi, M.A.F.: On the interaction between thyroid hormones and the
tranquillizers Librium (R) and Valium (R). Clin. Chim. Acta 63:
211221, 1975.
Faglia, G., Ferrari, C , BeckPeccoz, P., Spada, Α., Travaglini, P. and
Ambrosi, B.: Reduced plasma thyrotropin response to thyrotropin
releasing hormone after dexamethasone administration in normal sub
jects. Horm. Metab. Res. 5: 289292, 1973.
Faglia, G., Ambrosi, Β., BeckPeccoz, P., Travaglini, P. and Ferrari, C :
The effect of theophylline on plasma thyrotropin (HTSH) response to
thyrotropin releasing factor (TRF) in man. J. Clin. Endocr. 34: 906
909, 1972.
Gamstedt, Α., Järnerot, G., Kågedal, B. and Söderholm, B.: Corticosteroids
and thyroid function. A cta Med. Scand. 205: 379383, 1979.
Hamo1sky, M.W., Stein, M. and Freedberg, A.S.: The thyroid hormone
plasma protein complex in man. II. A new in vitro method for study
of "uptake" of labelled hormonal components by human erythrocytes.
J. Clin. Endocr. 17: 3344, 1957.
Harland, W.A. and Orr, J.S.: The effect of Clofibrate on thyroxine metab
olism. Ed. W.A. Harland and J.S. Orr, pp. 6786 (A cademic Press,
London 1975).
Heyma, P., Larkins, R.G., PerryKeene, D., Peter, C T . , Ross, D. and
Sloman, J.G.: Thyroid hormone levels and protein binding in patients
on longterm diphenylhydantoin treatment. Clin. Endocr. 6: 369376,
1977.
Hollander, C.S., Scott, R.L., Burgess, J.Α., Rabinowitz, D., Merimee, P.J.
and Oppenheimer, J.H.: Free fatty acids: a possible regulator of free
thyroid hormone levels in man. J. Clin. Endocr. 27: 12191223, 1967.
Hilf ner, M. and Knöpf le, M.: Pharmacological influences on T» to T, con
version in rat liver. Clin. Chim. Acta 72: 337341, 1976.
Hvid Hansen, H.: Sephadex binding of 131llabelled Ltriiodothyronine as
a test of thyroid function. Scand. J. Clin. Lab. Invest. 18: 240
244, 1966.
Hvidberg, E.F. and Dam, M.: Clinical pharmacokinetics of anticonvulsants.
Clin. Pharmacokinet. 1: 161188, 1976.
Korsgaard Christensen, L.: Thyroxinereleasing effect of salicylateand
of 2,4dinitrophenol. Nature 183: 11891190, 1959.
Lamberg, B.A., Linnoila, M., Fogelholm, R., Olkinuora, M., Kotilainen, P.
arid Saarinen, P.: The effect of psychotropic drugs on the TSHre
sponse to thyroliberin (TRH). Neuroendocrinology 24: 9097, 1977.
Langer, P. and Greer, M.A.: Antithyroid substances and naturally occurring
goitrogens. (Karger, Basel 1977).
256
ABSTRACT
We studied the effect of some antiepileptic drugs on human laboratory
tests.
Among 150 epileptic subjects ("total population") we have singled
out 32 patients treated with phénobarbital (subpopulation I) and 18
treated with phénobarbital + phenytoîn association (subpopulation II)
without any other therapy.
These epileptic patients have been paired with a healthy population
according to their age, sex and overweight.
Some parameters such as urates, cholesterol, triglycerides and
Blipoproteins undergo no significant variations under the influence of
these treatments.
Most of the other biochemical parameters decrease while enzyme and
erythrocyte cellular mean volume increase.
We can observe the most important variations for creatinine, bili
rubin, alkaline phosphatase and gammaglutamyltransferase.
Moreover, combination of phénobarbital with Phenytoin leads to a
more important effect than phénobarbital itself.
INTRODUCTION
Antiepileptic drugs forma large pharmacological group, the principal
drugs of which are composed of very distinct chemicals. According to the
classifications, they may be linked to 8 or 9 chemical structures with
the same heterocyclic nucleus which seems to be necessary for an anti
epileptic activity.
Methods
Blood was taken with an anticoagulant from the fold of the arm and
by means of venepuncture. Immédiatly thereafter, plasma was separated
from blood cells.
Determination methods are summarized in table I.
TABLE I - METHODS OF BIOLOGICAL PARAMETERS MEASUREMENT
S t a t i s t i c a l analysis
For each sub-population, the variations of the different blood
constituents have been shown :
- b y a Student's t e s t carried out on the differences obtained between
the treated group and the control
- by comparing the values obtained for the p e r c e n t i l e s 5, 50 and 95.
RESULTS
Many parameters have been disturbed under the influence of a n t i -
e p i l e p t i c drugs, as can be seen in table I I .
Most of the biochemical parameters under study decreased among
patients undergoing t h i s treatment when the enzymes and the mean corpus-
cular volume of red c e l l s increased.
Soma parameters such as u r a t e s , c h o l e s t e r o l , t r i g l y c e r i d e s and
264
Gammaglutamy 1
Δ (0,001) Δ (0,001) Δ (0,001)
traneferaae
Alanine amino
transferase Δ (0,02)
κ
Evaluation of ceruloplaamin has been carried out on 80 aera only
80 gi- 4 β mmol.I·1
m
Total protei n - Glucose
Q"·
mmol. I -1
I I 1 ,
Γ~Γ~Ί
Q
- Albumi n - Urea
266
Creatinine Calcium
)jmol.l _1 mmol.I" 1
p o 10 20 |-| 0.8 10 1. 2 1.4
PT
Ι Γ
ι ι
Bilirubin Phosphates
26"!
200 4O0 Κ IO
E^
Π2-
80 90 100
J °
S
uu. ^
□ZL
Gamma-glutamyltransferase
MCV
DISCUSSION
Taking antiepileptic drugs modified some biological parameters.
Disturbances in the phosphocalcic metabolism, as we pointed out, have
been described by several authors (Greenlaw, et al., 1972, Gauchei,
et al., 1973, Siest, et al., 1974, Batt, et al., 1976, Fichsel, et al.,
1976, Young, et al., 1977, Pylypchuk, et al., 1978). They appear to be
the result of an osteomalacia which appears among epileptic patients
undergoing a long term treatment. The explanation of this complication is
a deficiency of vitamin D produced by an accelerated metabolism as a
consequence of an hepatic enzymatic induction. Thus, among some patients,
the decrease of serum calcium is correlated to the increase of glucaric
acid excretion.
Fichsel, H. (a): Change of GOT, GPT, LAP and GGT in epileptic children
during anticonvulsive treatment. Acta Univ. Carol. Med., 75: 196
197, 1976.
Fichsel, H. and Kling, R. (b): Disturbances of calciummagnesiumand
phosphatemetabolism during anticonvulsive treatment in epileptic
children. Acta Univ. Carol. Med., 75: 194195, 1976.
Gauchei, F.D., Lehr, H.J., Gauchei, G. and Von Harnack, G.Α.: Diphenyl
hydantoïn bei Kindern. Dtsch. Med. Wschr., 98: 13911396, 1973.
Greenlaw, R., Pryor, J., Winnacker, J., Hahn, T., Haddad, J. and Anast, C.
Osteomalacia from anticonvulsant drugs: therapeutic implications.
Clin. Res., 20: 56, 1972.
Grob, C.J. and Herold, G.E. Immunological abnormalities and hydantoins.
Br. Med. J., 2: 561563, 1972.
Hahn, T.J., Hendin, B.A., Sch arp, CR . and Haddad, J.G.: Effect of chronic
anticonvulsant therapy on serum 25hydroxycalciferol levels'in adults.
New Engl. J. Med., 287: 900904, 1972.
Heipertz, R., Eickoff, K. and Poser, W. : Anticonvulsant therapy and serum
γglutamyltransferase. Klin. Wochenschr., 56: 921928, 1978.
Hildebrandt, A.G., Roots, I., Speck, M., Saalfrank, K. and Kewitz, H.:
Evaluation of in vivo parameters of drug metabolizing enzyme activity
in man after administration of clemastine, phénobarbital or placebo.
Europ. J. C lin. Pharmacol., 8: 327336, 1975.
Hunter, J. and Chasseaud, L.F.: C linical aspects of microsomal enzyme
induction. In: Progress in drug metabolism, Eds. J.W. Bridges and
L.F. Chasseaud, 1: pp 129191 (J. Wiley and Sons, London, 1976).
Hutchinson, R.M., Clay, CM . , Simpson, M.R. and Wood, J.D.: Lowered
erythrocyte sedimentation rate with sodium valproate. Lancet, 8103:
1309, 1978.
Martin, P.J., Martin, J.V. and Goldberg D.M.: γglutamyltranspeptidase,
triglycerides and enzyme induction. Br. Med. J., 1: 1718, 1975.
Meijer, D.K.F., Vonk, R.J., Keulmans, Κ. and Weitering, J.G.: Hepatic
uptake and biliary excretion of dibromosulphtalein. Albumin depen
dence, influence of phénobarbital and nafenopin pretreatment and the
role of Y and Ζ protein. J. Pharmacol. Exp. Ther., 202: 821, 1977.
Nikkila, E.A., Kaste, M., Ehnholm, C and Viikari, J. (a): Increase of
serum high density lipoprotein in phenytoin users. Br. Med. J., 2:
99101, 1978.
Nikkila, E.A., Kaste, M., Ehnholm, C. and Viikari, J. (b): Elevation of
high density lipoprotein in epileptic patients treated with phenytoïn.
Acta Med. Scand., 204: 517520, 1978.
Nutt, J.G., Neophytides, A.N. and Lodish, J.R. : Lowered erythrocyte sedi
mentation rate with sodium valproate. Lancet, 8090: 636, 1978.
Pylypchuk., G., Oreopoulos, D.G., Wilson, D.R. , Harrison, J.E. , Me Nei 11,
K.G., Neema, H.E., Ogilvie, R., Sturtridge, W.C. and Murray, T.M.:
Calcium metabolism in adult outpatients with epilepsy receiving
longterm anticonvulsant therapy. CM A J . , 118: 635638, 1978.
Reynolds, E.H. and Laundy, M. : Haematological effects of anticonvulsants
treatment. Lancet, i: 682, 1978.
Rose, M. and Johnson, I.: Haematological effects of anticonvulsants.
Lancet, i: 994, 1978.
Seager, J.: Haemopexin, caerulopläsmin and C3 effect of diphenylhydantoïn.
Clin. Chim. Acta, 79: 603606, 1977.
Siest, G., Batt, A.M., Galteau, M.M., Weber, M. and Tridon, P.: Inter
ference des contraceptifs oraux et des antiépileptiques sur les
paramètres plasmatiques chez l'homme. Thérapie, 29: 907914, 1974.
273
ABSTRACT
The use of oral contraceptives by women may be associated with labo-
ratory tests results. These effects have to be known to affect interpre-
tation of laboratory data, and permit to use them in evaluating therapeutic
risk or choice of pill. These effects are different according to the type
and dosage of pill and also to the physiological or other variables such
as age, weight, hormonal status and duration of the treatment. This work
attempt to demonstrate the influence of these numerous factors on the
interpretation of laboratory data.
INTRODUCTION
The use of oral contraceptives represents an important example of a
long term drug intake by presumably healthy subjects. At this time, about
fifty five percent of women twenty to forty four years old, have used oral
contraceptives and twenty eight percent take the "pill" regularly in
France (Marie, 1979).
The knowledge of the effect of oral contraceptives intake on labora-
tory tests permits to use these tests in survey of a therapeutic risk or
in choice of "pill".
These effects on biological parameters have been studied and well
described. All human physiological systems were studied and variations
were shown for carbohydrate, lipid, hepatic and hormonal metabolism.
From a general point of view, oral contraceptive use causes
variations in numerous biological parameters. These modification can be
classified according to metabolic risk, or to biochemical parameters
.group.
However, if the knowledge of drug effect on laboratory test is an
important thing, all unexpected results must not be explain by drug
interference.
EFFECT OF ORAL CONTRACEPTIVE USE ON LABORATORY TESTS
In a review, Miale, et al., (1974) tabulated one hundred laboratory
tests, which were affected significantly by oral contraceptive use. These
authors collected 120 references from 1963 to 1971 and nine in 1973.
275
naiaatrol
Gloeooo 2 houra attar acetate
At leaat Spellacy et „
llucoM telatane« taat 0.5 a f
6 nontha el.
Glue··«« W an mtft pi « a u
Iart·»«· β·"" Χ) ι
276
E f f e c t s of o r a l c o n t r a c e p t i v e s use on l a b o r a t o r y t e s t s e v a l u a t i n g l i p i d
metabolism
Heatranol
0.08 mg 2 years
Horethindrone
Ι β
Ethinyl
estradiol
+ 6 Ζ in Ν.S. in
0.05 mg Gershberg
obeae normal
Ethynodiol et al.
patienta patienta
diacetate
1.0 mg
Meitrano1
0.05 mg
Horethindrone
1.0 mg
+ 5 1 ÍD 5 Ζ in
Oral contra
'women up women more Wallace
ceptives or
to 55 than 55 et al.
eatrogen
yeara old yeara old
Megeitrol
Spellacy
acetate
et al.
0.05 mg
Combined pill
Heade
estrogen
et al.
0.05 mg
Ethinyl
f 23 Ζ in estradiol
obeae 0.05 mg Gershberg
women Ethynodiol et al.
♦ 21 Ζ in diacetate
normal 1.0 mg
Heatranol
0.05 mg
Horethindrone
1.0 mg
277
Drag «ffect
■lelogicel Type of D o r a t i « of
»ill Aart tra Tears
fluid tn<BMt
lacrea·« Ζ Ho di—ga X Decrease Ζ
Triglycerid·· kaacraaol
0 . 0 · ■« •Utk
2 year·
■arackladroa M al.
■ ·«
• U I
• M a c «0
yaara eld
Oral cont r e
Plaaaui ai—a Vall·«
• SI «ora c e p t i v · or
ac a l .
eka· «0
yaara aided
• —ecke
•ara ♦ 71 I H77
ac laaat
»m
(anal ♦ 17 I Vario— ro—cea 117·
ac a l .
■Ckleyl
•acradiol
0.0S ag a cycl Laraaoa
i c — r g e a c rel Coaa ac a l .
0.25 ag
•celayl
eecradiol
0.0} at "
Levoaorgaecrel
0.15 a t
Iehinyl
aetradiol
« Ι · Ζ co
0.05 eg "
♦ 42 X
Levooorgeacrel
0.12} a«
•cala·
Varloua
at a l .
T r i g l y c e r i d · · 3 hour·
Coakiaad • aoatka
• f e e r « alanine load Iena ♦ 900 Ζ ι ac a l . Ι·77
0.2/Ug pill ac laaac
Po—Ita
•e a l .
•ehlayl
aacraaiol
l l u 0.05 eg • cyclaa
' 12 I ■orgaatrel
t ac a l .
0.2S a«
•tklayl
aacradiol
0.03 a«
■orgaacral
0 . IS a«
278
Ethinyl
estradiol
BDLcholeat«rol t cycles Lartson
0.05 m Cohn «t al.
■org··tral
0.123 ■«
Uhimyl
•stradiol
■PLpfcoepholipides 0.03 ag
■org«itral
0.123 ■«
Ethinyl
estradiol
0.03 ag
Morgestrei
0.123
Ethinyl
estradiol
0.05 s«
Norgestrel
0.123 ag
♦ 31 Ζ
woeta 30 to
VLDLtriglycerides 39 year·
old
♦ 18 I
voaen 30 to
LDLcholesterol 39 years
old
♦ 19 Ζ 20 to
29 years old
LDLtriglycerides ♦ 39 Ζ 30 to
39 years old
Under or
Fish
Red blood cell count 3 Ζ more than S
• t al.
years
7 Ζ
Mestrano1
Blood + 5 Ζ Ο.Οβ mg
Norethindrone
Under or Fish
Hematocrit more than 5
et al.
years
Red blood cell indices Blood ♦ 3 Ζ
MCV Blood + 1.5 Ζ
Heade
Platelets count 1976
et al.
Ethinyl Lorrain
estradiol 1972
et al.
Dimetti i
sterone 25 mg
279
Drag efface
•lolotical Typ« af Duraci« of ._ .
aataore
fluid pill treataaac
Iacroaea Ζ Mo ebaate Ζ Oser·«·« Ζ
Coaalned
Pill
latrogeo
0.05 at
•tbiayl
oetredici
0.1 at Lorraia
Maatkyl ac al.
atoroaa 25 ι S yaara
■tblayl
20 Ζ eetradiol
0.1 at Lorraia
ribrlaoeaa
U.S. Dieatbyl at al.
ataroaa 2) at S yeere
Coabiaad
pill Ha ala
Pibrlaogaa tarta ♦ 5» Ζ
Iatrogen at al.
0.05 at
Meetranol Craaff
Fibrinogen 0.1 at at ai.
« 10 Ζ Itbynodlol
♦ 17.« Ζ diacetate I ag
Coabiaad
pill Ma ado
Fibrinolytic activity iariai « 31 Ζ
getrogea at al.
0.05 at
Itbioyl
aatradiol
Soluble flbrio aoaoaer At least Craaff
Plaaaa ♦ Μ Ζ 0.05 at
f aoatba ot al.
llorgaatrol
0.25 at
Ithlnyl
aatradiol
3 to ·
0.03 at
aoatba
■orgoetrel
0.15 at
Naatraaol
0.1 at At laaat
Itboyodiol • aoatba
diacatat« I at
ttbiayl
« t Ζ aatradiol
Lorraia
0.1 at
at a l .
Diaatbyl
♦ 12 Ζ 5 yaara
■taroaa 25 ι
gtbioyl
♦ 17 Ζ aatradiol I year
Fl eoa! nogen 0. I at
Oiaetbyl
♦ «J Ζ 3 year
eteroae 25 at
280
Drug e f f e c t
Biological Type of Duration of
fluid treatnent Authors Tears
pill
Increase Ζ No Change Ζ Decrease Ζ
Chlormadinon·
Serua or I to 12 Bergsjö
Antithrombin III •cacata
plasma month· et e l .
0.5 a«
Combinad pill
«•erogan Me ede
0.03 ·| et · 1 .
Combined pill
Q 2 Microglobulin Serum Heade
eatrogan
et al.
0.05 mg
Combinad t
Serum or 0.05 mg Ondar Herbath
al antitrypsin + 36 Ζ
plasma estrogena 2 year· et e l .
0.030.0» ι
■· ♦ 22 Ζ Mora thai
5 years
Ondar or
Begre1
Combined pill mora than 1979
et e l .
2 year·
Ethinyl
estradiol
Total aminoacids 0.05 mg Nor« than Creft
Norethiataroi 3 montha et e l .
3.0 mg
Leukocytes 57 Ζ Tarallo
Combined p i l l 1977
et al.
Ithlnyl
CIutamine and eatradiol
More then Craft
0 . 0 5 mg
glutamic acid 3 month· et a l .
Bjorethiaterooe
31
281
gthlayl
aatradiol Mom than
Tyrosine Craft
0.03 a« 1*71
3 noothe et a l .
hor·tblaterone
3.0 η«
float
Alanina aninotranifar
Piaana ♦ MI et a l .
197«
Calteau
Piaana ♦ 12 I Variou· 1977
at a l .
Si.it
Plaaaa ♦ 12 Ζ Variou· 197«
Aapartata aninotranafara·· et a l .
Caltaau
Plana Variou· 1977
et a l .
Plaaaa Heet
Variou· 197«
et a l .
1 X co
Lactata dehydrogenase
13 Χ icblala
(according at a l .
Co at·)
Heet
10 X Variou·
et a l .
Pheaphataaea a l c a l i n a · 7 X to
ichiale
(accordio. *"lew· •t a l .
to a«·)
Pyruvate At laaat
Hood ♦ 33 X èia·*) pill no··
t aontba et a l .
282
E f f e c t s of o r a l c o n t r a c e p t i v e s use on hormonal t e s t s
The i n t e r a c t i o n s of o e s t r o g e n s and progestogens with o t h e r s hormonal
parameters i s w e l l known. Many authors s t u d i e d the e f f e c t s of o r a l c o n t r a
c e p t i v e s use on hormones ( t a b l e V) .
TABLE V EFFECTS OF ORAL CONTRACEPTIVES USE ON HORMONAL TESTS
Coafained to 6 Eats
Aldo·terone
ae·tranol on tbs at a l .
Angiotensin Morethindrone
2 ag, aestra
nol 0.1 ag
Ethinyl
estradiol 3 Months Beckerhoff
0.05 ag et a l .
Horeth indroae
2.S χ
Coaninad 1 to 6 Kats
Plasaa + 2S0 Ζ
aastranol lag months at a l .
Chloraadinone
Plasaa N.!
acetate
Ethinyl
+ 250 Ζ estradiol
Pre« C o r t i s o l Sana aspi i tude I aonth at Van Cantar
0.05 ng
increase least et al.
Norgestrel
0.5 g
Progestagen Durtor
only et al.
Combined
0 . 0 5 0 ag
Fourteen
estrogen
cycles
0.050 s«
progestagen
Coafained
0.050 s«
Plasma ♦ 240 Ζ estrogen Fourteen
0 . 0 5 0 ag cycles
progestagen
Ethinyl
estradiol
Gonadotropin Hore than He Cuire
0.035 g
18 aontha et e l .
Horethindrone
1.0 or 0 . 5 ag
Hegestrol
Grovthhoraone At laast Spellacy
acetate
6 aonth· et a l .
0 . 5 ag
283
Drug « f f « c t
Iiolofical Typ· of Durst i o « of
Author· Tear·
fluid pill traatnaat
I n c r * · · · Ζ Mo chang* Ζ Dacraas« Ζ
Ovulatory
peak 0 . 0 5 ag
auppresMd ■oretbiaton
U.S. I ■*
Ko peak
I to 6 Vi l é ñ e l a
cycles «t a l .
Ithiayl
0aetrof*na ι oaatrediol ♦ eitradiol
9 eyela« Joaaaaaoa 197)
Matron· 0.035 M
lyuastrol I ag
I to ft Vintola
Urin
cycl·· at a l .
ProfBMMdiol Urlo.
Ithinyl
eatrediol
Hor· than Mc Cuir«
0.035 a t
18 n o o t h · «t · 1 .
Vor« t tu adroni
1.0 or 0 . 5 m
Ithinyl
••tradiol
9 cycl·· Johaneson
0 . 0 3 5 η«
Lyn··trol la)
■oratili ndrona
2 >*
■•■tranol
0.1 a s ■ackarhoff
Ethinyl
estradiol
50 ng
Nor«thindrona
•catata 2.5ag
Morothtndroo·
Fr·· UilMtiroM ueatranol1/
1/50 íríi* ""
■org··tral
•thinyl
•atradio1
Nora··tral
PIUM * IM Ζ «thinyl
astradiol
Ethinyl
estradiol
Thyrotropin I aonth Tan Cantar
Ι .ν · I 0 . 0 5 ng
at least at al.
♦ 212 Ζ t o Noraaatrsl
1000 Ζ 0.5 · «
284
Ethinyl
estradiol
Total electrocute· HagoujioD
Salivary 0.05 mg 2 month·
concentration· •t «1.
Norgeatrei
0.5 mg
Ethinyl
estradiol
0.050 mg Four years Thin
No re thi s te rone
•cetate 3 mg
Hestranol
0.1 mg 1 to more
Siapion
Ethynodiol than 12
•t al.
diacetate months
1.0 mg
Batt
Plasma combined pill •t ·1.
197«
Hestranol
O.OB mg Smith
Serum 2 yaarf 1975
Norethindrone •t «1.
Hestranol
0.1 mg 1 to more
Simp·on
Ethynodiol than 12
et al.
diacetate months
1.0 mg
Combined pill
Ethinyl
estradiol
5 to 26 Hahn
0.05 mg
cycl·· at al.
Líneatrol
2.5 mg
285
Varioua ■θ twiCC
at a l .
Hi· traici
0.08 a« Smith
Roratbiodroaa 2 year·
at a l .
1 ·*
Coafcload p i l l ■riu·
at a l .
Haatranol
0.05 ms
•oralblod roo·
bmmlmadpiU .„.„,,
Saqoamcial
15 t
pill
Soaliofh
Coatload p i l l Siam ink
at a l .
Srista
Comaload p i l l
at a l .
Maatraool
U Z 0 . 0 · aa 2 vaara Smith
Bora catadromo at a l .
1 «t
22 Ζ At laaat Broa
Coahlaad p i l l
O.S.) t •ootoa at a l .
286
Drug effect _ * . .
Biological Type of Duración of
Authors Tun
fluid Increate Ζ Ho change Ζ Decreaie Ζ PiU treatment
20 Ζ At leeit Leklem
Combined pill 1975
(H.S.) 6 months et al.
Schiele
Combined pill 1977
et al.
3 to I» Boss«
Verioui 1979
monthi et al.
Coelinl
Urine ♦ «88 Ζ Combined pill Banning
et al.
2 to 60
Combined pill
months
Briggs
Combined pill ec al.
Hestrenol
0.0B mg Smith
2 years
Norethindrone at al.
At leest Stephana
3 months et al.
Hestrenol
0.08 mg 3 to 6 Faine
1975
Norethindrone montha et al.
I mg
Urine
(12 hours) 8,5 Ζ Combined pill Shogania I97S
Briggs
Combined pill 197«
et al.
Heetrenol
0.08 mg Smith
2 years 1975
Norethindrone et al.
Horwitt
Serum « 21 Ζ 1975
et al.
3 to t Aftergood
197«
montha et al.
Hestrenol
0.08 mg Smith
■lood ♦ 28 Ζ 2 yeers
NorethindroM et al.
Horvitt
et al.
Hestraool
0.05 mg or
21 Ζ to I yeer or Tengney
0.08 mg
23 Ζ Norethindrone more et al.
I mg
287
- drugs
. type of medication
. duration of therapy
. dosage
- individual physiological factors
. sex
. age
. overweight
- association with other drugs
The knowledge of the effect of oral contraceptive tests leads to
three points.
First, intake of oral contraceptive is another factor of variation
taking on laboratory tests. So, women taking oral contraceptives must be
excluded from a reference population in order to define reference values.
Second, laboratory data must be used as indicators of therapeutic
risk or choice of pill. In this case, the interpretation of laboratory
results must take into account the physiological variations of biological
parameters. To use laboratory tests results, it is necessary to know
values before and during the administration according to physiological
status of women.
In the future, it would be possible to define reference values for the
particular group of women on oral contraceptives according to physiolo-
gical factors and perhaps type of pill.
290
REFERENCES
Af tergood, L., Alexander, A.R., and AlpinSlater, R.B.: Effect of oral
contraceptives on plasma lipoproteins, cholesterol and ofocophenol
levels in young women. Nutr. Rep. Int.,11: 295304, 1975.
Applegate, M.V., Forsythe, A. and Bauernfeind, J.B.: Physiological and
psychological effects of vitamins E and Bg on women taking oral
contraceptives. Internat. J.V.T. Nutr. Res.,49: 4350, 1979.
Aznar, R., Lara, R., Zarco, D. and Gonzales, L.: The effect of various
contraceptive hormonal therapies in women with normal and diabetic
oral glucose tolerance test. Contraception, 13: 299311, 1976.
Bagrel, Α., Dalo, Β. and Siest, 6.: Determination de la céruléoplasmine
sérique par néphélémétrie laser. C R . des journées du Club Laser
Behring Bendor, 20 Septembre 1979 (In press).
Batt, A.M., Siest, G., Loppinet, V. , Guérin, P., Gueguen, R. and Floch',
A.Y.: Médicaments et valeurs de référence en biologie I. Contracep
tifs oraux. Ann. Biol. clin., 32: 245256, 1974.
Beck, P.: Alterations of lipid metabolism by contraceptive steroids. J.
Steroid Biochem., 6: 957963, 1975.
Beckerhoff, R., Luetscher, J.A., Beckerhoff, J. and Nokes, G.W.: Effect
of oral contraceptives on the reninangiotension system and on blood
pressure of normal young women. Hopkins Med. J., 132: 8087, 1973.
Bergsjö, P., Fagerhol, M.K. and Abildgaard, U.: Antithrombin III concen
tration in women using lowdosage progestogen for contraception.
Am. J. Obstet. Gynecol., 112: 938940, 1972.
Bossé, R.T. and Donald, E.A.: The vitamin Bg requirement in oral contra
ceptive users. I. Assessment by pyridoxal level and transferase
activity in erythrocytes. Am. J. Clin. Nutr., 32: 10151023, 1979.
Bradley, D.D., Wingerd, J., Petitti, D.B., Krauss, R.M. and Ramcharan, S.:
Serum highdensity lipoprotein cholesterol in women using oral
contracpetives estrogens and progestins. New. Engl. J. Med., 299:
1720, 1978.
Briggs, M.M. and Briggs, M.: Effects of oral ethinylestradiol on serum
proteins in normal women. Contraception, 3: 381, 1971a.
Brown, R.R., Rose, D.P., Leklem, J.E., Linkswiler, H. and Anand, R. :
Urinary 4pyridoxic acid, plasma pyridoxal phosphate and erythrocyte
aminotransferase levels in oral contraceptive users receiving
controlled intakes of vitamin Bg. Am. J. Clin. Nutr., 28: 1019,
1975.
CoelinghBennink, H.J.T., Schreurs, W.H.P.: Disturbance of tryptophan
metabolism and its correction during hormonal contraception.
Contraception, 9: 347356, 1974.
Conard, J., Salomon, Y. and Samama, M.: Variations de l'antithrombine III
chez les femmes sous contraception orale. Path. Biol., 22: 7780,
1974.
Craft, J.L. and Peters, T.J.: Quantitative changes in plasma amino acids
induced by oral contraceptives. Clin. Sci.j 41: 301307, 1971.
Dale, E. and Simpson, G.: Serum magnesium levels of women taking an oral
or long term injectable progestational contraceptive. Obstet. Gyn.,
39: 115119, 1972.
Donald, E.A. and Bossé, R.T.: The vitamin Bg requirement in oral contra
ceptive users. II. Assessment by tryptophan metabolites, vitamin Bg,
and pyridoxic acid levels in urine. Am. J. clin.·Nutr., 32: 1024
1032, 1979.
291
Durber, S.M., Leweon, J. and Daly, J.R.: The effect of oral contraceptives
on plasma Cortisol binding capacity throughout the menstrual cycle
in normal women. British J. Obstet. Gyn., 83: 814818, 1976.
Elstein, M., Briston, P.G., Jenkins, M., Kirk, D. and Miller, H.: Effects
of a low estrogen oral contraceptive on urinary excretion of
luteinizing hormone and ovarian steroids. Brit. Med. J., 1: 1113,
1974.
Fish, I.R. and Freedman, S.H.: Oral contraceptives and the red blood cell.
Clin. Lab. Therap., 14: 245249, 1973.
Galteau, M.M., Schiele, F., Le Perron, B. and Siest, G.: Interprétation
des mesures d'activités enzymatiques du plasma chez les individus
prenant des médicaments I. 2ème Symposium de Biochimie Clinique
Carcinologique, Reims, 12 Décembre 1977.
Gershberg, H., Holse, M. and Galler, M.: Serum lipid changes during
contraceptive administration in obese women: relation to serum
insulin levels. J. Clin. Endocrinol. Metab., 43: 861865, 1976.
Graeff, H., Battis, P., Hafter, R. and Zander, J.: Evaluation of hyper
coagulability in users of oral contraceptives. Klin. Wschr., 55:
175179, 1977.
Hahn, Ν. and Fuchs, C : Das Verhalten von Zink im Normalen und Anovula
torischen Zyklus und unter Einahme von Ovulationshemmern. Arch.
Gynäk., 217: 309314, 1974.
Herbeth, B., Dalo, B., Bagrel, Α., Siest, G., Ledere, J. and Rauber, G.:
Etude de l'influence de la prise de contraceptifs oraux différemment
doses sur l'ai antitrypsine, la gammaglutamyltransférase et la
phosphatase alcaline. Clin. chim. Acta, (submitted for publication).
Horwitt, Μ.Κ., Harvey, C.C. and Dahin, C.H.: Relationship between levels
of blood lipids, vitamins C, A and E, serum copper compounds and
urinary excretions of tryptophan metabolites in women taking oral
contraceptive therapy. Am. J. Clin. Nutr., 28: 403412, 1975.
Johansson, E.D.E.: Plasma levels of progesterone and oestrogens in women
treated with an oral contraceptive of low oestrogen content (ovostat
1375). Acta Obstet. Gynec. Scand., 54: 217221, 1975.
Katz, F.H. and Beck, P.: Plasma renin activity, renin substrate and aldos
terone during treatment with various oral contraceptives. J. Clin.
Endocrinol. Metab., 39: 10011004, 1974.
LarssonCohn, U., Vallentin, L. and Zador, G.: Plasma lipids and high
density lipoproteins during oral contraception with different combi
nations of ethinylestradiol and levonorgestrel. Horm. Metab. Res.,
II: 437440, 1979.
Leklem, J.E., Rose, D.P. and Brown, R.R.: Effect of oral contraceptives on
urinary metabolite excretions after administration of Ltryptophan
or Lkynurenine sulfate. Metabolism, 22: 1499 1505, 1973.
Leklem, J.E., Brown, R.R., Rose, D.D., Linkswiller, H. and Arend, R.A .:
Metabolism of tryptophan and niacin in oral contraceptive users
receiving controlled intakes of vitamin B¿. Am. J. Clin. Nutr., 28:
146, 1975a.
Leklem, J.E., Brown, R.R., Rose, D.D., Linkswiller, H.: Vitamin B&
requirements of women using oral contraceptives. Am. J. Clin. Nutr.,
28: 535541, 1975b.
Lorrain, J. and Hakel, P.: Effects of certain contraceptive hormones on
blood coagulation. Fert. Steril., 23: 422427, 1972.
Lumeng, L., Cleary, R.E. and Ting Kai Li: Effect of oral contraceptives
on the plasma concentration of pyridoxal phosphate. Am. J. Clin.
Nutr., 27: 326333, 1974.
292
Mc Guire, J.L., Bariso, L.D., Yuliano, E., Hume, R.J. and Pasquale, S.A .:
Effects of low dose oral contraceptives containing norethindrone
and ethinylestradiol in serum levels of progesterone and pituitary
gonadotropines. Contraception, 11: 329338, 1975.
Magnusson, I., Ericson, T. and Hugoson, Α.: The effect of oral contra
ceptives on the concentration of some salivary substances in women.
Archs. Oral Biol., 20: 119126, 1975.
Manninen, V., Malkonnen, M. : Hormones and highdensity lipoproteins.
Lancet, 2: 1155, 1978.
Marie, Α.: Etude de 1'INEDINSEE. Contraception orale en France, la
proportion d'utilisatrices régulières semble atteindre un palier.
Le quotidien du Médecin, N° 1846, ρ 9, 1979.
Meade, T.W., Brozovic, Μ., Chakrabarti, R., Howarth, D.J., North, W.T.S.
and Stirling, Y.: An epidemiological study of the heamostatic and
other effects of oral contraceptives. British J. Haemat., 34: 353
363, 1976.
Miale, J.B. and Kent, J.W.: The effect of oral contraceptives on the
results of laboratory tests. Am. J. Obst. Gynecol., 120: 264272,
1974.
Miller, L.T., Dow, M.J. and Kokkeler, S.C.: Methionine metabolism and
vitamin Bg status in women using oral contraceptives. Am. J. Clin.
Nutr., 31: 619625, 1978.
Neuman, M.: Interférences entre contraceptifs oraux et médicaments. Gaz.
Med. de France, 85: 137139, 1978.
Newman, L.J., Lopez, R., Cole, H.S., Boria, M.C. and Cooperman, J.M.:
Riboflavin deficiency in women taking oral contraceptive agents.
Am. J. Clin. Nutr., 31: 247249, 1978.
Paine, C.J., Grafton, W.D., Dickson, V.L. and Eichner, E.R. : Oral
contraceptives serum folate and hematologic status. J. Am. Med.
A s s o c , 231: 731733, 1975.
Phillips, N. and Duffg, T.: One hour glucose tolerance in relation to the
use of contraceptive drugs. Am. J. Obstet. Gynecol., 116: 91100,
1973.
Pometta, D. and Micheli, H.: Influence de la contraception hormonale sur
les lipoprotéines sériques. Schweiz, med. Wsehr., 108: 20122015,
1978.
Rose, D.P., Leklem, J.E., Brown, R.R. and Potera, C : Effect of oral
contraceptives and vitamin Bg. Supplements on alanine and glycine
metabolism. Am. J. Clin. Nutr., 29: 959960, 1976.
Rose, D.P., Leklem, J.E., Fardai, L.L., Baron, R.B. and Shrago, E.: Effect
of oral alanine loads on the serum triglycerides of oral contraceptive
users and normal subjects. Am. J. Clin. Nutr., 30: 691694, 1977.
Salkeld, R.M., Knorr, K. and Körner, W.F.: The effect of oral contracep
tives on vitamine B6 status'. Clin. chim. Acta, 49: 195199, 1973.
Schenker, J.G., Pinson, A. and Folishik, W.Z.: The effect of oral contra
ceptives on serum lipids. Fert. Steril., 22: 604608, 1971.
Schiele, F., Le Perron, Β., Galteau, M.M. and Siest, G.: The effect of
drugs on enzyme reference values. (Abstr.) Clin. Chem., 23: 1120
1121, 1977.
Schiele, F., Neuman, J.L., Le Perron, Β., Galteau, M.M. and Siest, G.:
Plasma enzyme reference intervals. Influence of medications taken
on a longterm basis, In: Drug measurement and drug effects in labo
ratory health science, Ed. G. Siest and D.S. Young (Karger, Basel,
Pubi., 1979).
293
She Iton, J.D., Petitti, D.: Formulation dependent effect of oral contra
ceptive on HDLcholesterol. Lancet, 2: 677, 1978.
Shojania, A.M.: The effect of oral contraceptives on folate metabolism
III. Plasma clearance and urinary folate excretion. J. Lab. Clin.
Med., 85: 185190, 1975.
Siest, G., Batt, A.M., Galteau, M.M., Weber, M., Tridon, P.: Interférence
des contraceptifs oraux et dew antiépileptiques sur les paramètres
plasmatiques chez l'homme. Etude particulière des enzymes. Thérapie,
29: 907914, 1974.
Simpson, G.R. and Dale, E.: Serum levels of phosphorus, magnesium and
calcium in women utilizing combination oral or longactivity injecta
ble progestational contraceptives. Fertility and Sterility, 23: 326
339, 1972.
Smith, J.L., Goldsmith, G.A. and Lawrence, J.D.: Effects of oral contra
ceptive steroids on vitamin and lipid levels in serum. Am. J. Clin.
Nutr., 28: 371376, 1975.
Spellacy, W.N., Βuhi, U.C., Birk, S.A. and Mc Creary, S.A.: Metabolic
studies in women taking norethindrone for 6 months'time (measurements
of blood glucose, insulin and triglyceride concentrations). Fert.
Steril., 24: 419425, 1973a.
Spellacy, W.N., Newton, R.E., Buhi, W.C. and Birk, S.A.: Carboxyhydrate
and lipid studies during six months'treatment with megestrol acetate.
Am. J. Obstet. Gynecol., 116: 10741078, 1973b.
Spellacy, W.N., Mahan, C.S., Buhi, W . C , Dumbaugh, V.A. and Birk, S.A .:
Blood glucose, insulin, cholesterol and triglyceride levels, in
women treated for six months with the weekly oral contraceptive
R 2323. Contraception, 18: 121126, 1978.
Steinmetz, J., Panek, E., Siest, G. and Gueguen, R.: Factors affecting
the concentration of the triacylglycerols (triglycerides) in plasma:
reference values for adults. Clin. Chem., 25: 924932, 1979.
Steinmetz, J., Gaspart, E. and Notter, D.: Pharmacological effects due to
hypolipidemic drugs, this Book.
Stephens, M.E.M., Craft, I., Peters, T.J. and Hoffbrand, A.V.: Oral
contraceptives and folate metabolism. Clin. Sci., 42: 405414, 1972.
Tangney, C.C. and Driskell, J.Α.: Vitamin E. Status of young women on
combinedtype oral contraceptives. Contraception, 17: 499512, 1978.
Tarallo, P., Houpert, Y. and Siest, G.: Influence des contraceptifs oraux
sur la concentration des acides aminés granulocytaires chez les
femmes supposées saines. Clin. chim. Acta, 81: 283286, 1977.
Tazi, Α., Galteau, M..M and Siest, G.: Effect of Imipramine on hepatic la
laboratory tests, this Book.
Thin, C G . : The effect of an oral contraceptive agent on the concentrations
of calcium and magnesium in plasma, erythrocytes and platelets in
women. Ann. Clin. Res., 3: 103106, 1971.
Tremblay, R.R. and Dube, J.Y.: Plasma concentrations of free and non TeB6
bound testosterone in women on oral contraceptives. Contraception,
10: 599605, 1974.
Van Cauter, E., Golstein, J., Vanhaelst, L. and Leclercq, R.: Effects of
oral contraceptive therapy on the circadian patterns of Cortisol and
thyrotropin (TSH). Europ. J. clin. Invest., 5: 115121, 1975.
Wallace, R.B., Hoover, J., Sadler, D. and Rifkind, B.M.: Altered plasma
lipids associated with oral contraceptive estrogen consumption.
Lancet, 2: 1114, 1977.
294
Wertalik, L.F., Metz, E.N., Lo Buglio, A.F. and Balcerzak, S.P.: Decreased
serum B|2 levels with oral contraceptive use. J. Am. Med. A s s o c ,
221: 1371-1374, 1972.
Widholm, 0. and Alapiessa, U.: The biological effects of a new modified
sequential oral contraceptive contraception, 15: 1-13, 1977.
Yeung, D.L.: Effects of oral contraceptives on vitamin A metabolism in the
human and the rat. Am. J. Clin. Nutr., 27: 125-129, 1974.
ACKNOWLEDGMENTS
We thank Anne-Rose MAIRE for her documentation assistance.
PHARMACOLOGICAL EFFECTS DUE TO HYPOLIPIDEMIC DRUGS
ABSTRACT
In order to know the unexpected biological effects of hypolipidemic
drugs, we performed different plasmatic tests on hyperlipidemic subjects
treated by Clofibrate and Fenofibrate and control group.
The hypolipidemic action of Fenofibrate and Clofibrate is evident.
The concentration of bilirubine, the enzymatic activities of alkaline
phosphatases and gamma-glutamyltransferase were decreased with the two
treatment.
In general, the transaminase activity (TGP) was not significantly
different between treated and control subjects. However, some treated
women had higher values than controls.
INTRODUCTION
Our aim was to study the effects of hypolipidemic drug intake on the
biological tests carried out in the laboratory, in order to elucidate
the shift in distribution of the biological values due to these drugs.
A research procedure in two parts was therefore devised. The first is
concerned with the biological variations which are observed in the entire
o
population of patients undergoing Fenofibrate or Clofibrate treatment,
regardless of whether or not other treatment is coadministered.
In the second part of the study, the possible effects of related
treatments upon the studied parameters were eliminated since we only
considered patients treated by one of the two hypolipidemic drugs. The
results obtained in these two phases are compared with those of the control
groups that are matched with the groups under treatment.
MATERIALS AND METHODS
The drug index
The evaluation of drug interference on laboratory test results is made
possible by our drug index.
Indeed, all the persons who are invited to Center for Preventive
Medicine (CPM) are questioned, during blood sampling, about a possible drug
intake. The name of the patent medicine is noted on a specially printed
Lipanthyl ® Laboratoires Fournier, Dijon, France
296
Number of treated
malea Percentagea
Tranquiliiera 389 13
Analgeaica 374 13
C a a t r o - i n t a a t i n a l therapeutcia 307 10
Antlaathmatic 283
Ant langor 280
Vaaodilatator 270
Paychotonic 231
Antihypartenaiva 185
Antibiotic 178
Hypolipidemic 163
Hypoglycemiant 149
Antiinflammatory 135
Hypouricemlc 119
Vaaculotrop 114
Antiarythmic 1 10
Anticoagulant 104
Diuratic 92
Hypnotic 91
Neuroleptic 88
Hepatic therapeutic 87
Antiepileptic 74
Antidepreaaant 58
Sedativa 54 1
Cardiotonic 53 1
Antiparkinaon 46 1
298
The population taking drugs included 9225 persons with 2849 men
(31 2) and 6376 women (69 Z ) . Women taking drugs are about two times more
numerous than men.
The oral contraceptives are at the first place (41 % of drugs intake),
The tranquilizers take the second place with 13 %, followed by
analgesics (7 Z) and vasodilatators (7 %). Only 1 % of females are
treated with hypolipidemic drugs.
In men, the most frequently used drugs are tranquilizers (13 %) and
analgesics (13 % ) . A higher percentage (5 %) of men than of women ingest
hypolipemics.
Description of population sample
411 patients treated with hypolipidemic drugs, were examined at the
Center for Preventive Medicine during 1976, 1977, 1978. Among these 411
patients, males were 262 (63,7 %) and females 149 (36,3 % ) . Their
repartition according to age, sex and hypolipidemic drug is summarized
in table III.
TABLE III - DISTRIBUTION OF SUBJECTS TREATED WITH HYPOLIPIDEMIC DRUGS
Fenofibrate 15 83 28 6 35 36
Clofibrate II 97 28 3 42 27
Statistical analysis
The statistical analysis has been previously described (Steinmetz,J.,
et al., 1978).
RESULTS AND DISCUSSION
The hypolipidemic drugs have no effect upon concentrations of total
proteins, albumin, glucose, urea, creatinine, calcium and upon LDH
activity.
The hypolipidemic effect of Fenofibrate is confirmed in the two
groups of treated patients (first and second phases of the study). In the
treated male patients, the uric acid concentration, for the percentile
50 is 315 ptnol/l and 393 iimol/1 in the control group. In the female
group, the concentrations are respectively 280 Umol/l and 303 Umol/1.
These differences are statiscally significant (p < 1 2 ) . This uricemie
effect, already reported by Drouin P., et al. (1976) is a positive effect
of the drug since hyperuricemia is correlated with the increase of plasma
lipids. We did not find any significant decrease of uricemia during
Clofibrate treatment.
The decrease of bilirubin is established in the subjects treated
with Fenofibrate or Clofibrate. The difference between the treated and
control groups is slight (3 Vimol/1) , but statistically significant regard
less of whether or not the subjects are treated by several drugs or only
by the hypolipidemic agent. This decrease seems to be related to an
inducing effect of the hypolipidemic drugs. In rats, the protein synthesis
in the liver increases and is accompanied by an increase in liver weight
(Batt, A.M., et al., 1978, Foliot, Α., et al., 1977, Mackerer, C R . , 1977).
This hepatomegaly is due principally to a proliferation of the smooth
endoplasmic reticulum and to an increase in the number and the size of
mitochondria and lysozomes (Salvador, R.A., et al., 1970, Taylor, K.G.,
et al., 1977) the increased urinary excretion of glucaric acid, of the
glucuronolactone deshydrogenase activity and of cytochrome F450 confirms
the inducing effect of the drugs Fenofibrate and Clofibrate (Batt, A.M.,
et al., 1978).
The plasma concentration of inorganic phosphates seems to be parti
cularly sensitive to Fenofibrate intake. The values in the treated
subjects (0.97 mmol/1) are statistically lower than those in the corres
ponding controls (1.04 mmol/1).
300
CGT
Mea 77 12 29 82 II 30 152 39 8 21 74 11 31 172
Uomen 50 7 17 87 9 22 63 25 6 12 35 9 22 57
Alkaline phosphates
Hen 126 21 42 76 33 51 82 136 23 41 70 31 51 91
Women 77 24 44 86 30 54 91 73 26 42 82 36 58 91
TGP
Men 109 15 26 64 15 29 66 109 16 27 51 15 27 69
Women 66 15 25 73 II 20 42 62 13 23 69 II 19 36
50
Fenofibrate
68
Control
Hepatic isoenzyme
29 .
Fenofibrate
1=3 Control
Bone isoenzyme
28
Fenofibrate
29
Control
We find this same difference regarding the hepatic isoenzyme (20 U/l
in the treated group and 37,5 U/l in the control group). A similar effect
has been shown for Clofibrate (Shade, R., et al., 1978, Zunmoff, Β., 1978).
The TCP activity is the same in the treated and control groups
(table IV). However, the value for percentile 95 is 34 U/l higher in the
treated women compared with the controls, regardless of the hypolipidemic
agent used. An increase of transaminase activity in the Clofibrate treated
subjects has been pointed out (Delwaide, P.A., et al., 1973, Sundermann,
F.W., 1970). However the patients under Fenofibrate treatment did not
show this increase.
302
CONCLUSION
The intake of hypolipidemic drugs induces disturbances in the
biological test results of treated subjects, (decrease of the values of
uric acid, bilirubin, inorganic phosphates and of enzymatic activity of
GGT and alkaline phosphatase). These modifications are not necessarily of
a pathologic nature. However, subjects who show serious changes particu
larly of enzyme activity should be submitted to more frequent biological
testing.
REFERENCES
Batt, A.M., Siest, G., Loppinet, V., Guerin, P., Gueguen, R., Floc'h, Α.:
Médicaments et valeurs de référence en biologie. I Contraceptifs
oraux. Ann. Biol. Clin., 32: 245256, 1974.
Batt, A.M., Siest, G., Khodjet El Khil, R., Le Perron, B., Weber, M.,
Tridon, P.: Drugs and reference values in clinical chemistry. II
Anticonvulsivants. In: Drug interference and drug measurement in
clinical chemistry, Siest G. Ed., 3341 (Karger, Basel), 1976.
Batt, A.M., Khodjet El Khil, R., Ν'Guyen, T., Siest, G.: Effet des
hypolipémiants sur l'hydroxylation et sur la synthèse de l'acide
glucarique. Soc. Chim. Thérap., 1978.
Delwaide, P.A., Jaclin, Α., He us ghem, C : Interference des medicaments sur
les déterminations effectuées en chimie clinique. In: Les effets
indésirables des médicaments. 698709, 1973.
Drouin, P., Mejean, L., Sauvanet, J.P., Pointel, J.P., Gay, G., Debry, G.:
Etude de l'action hypolipidémiante du Procétofène chez des malades
porteurs d'une HLP du type IIa ou IIb. Gaz. Med. France, 83:
38483860, 1976.
Foliot, Α., Droucourt, J.C., Etienne, J.P., Housset, E., Fiessinger, J.N.,
Christoforov, B.: Increase in the hepatic glucuronidation and
clearance of bilirubine in Clofibrate treated rats. Biochem.
Pharmacol., 26: 547549, 1977.
Fromentin, M., Drouin, P., Sauvanet, J.P., Rouffy, F.: Etude de la to1eran
tolérance hépatique après quatre ans de traitement par le Procétofène.
Nouv. Presse. Med., 7: 938940, 1978.
Mackerer, C.R.: Effect of'Clofibrate administration on several biochemical
parameters of normal and thyroidectomized rats. Biochem. Pharmacol.,
26: 301306, 1977.
Salvador, R.A., Haber, S., Atkins, C , Gommi, B.W., Welch; R.M.: Effect of
Clofibrate and lmethyl4piperidyl bis (pchlorophenoxy) acetate
(Sandoz 42348) on steroid and drug metabolism by rat liver microsoms.
Life Sciences, 9: 397407, 1970.
Shade, R.W.N., Demacker, P.N.M., Van't Laar, Α.: Clofibrate effect on
alkaline phosphatase. Bone or liver fraction. New Engl. J. Med.,
297: 669, 1978.
Simone H i , C., Eaton, R.P.: Effect of Clofibrate on in vivo triglyceride
production and clearance in genetically hyperlipemic rats.
Atherosclerosis., 29: 269275, 1978.
Steinmetz, J., Gaspart, E., ?anek, E., Morin, C , Drouin, P.: Effect of
hypolipidemic drugs on ten blood constituents. In::Drug measurement
and drug effects in laboratory health science. The International
303
ACKNOWLEDGMENTS
ABSTRACT
The effects of tranquilizers on laboratory tests may be related
to their pharmacological activity. The molecular basis of pharmacological
effects of major tranquilizers are dominated over by action on membranes,
and dopaminergic neurons receptors.
In the case of minor tranquilizers, basis of molecular action is
not clear, and cooperative effects on Gamma Aminobutyric Acid (GABA)
receptors is the usual hypothesis. Unfrequents effects on laboratory
tests are observed. However, some of them, specially on endocrine system
must be known.
INTRODUCTION
Tranquilizers are psychotropic drugs and represent a major milestone
in the history of psychopharmacology.
They are classified in two main categories :
- Major tranquilizers, or antipsychotics or neuroleptics drugs.
- Minor tranquilizers or anxiolytics drugs.
Each classes may be further divided as :
- Major tranquilizers :
. Phenothiazines (Chlo.rpromazine, Prochlorperazine, Thioridazine)
. Butyrophenones (Haloperidol, Dorperidol, Penfluridol, Lenperone)
. Thioxanthenes (Thiothixene, Chlorprothixene, Flupenthixol)
. Miscellaneous (Poxapine, Metrapine, Clorapine, Sulpiride).
- Minor tranquilizers :
. Benzodiazepines.
. Propanediol carbamate.
305
REFERENCES
Acland, J.D. : The interpretation of the serum protein bound iodine :
a review. J. Clin. Pathol. 24: 187213, 1971.
Anden, Ν.E. : antipsychotic drugs and catecholamine synapses in Matthysse,
W., Ketty, S.S., editor Catecholamines and Schyzophrenia
(Oxford, Pergamon Press, 1975).
Bartholini, G., Stadi er,H., GadeaCiria, M. and Lloyd, K.G. : Nobel
symposium on antipsychotics drugs. Pharmacodynamics and Pharmako
kinetics, Edited by G.B. Sdaxl and B. Uvnà's pp. 105116 (Pergamon
Press, Oxford 1974).
Copperberg, A.A. and Eidlow s. : Haemolytic anemia, jaundice and diabetes
mellitus following chlorpromazine therapy, Can. Med. Ass. J. 75 :
746752 (1956).
Fuxe, K., Agnatti.L.F., Corrodi, H., Everitt, B., Hokfelt, T., Lofström,
Α., and Ungerstedt, U. : Action of dopamine receptor agonists in
forebrain and hypothalamus, Rotational behavior, ovulation and
dopamine turnover., Adv. Neurol. 9 : 223242 (1975).
Garb, S. : Laboratory tests in common use 4th Ed. Springer Pub Co. NY
10003 (1966).
Gaunt, R., Steinetz, B.G. and Chart, J.J. : Pharmacologic alteration of
steroid hormone functions, Clin. Pharmacol. Thera 9 : 657, 1968.
Gruener, R. and Narahashi, T. : The mechanism of excitability blockade
of chlorpromazine, J. Pharmacol. Exp. Ther. 181: 161170, 1972
Hunter, F.R., George, J. and Ospina, B: Possible carriers in erythrocytes
J. Cell. Comp. Physiol. , 65: 299311, 1965.
Loppinet, V., Siest, G., Lahrichi, M. : Influence of electronic, steric
and conformational factors in the membrane interferences of drugs,
Application to the phenothiazine structure tested on granulocytes,
in drug interference and drug measurement in Clinical Chemistry,
5867, Siest,G. and Young, D.S., Editors Karger 1976.
Metcalfe, J.C. and Burgen, A.S.V., : Relaxation of anaesthetics in the
presence of cyto membranes. Nature 220: 587588, 1968.
Meyler, L. and Herxheimer, Α., : Side effects of drugs vol. 5: 6777,
Experta Medica Foundation, Mouton and Co The Hague.
Pare, C.M.B., : Unwanted effects of long term medication in schizophrenia
and depression. Pharmakopsychiatry, Neuro, Psychopharmakology,
9: 187192, 1976.
Seeman, P. : The membrane action of anesthetics and tranquilizers,
Pharmacol. Rev. 24: 583655, 1972.
Seeman, P., Staiman, Α., Lee, T., Chau Wong, M.: The Phenothiazines and
Structurally related drugs, Forrest. I.S., Carr, C.J., Usdin, E.
Editors, pp. 137148, Raven Press NY, 1974.
■Sherman, L., Kim,S., Benjamin, F., Kolodny, M.D., : Effects of chlorproma
zine on serum growth hormone, New Eng. J. Med. 284 : 7274, 1971.
Spano, P.F., Di Chiarra, G., Loddo, P., Tonon, G.C., and Trabbuchi, M., :
Dopamine stimulated adenylate cyclase in rat substancia nigra,
localisation and effects of neuroleptics in non striatal Dopaminer
gic Neurons, Costa, E., Gessa, L., Edit. Advances in biochemical
psychopharmacology vol. 16:, 1977.
Sunderman, F.W., Jr : Drug interference in clinical Biochemistry, Crit.
Rev. Clin. Lab. Sci.i 1 : 427441, 1970.
311
ABSTRACT
The mean value of gamma-glutamyltransferase activity was significantly
(+ 38%) increased (p < 0.01) in a population of 24 subjects treated over a
long term with Imipramine when compared to a corresponding control popula-
tion. This increase was especially high in women (+ 59% against 14% in
men). A slight elevation in the mean cholesterol values (+ 17%) was also
observed (p < 0.02) in the Imipramine treated population. Furthermore, an
increase of 140% in the gamma-glutamyltransferase was found in 5 women who
were simultaneously taking Imipramine and oral contraceptives.
The variations óf other studied parameters, such as alkaline phospha-
tase, lactate dehydrogenase, glutamate pyruvate transaminase bilirubin and
triglycerides were not significant either in the Imipramine treated popu-
lation, or in the case of the women who were treated with both Imipramine
and oral contraceptives. These data indicate that Imipramine increased
plasma ganrnia-glutamyltransferase activity, which could be related to the
hepatic membrane effect caused by this drug.
INTRODUCTION
The side effects of the treatment with antidepressants have been well
described in the literature. Most of the undesirable effects are minor, but
may, however, cause more serious troubles if their dose is not limited.
The hepatic toxicity of Imipramine, which is the most used tricyclic anti-
depressant drug, can lead to intrahepatic cholestasis (Hoaken, 1964;
Karkalas, et al., 1971) or necrosis (Powell, et al.,1968).
A relation between the metabolism of Imipramine and its side effects has
been discussed but never established. The effects of Imipramine on the
biological laboratory tests, and moreover, on the hepatic parameters were
-not even discussed. The pharmacological interaction of Imipramine with oral
contraceptives was extensively studied in several species (Meyerson, 1966;
Calhoun, et al., 1971; Bellward, et al., 1973; Fludder, and Tonge, 1977).
This interaction was often manifested by mental disturbances (Greengrass,
and Tonge, 1972; Khurana, 1972). This seems to be due to an interaction of
the hepatic metabolism of these two drugs. In fact, the oral contraceptives
are known to decrease the activities of drug metabolizing enzymes (O'Malley,
et al., 1972; Hertz, et al., 1978). It seems that patients who are
313
has a direct effect on the hepatic cell membranes (Kappus, and Remmer, 1975).
treatment with this drug, and in another population of women treated with
this drug together with oral contraceptives. They were both compared to
The subject of our study were all chosen among the individuals who
This population was screened from the drug index (Steinmetz, et al.,
in press)
chosen to correspond in sex, age, overweight and the date of analysis with
1 12 M 13 12 M 16
2 10 M 17 11 M 14
3 36 F 8 34 F 8
4 12 M 6 12 M 7
5 36 M .5 37 M 7
6 17 M 8 16 M 6
7 52 M 1 50 M 5
8 27 F 2 28 F 4
9 8 M 4 8 M 4
10 8 F 9 7 F 4
11 5 M 3 5 M 3
12 5 F 0 5 F 3
13 36 F 3 36 F 2
14 14 M + 2 14 M 0
15 11 F + 2 10 F + 4
16 47 M + 3 47 M + 7
17 35 M + 10 33 M + 12
18 39 F + 9 39 F + 12
19 40 M + 14 40 M + 13
20 45 F + 15 48 F + 17
21 36 F + 13 37 F + 19
22 44 M + 16 44 M + 18
23 55 F + 33 53 F + 42
24 55 F + 35 56 F + 44
Then we selected:
. 8 women who had been treated over a long term with Imipramine
and oral contraceptives. This was a heterogeneous population in that the
women selected were taking another drug in addition, which was in almost
all cases a tranquillizer (Table 2). For this population we present only the
preliminary results
. 8 women (controls) by the same criteria described above
315
TABLE 2 - CHOICE OF TREATED WOMEN WITH IMIPRAMINE AND ORAL CONTRACEPTIVES
AND THE CORRESPONDING CONTROLS
23 - 18 25 _ 18 1 Tranquillizer
19 - 3 19 - 6 1 Tranquillizer
31 + 1 32 + 3 2 Tranquillizers
34 + 5 35 + 5 None
30 + 8 30 + 11 1 Tranquillizer
44 + 17 43 + 20 1 Tranquillizer
39 + 45 40 + 38 None
31 + 41 30 + 40 1 Tranquillizer
,s
Overweight is calculated as in Table 1.
Gamma-glutamyItransferase
(GGT, E.2.3.2.1) Szasz, 1969 GSA II Greiner
Alkaline phosphatase
(ALP, EC.3.1.3.1) Morgenstern, et al.,1965 SMA 12/60 Technicon
RESULTS
1. Variations due to the Imipramine:
. GGT:
The mean of the GGT activities in the treated population vas
38.5% higher than that of the corresponding control group, as shown in
table 4. This difference is a little higher in individuals over 14 years
(+ 37%) than in children (+ 30.6%); the variation in the adults is
emphatically larger in women (+ 59%), whereas only + 14% in men (Table 5 ) .
TABLE 4 VARIATIONS OF LABORATORY TEST VALUES AFTER IMIPRAMINE TREA TMENT
30
20
10
Patient No
-r-
10 15 20
. Cholesterol:
There is a small (+ 17.8Z) but significant (p < 0.02) difference
between the mean of the values of cholesterol in the treated population
and that of the control population (Table 4 ) . This difference does not
occur in all studied cases (Fig. 2 ) .
318
mmol/l
10-
Patient No
if 15 20
. Other parameters:
The variations of ALP, ALT, LDH, bilirubin and triglycerides
between treated and control populations are small and not significant
(Table 4 ) .
2. Variations due to treatment by the Imipramine associated with
-oral contraceptives.
The mean of the GGT values measured in 5 of the treated women was
higher (+ 140%) than in the corresponding controls. The variations found
for the other parameters are not significant.
319
DISCUSSION
Among the biological parameters studied, only the values for GGT
activity and cholesterol differed significantly in the Imipramine treated
population when compared to the corresponding control population.
GGT activity is known to be increased in plasma of subjects treated by
various drugs, especially those of the phénobarbital group (Rosalki, et aL,
1971; Hildelbrandt, et aL, 1975). Also, a 20Z increase is observed in women
receiving oral contraceptives (Weinberg, et aL, 1976). In experiments with
rabbits, we have recently shown that althrough pretreatment with phéno
barbital induces the hepatic plasma membranes GGT, it does not lead to a
direct increase in plasma enzyme activity. This occurs only later and was
explained by a possible perturbation of the membranes structures caused by
phénobarbital treatment (Tazi, et al.,in press). On the other hand, we found
(not yet published results) an increase of plasma GGT in rats under Imipra
mine treatment, while the hepatic activity was not induced.
The binding of Imipramine to hepatic membranes, as has been shown by
Kappus and Remmer (1975) leads to membranes disturbances (Romer, and
Bickel, 1979). The membrane effect of Imipramine is probably responsible
for the release of GGT into the plasma in the Imipramine treated subjects.
Furthermore, our present results demonstrate that the increase of GGT
activity in the Imipramine treated population is higher in women than in
320
CONCLUSIONS
From this study of the effect of Imipramine on laboratory tests, the
important point to be retained is the increased GGT values in most of
subjects treated with this drug in comparison to those of the corresponding
controls. This phenomenon is of importance in clinical chemistry to avoid
misinterpretation of GGT high values in subjects under Imipramine treatment.
Moreover very high values of GGT in cases under treatment with this drug
can indicate a possible hepatic membrane damage and so the prescription or
the dose of Imipramine has to be modified.
This study must be extensived to other tricyclic antidepressants and to
their interaction with contraceptives towards usual laboratory tests.
REFERENCES
Bellward, G.D., Morgan, R.G. and Szombathv. V.E:: The effects of
pretreatment of mice with norethindrone on the metabolism of
C-imipramine by the liver microsomal drug-metabolizing enzymes.
Can. J. Physiol. Pharmacol. 52: 28-38, 1973.
Bucolo, G. and David, H.: Quantitative determination of serum triglycerides
by use of enzyme. Clin. Chem. 19: 476-482, 1973.
Calhoun, F.J., Toison, W.W. and Schrogle, J.J.: Effects of various drugs
on the uterotropic response to mestranol and norethynodrel in the rat.
Soc. Exp. Biol. Med. 136: 47-50, 1971.
Chu, T.M., Bishop, C.H.: Optimal conditions for the assay of lactate
dehydrogenase. Med. Lab. Technol. 29: 3-7, 1972.
321
ISBN 90-247-2419-8